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Many women fear being diagnosed with breast cancer; and rightfully so.

capabilities of modem

Despite the

medicine, the cumulative lifetime risk of getting the disease has risen to

one in eight and, despite decades of researr:h, no cures exist. In this Article, the autlwrs explore
the commerr:ializ.ation of so-called breast cancer gene tests, based upon generic alterations
linked to the disease. Although the authors fully address this specific technology, they use what
constitutes the seminal case of predictive genetic testing to analyze the adequacy of the existing
regulatory framework. The authors conclude that the present regulatory system is inadequate
and places a dangerous amount of reliance on primary care physicians. Their conclusion is
grounded in the observation that most primary care physicians lack sufficient knowledge about
this evolving investigative technology-which is highly subject to misinterpretation, and,
though potentially helpful

to

some "high risk" patients, offers questionable clinical value for

the general public. The authors set forth numerous proposals to promote both the quality and
clinical value of predictive genetic testing so that it confonns to public health standards and
can be properly integrated as a reliable component o f medical care in specific situations.
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INIRODUCTION

OncorMed, Inc. (OncorMed), a small Gaithersburg, Maryland,
biotechnology company involved in general cancer testing, announced
in January 1996 that it had begun selling a testing service1 to identify
1.

We employ definitions pertaining to genetic testing adopted by the Task Force

on Genetic Testing, which was created through the Ethical, Legal, and Social Implications
(ELSI) Subprogram of the Human Genome Project (HGP). The ELSI Task Force has
defined "predictive genetic test" as the "test of a person's or fetus's genes or gene products

for the purpose of determining the presence of abnormalities, including carrier status, that

are known to be associated with an increased risk of d evelopment of a disease or disorder."

Meeting Minutes from the Second Meeting of the Task Force on Genetic Testing 3 (Nov.

15, 1995) [hereinafter Meeting Minutes].

As recognized by the

predictive element of this definition must be underscored:
Genetic tests are already

an

ELSI

14-

Task Force, the

important part of medical practice. In patients

with overt manifestations of disease, they can rule out mistaken diagnoses or
establish the correct diagnosis promptly, avoiding needless referrals and elaborate
workups (e.g. [sic] a test for cystic fibrosis in a child with recurrent pulmonary

infections).

ELSI TASK FORCE

ON GENETIC TEsTING, INTERIM PRINCIPLES 2 (1996). We emphasize the

distinction between predictive genetic testing and presymptomatic diagnostic testing. The
latter assumes predictability. See

infra

also recognize that breast cancer is not

note 12 for further clarification of these terms. We
100% gender-specific, meaning that men too may be

stricken with the disease. However, for the sake of simplicity and to reflect the vast majority

1 997]
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the presence of genetic alterations linked to breast and ovarian cancer.2
Within a few months, Genetics & IVF Institute

(NF)

of Fairfax,

Virginia, began to offer a variation of the test3 to any Jewish4 woman

of breast cancer patients, throughout this Article we use the female gender to refer to breast
cancer patients.
2.
The stated purpose of the test is to determine the presence of a specific genetic
alteration, or allele, linked to breast and ovarian cancer. The testing process consists of
extracting DNA from a blood sample and sequencing the DNA to detennine whether the
genetic alteration is present. This technology is based upon the discovery that a gene called
BRCAl (breast cancer 1), found on chromosome 17, codes for a protein that has a tumor
suppressor function. See Yoshio Miki et al., A Strong Candidate for the Breast and Ovarian
Susceptibility Gene BRCAJ, 266 SCIENCE 66, 66-71 (1994); Stephen C. Rubin et al.,

Clinical and Pathological Features of Ovarian Cancer in Women with Genn-Line
Mutations of BRCAJ , 335 NEW ENG. J. MED. 1413, 1413 (1996) (reporting, however, that
this form of inherited cancer is more responsive to clinical treatment); see also Frances S.
Collins, BRCAJ-Lots of Mutations, Lots of Dilemmas, 334 N EW ENG. J. M E D. 186, 186
(1996) (emphasizing the scientific unreliability of current testing capability). Alterations in
the gene may interfere with the production of this protein or with the gene 's function in
some other way, and thus cause an increased risk of developing breast cancer. Already
more than 130 different mutations have been found in the breast cancer gene.
Some are probably meaningless, and others deadly, but most have not been
studied yet. Standard gene tests available today detect only . .. a few of the more
common mutations, so a negative test doesn't guarantee that a woman is safe.

Rick Weiss, Tests' Availability Tangles Ethical and Genetic Codes, WASH. POST, May 26,
1996, at Al; see also D. Shattuck-Eidens et al., A Collaborative Study of 80 Mutations in
the BRCAJ Breast and Ovarian Cancer Susceptibility Gene, 273 JAMA 535, 535-41 (1995)
(stating that over 100 distinct mutations of BRCAl have been identified). A second gene,
known as BRCA2, also has been linked to breast and ovarian cancer. See Richard Saltus, 2d
Cancer Gene Cited in I of 100 Ashkenazi Jewish Women , BOSTON GLOBE, Oct. 2, 1996, at
Al8 (citing Oct. 2, 1996 issue of Nature Genetics). In early 1997, a third gene, CHK, was
lined to breast cancer. See Judy Foreman, Another Gene with Breast Cancer Role Identified,
BOSTON GLOBE , Jan. 16, 1997' at A23.
3.
IVF uses allele-specific hybridization techniques rather than sequencing.
4.
One BRCAl mutation, 185deIAG, is believed to occur in one percent of the
people who are of Ashkenazi (Eastern European) Jewish ancestry. See J.P. Struewing et al.,
The Carrier Frequency of the BRCAJ 185delAG Mutation is Approximately J Percent in
Ashkenazi Jewish Individuals, 11 NATURE GENETICS 198, 198-200 (1995). Research is
ongoing, as other ethnic groups may be more susceptible to inherited breast cancer and,
further, inherited susceptibility may be offset by environmental factors not yet identified.
Still, according to recent data, one in 50 Ashkenazi women carry at least one of the BRCAI
and BRCA2 mutations that are believed to raise a woman's susceptibility to inherited breast
and ovarian cancer. See Saltus, supra note 2, at Al 8. However, only five to ten percent of
incidents of breast cancer are believed attributable to inherited genes. See id. See generally
The Scientific Questions, 18 PERSP. GENETIC COUNSELING 4 (1996) (estimating that 10% of
breast cancers are due to gennline mutations); David S. Hilzenrath, Md. Finn s Gene Test to
Intensify Bioethics Debate, WASH. POST July 25, 1996, at D14 (describing a service to
detect predisposition to breast and ovarian cancer). For discussion of the danger of "ethnic
genetics," see Ruth Hubbard & Wendy McGoodwin, The Danger of "Ethnic G enetics,"
BOSTON GLOBE, Oct. 13, 1995, at 3. See also E.J. Kessler, The Secret Shake-Up in the
Shiduch, Forward, CANCER & Us, July 26, 1996, at 11, 13 (reporting from New York City's
Orthodox Jewish Community that, "[d]iagnosed with breast cancer-a terrifying disease
,
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willing to pay $295.5 OncorMed then expanded its service to include
tests for genetic alterations of BRCA 1

and BRCA2 for

between $400

and $1,200 (the latter for combinations of the genetic alterations).6 In
the fall of 1996, Myriad Genetic Laboratories, Inc. (Myriad), a Salt
Lake City subsidiary of Myriad Genetics, also began selling a
combined test for several alterations of the two genes for $2,400.7 All
of these companies are actively developing markets for their testing
services.

According to one report, "[i]n the future, OncorMed is

expected to market its testing service to disease management facilities
and insurance c ompanies, which would benefit from information
about patients' susceptibility to breast and ovarian cancer, as well

as

other diseases."8 NF, Myriad, and OncorMed have not submitted and
do not intend to submit their testing services to the Food and Drug

under any circumstances-these women feel they.must hide their trouble, traveling far from
home for treatment and disguising their hospital stays as out-of-town visits, lest the news of
their affliction poison the marriage prospects of their daughters"). It is important to note that
OncorMed has directly addressed some of the implications of singling out Ashkenazi Jews
for BRCA testing through the formation of a special protocol and information packet to
accompany its "Heritage Panel" test, a test for three BRCA mutations found at an elevated
level in families of Ashkenazi Jewish descent. See OncorMed Heritage Panel Education and
Testing Packet (undated) (on file with authors).
See Meredith Wadman, Women Need Not Apply, WASH. POST, May 5, 1996, at
5.
C3 (reporting that, in collaboration with IVF, Dr. Joseph Schulman is offering the test to
Jewish women referred by a physician for $2 95); Weiss, supra note 2, at A I.
See Hilzenrath, supra note 4, at D 1 4 ("OncorMed . . . plans next week to
6.
introduce a new service that will raise the stakes in one of biotechnology's biggest ethical
f ered for Cancer Gene, NEWSDAY, July 24, 1996,
debates . ..."); Ridgely Ochs, New Test Of
atA7.
7.
See MYRIAD LABORATORIES, INC., BRCA l: GENETIC SUSCEPTIBil.ITY FOR BREAST
AND OVARIAN CANCER 2 ( 1 996); see also Saltus, supra note 2, at A 18; Sean Taytigian et al.,
The Complete BRCA2 Gene and Mutations in Chromosome 13q-Linked Kindreds, 12
N ATURE GENETICS 333, 333-37 (1996) (publishing full sequence of BRCA2 breast cancer

gene by Myriad Genetics). To advance compilation of the data needed to raise the clinical
value of its BRCA testing, Myriad has established a registry at the Dana-Farber C ancer
Institute. See Richard Saltus, Gene Testfor Cancer Risk is Offered, BOSTON GLOBE, Oct. 25,
1996, atAl.
8.

OncorMed BRCAJ Testing Service Commercialization Enters Second Phase

Through New !RB Protocol, 39 BLUE SHEET 6, 6- 7 ( l 996) (hereinafter OncorMed BRCAJ
Testing Service]. In contrast, Europe is considering an outright ban on the use of genetic

testing information by insurers in the absence of comprehensive self-regulation. See
Insurers Risk Ban Over the Use ofGenetic Testing, DAILY EXPRESS, July 19, 1996, available
in Westlaw, 1996 WL 6714032 [hereinafter Insurers Risk Ban].
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Administration (FDA) for review.9 According to their interpretation of
existing FDA and other federal regulations, they are not required to.10
The commercialization of these so-called "breast cancer tests"''
marks the advent of a generation of predictive12 genetic testing
products derived from discoveries reported intensely in the media
during the past several years. 13
The public is demanding more
9.

We note, however, that these companies have taken very different approaches to

many of the patient issues raised in this Article. We commend the work of OncorMed and,
in particular, Dr. Patricia Murphy in developing meaningful protocols for genetic testing.
See App. I.
l 0.

See Proposed Recommendations of the Task Force on Genetic Testing, Meeting

Notice, 62 Fed. Reg. 4539, 4544 (1997) ('The Task Force recognizes that developers of
genetic tests who do not rely on federal funds are under no legal obligation to submit
protocols to the proposed NGB and have not always obtained IRB approval for validation
protocols of tests they plan to market as laboratory services."). However, the FDA has not
completely acceded that it lacks the statutory authority to regulate genetic testing.

See

OncorMed BRCAJ Testing Service, supra note 8, at 7 ("Currently, the FDA is not regulating
the testing; the agency maintains that it has such authority but Jacks the resources to review
the technology or make and enforce new regulations for the field.").

11.

As discussed fully infra at note 25, the clinical predictive value of these tests for

determining whether an individual who has tested positive for the alleles will suffer breast
cancer in her lifetime has not been determined, except for a very small percentage of the
population.

12.

It

is

important

to

distinguish

predictive

genetic

testing

from

reliable

presymptomatic genetic testing, as the meaning of these terms is being muddled in the
current genetic testing debate. The distinction between these terms is certainty, clinically
known as "positive predictive value" (PPV),

which

is defined infra

at

note 25.

Presymptomatic genetic testing refers to testing for genetic alterations causative of disorders
and often controlled by a single genetic alteration, prior to the onset of symptoms.
disorders include

Huntington's

Disease

and

Amyotrophic Lateral Sclerosis

Such
(ALS),

commonly known as Lou Gehrig's disease. So-called "predictive" genetic testing is also
testing for genetic alterations linked to health conditions and disorders. However, due to the
influence of other genes and environmental factors over the target health conditions,
predictive genetic testing at most offers the general public estimated chances of actually
developing the health condition.

13.

Even years ago, leaders in the field of genetics were responding to "the very real

possibility that the explosion of knowledge in the field of genetics will produce a windfall of
diagnostic and therapeutic technologies."

Philip J. Boyle, Sh aping Priorities in Genetic

Medicine, HASTINGS CENTER REP. , May-June 1995, supp. at l ; see also Weiss, supra note 2,
at Al ("New genetic tests are moving rapidly from research laboratories into doctors'

offices, where they are being marketed as a way to predict people's chances of getting
common diseases such as colon cancer, breast cancer and Alzheimer's disease."). The truth
has become undeniable.

"Scores of genetic tests have been developed for dozens of

diseases.

Some are used to diagnose existing conditions and others are used in healthy
people to predict the odds that a disease will occur." Id. Representative genetic tests in
various stages of development include the following:
Medically useful:

(a) APC gene, which is linked to familial adenomatous

polyposisa condition that leads to colon cancer; (b) MEN gene, which is linked to
multiple endocrine neoplasia and indicates a very high risk of cancer of the
endocrine glands; and (c) RB gene, which is linked to retinoblastoma---<:hildhood
eye cancer;

1 216
information about
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and
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other commercial

and

academic laboratories are introducing their own tests for genetic
influenced disorders that may help assess future disease risk.15 From a

More research needed: (a) BRCAI and BRCA2, which have been linked
to breast and perhaps ovarian cancer; (b) MSH2 and MLHl, which have been
linked to hereditary nonpolyposis colon cancer; and (c) p53, which has been
linked to Li-Fraumeni syndrome, an elevated risk of many cancers; and
Little clinical utility at present:
(a) p 16, which has been linked to
malignant melanoma, a serious skin cancer; and (b) APOE-4, which has been
linked toAlzheimer's disease.
Id.

14.
As recognized by Professor Annas, 'The gene has become more than a piece of
information; it has become 'a cultural icon, a symbol, almost a magical force."' George
Annas, Genetic Prophecy and Genetic Privacy, TRIAL, Jan. 1 996, at 19, 24-25 (quoting
DOROTHY NELKIN & M. SUSAN LINDEE, THE DNA MYSTIQUE: THE GENE AS A CULTURAL
ICON 2 (1995)); see also Richard Saltus, Sounding the Alarm, BOSTON GLOBE, May 26,
1 996, (Magazine), at 14 [hereinafter Saltus, Sounding the Alarm] ("No longer merely a
scientific schematic, it is now a staple of pop culture. It appears time and again in op-ed
pieces, newspaper and magazine articles, and books that tackle the thorny dilenunas of the
genetic revolution."). Dr. Richard C. Lewontin, a Harvard scientist who is critical of present
priorities in gene research and also affiliated with the C ouncil for Responsible Genetics, a
consumer group based in Cambridge, Massachusetts, has coined the term "genomania," that
is, "the idea that almost everything-a baby's chin or nose, someone's personality quirks, or
a preponderance of men in positions of power-can be explained by genes." Id. But see
Richard Saltus, Early Alzheimer's: Do You Want to Know?, BOSTON GLOBE, July 3 , 1 995, at
39 [hereinafter Saltus, Early Alzheimer's] ("Recently developed gene tests ... for inherited
predispositions to breast cancer and other cancers have raised this issue for an increasing
number of families. If any conclusion can be drawn thus far, it's that people are more
hesitant and ambivalent about learning their genetic destiny than anyone expected."). It is
important to emphasize that industry is attempting to facilitate consumer interest in and
demand for genetic testing. For example, "Myriad is currently establishing a genetic testing
and information business to identify individuals who have inherited gene mutations which
increase their risk for specific illnesses." MYRIAD LABORATORIES, I NC , supra note 7, at 2.
T he predominant force that drives consumer demand for a great deal of predictive genetic
testing may be social pressure. See Daniel Callahan, The Genetic Revolution, in BIRTH TO
DEATH: SCIENCE AND BIOETHICS 15 (David C. Thomasma & Thomasine Kushner eds., 1 996)
("New medical technologies rarely remain discretionary for long. If they are not legally
imposed on people, something hard to do in our western society, they can just as effectively
be imposed by social pressure.").
15.
See ASSESSING GENETIC RISKS (Lori Andrews et al. eds., 1 994) (reporting on
pervasive, informal genetic testing by research); ELSI TASK FORCE ON GENETIC TEsTING,
supra note 1 , at 2; Paul H. Silverman, Commerce and Genetic Diagnostics Laboratories),
HASTINGS CENTER REP., May-June 1995, supp. at S l5 ('The prospect of routine genetic
diagnostics for a wide variety of diseases ranging from rare monogenetic afflictions (for
example, Tay-Sachs) to conunon polygenic diseases (for example, many cancers) have
attracted the attention of conunercial testing laboratories and venture capitalists."); Joan
Stephenson, Questions on Genetic Testing Services, 274 JAMA 1 661 (1995) ("As scientists
pinpoint genes that underlie such diseases as cystic fibrosis and breast cancer, co mmercial
and academic laboratories are scrambling to provide genetic testing services aimed at
diagnosing gene-related disorders and assessing future disease risk."); Ronald Rosenberg,
For Matritech, an Encouraging Prognosis, BOSTON GLOB E, Feb. 18, 1996, at 80 ("Matritech
.

1 997]

1217

GENETIC TESTING SERVICES

business perspective, these laboratories are doing so ( 1) to generate
immediate revenue streams to finance their scientific research and
development (R&D); (2) to amass patient data to determine the extent
to which their tests predict the onset of breast and ovarian cancer for
the general population, thereby giving them the option to sell their tests
6
as kits and charge market prices rather than simply recouping costs; 1

(3) to obtain subject samples for gene sequencing and outpace their
science competitors; (4) to accelerate the development of more
marketable diagnostics, therapeutics, and maybe even gene therapies;
and/or (5) to increase familiarity, acceptability, and demand for such
tests among physicians and the public, and thereby perhaps achieve
standard care acceptance and insurance coverage for their products. 17
The precedent set by IVF, Myriad, and OncorMed

(as

well as

academic research institutions) conceivably affects all Americans
directly.

More than five thousand genetic alterations have been
1
identified, 8 and estimates are that every person has four or five genetic

alterations linked to serious health conditions.19 Now that a "critical
mass" of the human genome has been mapped through the Human

and other biopharmaceutical finns are developing a new generation of simple diagnostic
tools, or exams, to track the progress of the cancer itself in recovering patients.").
l 6. See infra note 64 and accompanying text.
According to the ELSI Task Force, the four primary forces fueling expansion of
17.
the commercialization and availability of predictive genetic testing are: (1) the reward
structure of science, which encourages immediate repor ting of findings; (2) public demand
for progress in the fight of disease; (3) biotechnology companies' objective o f developing
markets large enough to make testing profitable; and (4) media coverage of genetic
discoveries. See ELSI TASK FORCE ON GENETIC TEsTING, supra note I, at 4. For a general
discussion of the inconsistency of insurance coverage in the United States for state of the art
medical treatments, see Karen L. Illuzzi Gallinari, Commentary, The State of the Law on
Insurance Coverage for State of the Art Medical Treatments, MEALEY's LIT. REP.: BAD
FAITH, Oct. 18, 1995, at 16.
A catalog of human genes and genetic disorders has been compiled by Dr. Victor
18.
A McKusick, doctor of medical genetics and professor at the National Center for Human
Genome Research at John Hopkins University. This catalog, which is updated daily and
available on the World Wide Web, lists more than 5,000 genes/genetic disorders. See Ellie
McCormack, Sought-After Counselors Find It's All in the Genes, BOSTON Bus. J., Apr. 26May 2, 1996, at 3, 23; see also Do You Really Want to Know?, Nightline (ABC television
broadcast, Apr. 26, 1996) (videotape on file with authors). Consider that, in 1966, this list
consisted of just l ,500 entries. Id.
19. "According to the British Medical Association, '[g]enetic and part-genetic
diseases affect one in every twenty people by the age of 25 and perhaps as many as two in
three people during their lifetime."' Sheila A.M. M clean, Genetic Screening of Children:
The U.K. Position, 12 J. CONTEMP HEALTH L. & PoL'Y 113, 114 (1995) (stating also that
the proportion of childhood deaths attributable to genetic factors, wholly or partly, is
approximately 50%) (citing B RITISH MEDICAL ASSOCIATION, OUR GENETIC FUTURE: THE
SCIENCE AND ETHICS OF GENETIC TECHNOLOGY l (1992)).
.
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linkages

between

[Vol. 7 1 : 1 2 11
genes

and

health

conditions should increase exponentially.21 Technology also has made
testing for genes associated with health cheaper and easier, and
standard medical practice soon will include much more genetic
testing.22 Kaiser Permanente, the nation's largest health maintenance
organization, already has decided to allow its divisions to offer BRCA
genetic testing to its members.23
The danger is that, absent regulatory safeguards and quality
controls, the forthcoming multitude of predictive genetic testing

20. The HGP is a three-billion-dollar initiative launched by the federal government
to map the entire human genome by the year 2005. For discussion of the HGP, see generally
ROBERT M. COOK-DEEGAN, THE GENE WARS 169 (1994); Robert M. Cook-Deegan, Origins
of the Human Genome Project, 5 RISK: HEALTH, S AFET Y & ENV . 100 (1994). The impact of
the HGP on the biotechnology industry is addressed i n Michael J. Malinowski & Maureen
A. O'Rourke, A False Start? The Impact of Federal Policy on the Genotechnology
Industry, 13 YAIEJ. REG. 163, 190-91 (1996).
21. See Detailed Human Physical Map Published by Whitehead-MIT: STS-Based
Map Represents Halfway Point to JOO-kb Human Genome Project Goal, HUMAN GENOME

NE WS Jan.-Mar. 1996, at 5 [hereinafter Human Physical Map] ('The new map, which
contains more than 15,000 STS DNA markers spaced an average of 199 kb apart, covers
almost 95% of the entire genome . . . . Although originally slated for 1988, map completion
by Whitehead-MIT and other groups is expected b y the end of this year. "). The HGP is a
"global attempt to identify the blueprint of every individual's genetic makeup." Mclean,
supra note 19, at 114-15. For a full discussion of the HGP, see Malinowski & O' Rourke,
supra note 20, at 190-93; Michael J. Malinowski, Coming into Being: Law, Ethics, and the
Practice of Prenatal Genetic Screening, 45 HASTINGS L.J. 1435, 1441-45 (1994). See also
infra Part II.A. One of the fundamental goals underlying HGP is "[t]he rapid transfer of
technology to industries that can develop economically and medically useful applications
.. . that affects us all." ROBIN J.R. BLATT, CONCEIVING THE FUTURE: THE X's AND Y's OF
GENETIC TEsTING IN PREGNANCY (forthcoming 1997) (on file with the authors).
22.
See Dee Lord, Something in the Genes, ABA J., Apr. 1996, at 86; Richard
Saltus, Curbs on Use of Genetic lnfonnation Studied, B OSTON GLOBE, Feb. 23, 1996, at 19.
The capability to test for multiple mutations at one time is known as multiplex testing. See
Lori B. Andrews, Prenatal Screening and the Culture of Motherhood, 47 HASTINGS L.J. 967
(1996) (addressing multiplex testing in the context of prenatal screening). An advanced
form of this technology, Multiple Allele Specific Diagnostic Assay (MASDA), developed by
Genzyme Genetics i n Framingham, Massachusetts, makes it possible to test over 500 patient
samples for over I 00 known mutations simultaneously. See Private Communication
between Robin Blatt and Judith King, Former Education and Corporate Communications
Manager, Genzyme Genetics (July 1996).
23. According to one report, Kaiser
,

plans to offer genetic tests to show the predisposition to breast cancer among
some of its 6.8 million members. Kaiser guidelines will lay out the process for
getting the test, and will probably require any candidates to undergo
comprehensive counseling in advance.
Patients and their families will be
included in a registry and will be followed afterward to monitor the consequences
of the test.
Robert B. Whitcomb, Our Genetically Evolving Future, P ROVIDENCE JOURNAL-BUUETIN,
Sept. 5, 1996, at 7B.
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services will be overused. Even tests that are good predictors for some
people may be overused and misinterpreted by patients, providers,
insurance companies, and employers. 24 Biotechnology companies can
sell their testing services outside major research centers and through
the broad community of primary care physicians. This substantiates
concern that genetic tests will become widely available to patients
without

adequate

pretest

counseling

by

providers

who

either

"interpret" them without appreciation for the technologies' predictive
limits or, worse, leave patients to make their own interpretations. In
other words,

genetic

testing may

be

mainstreamed

before

the

predictability of such testing is detennined with scientific accuracy.
Such tests may become the equivalent of biological tarot cards,
subject, like the Tarot, to misinterpretation and overreliance.
This Article explores both the patient-care and public-health
implications

of

commercialization

of

predictive genetic

services under the existing regulatory scheme.

testing

A central premise is

that regulatory safeguards must be introduced to ensure that genetic
testing is made available only when it carries scientifically valid
predictive value (positive predictive value, or PPV).25
24.

Equally as

See Stephenson, supra note 15, at 1 66 1 (stating,

[t]he problem with this development, according to a new survey, is that some of
the laboratories offering genetic testing are bypassing the admittedly vague
regulatory controls or other less formal measures that exist to help assure test
validity. Some are also failing to make it clear to physicians and patients that
many such procedures are still investigational in nature.

); see also Proposed Recommendations of the Task Force on Genetic Testing, Meeting
Notice, 62 Fed. Reg. 4539, 4539-44 (1997). This conclusion is supported by a recent study,
conducted by Dr. Neil Holtzman, that sampled 594 commercial and 4 2 5 nonprofit
laboratories (mostly academic institutions) and realized a response rate of approximately
80%. See id.; see also Barbara Koenig, Gene Tests: What You Know Can Hurt You, N.Y.
TIMES, Apr. 6, 1996, at A23 ("Unfortunately, nothing prevents laboratories from offering
genetic tests, nor are there any regulations to insure the quality of the tests."). Although Dr.
Holtzman has not yet published the results of his survey, according to one interpretation:
The poll revealed that most commercial enterprises that currently market such
tests are doing so without gaining clearance from the Food and Drug
Administration (FDA), and thus there is no guarantee that the laboratory tests are
performed properly or that they are even appropriate for the disease in question.
The researchers also found that many testing organizations are failing to seek
approval from institutional review boards-panels composed of physicians,
scientists, ethicists, clergy, and representatives from the lay community-which
hospitals often establish to discuss whether new procedl1res or technologies
should be put into effect.

The Hazards ofGenetic Testing, HARV. WOMEN'S HEALTH WATCH , Dec. 1 995, at 6.
25. As explained by the ELSI Task Force, the penetrance of the genetic factor
(genotype) is the probability that the related condition will appear in the physical makeup
(phenotype) when the genetic factor is present. See ELSI TASK FORCE ON GENETIC TESTING,
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important, providers and patients must be educated about both the
technology's

limitations

and

their

respective

legal

rights

and

responsibilities.
Part II presents an overview of genetic testing capabilities,
existing regulations, and the dangers of premature use of genetic
testing. Part ill e mploys legal storytelling to illustrate implications of
the commercialization of genetic testing services.

Part IV addresses

these implications by presenting diverging theories on the appropriate
regulatory response to the advent of commercialized genetic testing
services.

Part

V

sets

forth

proposals

for

the

responsible

commercialization of these technologies.

II.

TODAY'S TECHNOLOGY, YESIBRDAY'S REGULATIONS
Expansive genetic testing capabilities have been a long time in

coming.26 Such technology
the HGP in 1990.27

was

foreseeable at the commencement of

Concern about the impact of such testing on

supra note 1, at 9. 'The quantitative measurement of penetrance is [] 'positive predictive
value (PPV) . . . . "' Id. The application of PPV to BRCA tests is illustrative of the concept.
"The observed lifetime PPV for breast cancer due to inherited BRCAl mutations is 85%90% in women in high risk families, but some women with these mutations will develop
breast cancer for other reasons." Id. at 9-10. To accurately detennine the PPV, it must be
detennined through clinical research what percentage of women with the mutation will get
the disease for other reasons. In other words, what percentage of women without the
mutation will still get the disease? Further, the percentage of women with the mutation who
do not develop the disease must also be determined. Several studies raise some doubts on
inherited risk, suggesting that "environmental factors, such as age at first childbirth, diet, and
exposure to hormones, can alter the effects of the BRCAl and BRCA2 genes, and other
genes may have an impact as well." Richard Saltus, New Data Add to Confusion on Breast·
Cancer Gene Issue, BOSTON GLOBE, Apr. 30, 1996, at 9. Due to the factors that must be
considered and the potential importance of interaction between factors, "[ o]btaining data for
PPV may take years to accomplish, particularly for late-onset disorders." ELSI T ASK FORCE
ON GENETIC TEsTING, supra note 1, at 10. This BRCA example illustrates that presently the
PPV and clinical sensitivity of genetic tests are intrinsically limited. For example, "[m]any
different alleles in the same gene (allelic diversity) or alleles of different genes (locus
heterogeneity) can lead to the same disease ... . Failure of a test to detect all disease-related
mutations reduces its clinical sensitivity." Id. at 8. A test carries high clinical sensitivity
when it is immune from being skewed by other substances (such as substances in food or
drink) and high clinical specificity when it can determine the exact substance(s) linked with
a condition. See id. at 5-12.
26.
Predictions by scientists that genetic technology would greatly improve human
health date back at least 15 to 20 years. See Saltus, Sounding the Alann, supra note 14, at
14.
27.
Strong concerns about the uses of genetic information by insurance companies
were raised by public officials, such as Congressman Obey, during House appropriations
hearings for the HGP back in 1990. See COOK-DEEGAN, supra note 20, at 169; see also
DEPARTMENTS OF LABOR, HEALTH AND HUMAN SERVI CES EDUCATION, AND RELATED
AGENCIES APPROPRIATIONS FOR 1991 pt. 48, at 887-960. In fact, today's pressing genetic
,
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society inspired James Watson, codiscoverer of the double-helix
structure of DNA and the first head of the HGP, to insist at the outset
of the HGP that a respectable percentage of the annual budget be
committed to addressing the project's e.thical, legal, and social
8
implications. 2
Nevertheless, most public health officials and other regulators,
both federal and state, are only
implications

of

new

to become aware of the full
technologies.29
Similarly, the

beginning

genetic

·

testing issues were readily foreseeable as early as 1 9 86. See Mame E. Brom, Note, Insurers
and Genetic Testing: S h opping for that Perfect Pair of Genes, 40 DRAKE L. REV. 1 2 1 , 1 28
·

(199 1 ) ("In a 1986 survey of biotechnology companies, eight planned to offer genetic tests
as a laboratory service for clinicians and researchers, and six predicted that diagnostic kits
would be available for sale by 199 1 .").

28.
29.

See COOK-DEEGAN, supra note 20, at 237.
This is true both domestically and abroad. Domestically, the National Institutes

of Health (NIH) and Department of Energy (DOE), though their ELSI program, assembled
the Task Force on Genetic Testing and charged it with completing a report by the end of

1997. See generally ELSI TASK FORCE ON GENETIC TESTING, supra note 1 , at 2. Also, the
Clinton Administration recently appointed a fifteen-member National Bioethics Advisory
Commission (NBAC) whose initial studies will cover the appropriateness of patenting genes
and the rights of patients who participate in genetic research.

See Jeffrey L. Fox, US

Bioethics Commission Meets, Outlines Agenda, 1 4 N ATUR E BIOTECHNOLOGY 1 533, 1 533

(1996) (emphasizing importance placed on genetic privacy issues); Russ Hoy le, US
National Bioethics Commission: Politics as Usual?, 14 NATURE BIOTECHNOLOGY 927, 927

(1996) ("(A]n effective bioethics commission must take as its mission the review of difficult,
or 'big time' research in public before it is done."); Eric Convey, Mass. Exec. Named to

1996, at 29 (announcing appointment to

Bioethics Panel, BOSTON HERAID, July 25,

presidential panel to explore ethical issues surrounding the biotech industry); Charles Craig,
National Commission to Study Ethics of Genetic Medicine, 7 B10WORLD TODAY, July 2 5

,

1996, at 1 ; see also Office of Science and Technology Assessment, National B ioethics
Advisory Comm. Proposed Charter, 59 Fed. Reg. 4 1 ,584, 4 1 ,584-86 (1 994) (announcing the
establishment of such a commission); US Agencies Seek Rules on Human Testing, BO STON
GLOBE, Jan. 23, 1 997, at A l l (reporting that five Cabinet departments and two agencies
agreed to a formula to share the $1 .1 million operational cost). "In Europe, similar
commissions are already well established, from B ritain's Nuffield Council o n Bioethics
(London) and UNESCO's International Bioethics Committee (Paris) to the European
Commission's Group of Advisers on Ethical Implications of Biotechnology (Brussels)."
Hoyle, supra, at 927. Also, in July 1 996, the U .K. government announced the establishment
of a Human Genetics Commission to serve as a strategic body to monitor medical genetics in
response to parliamentary pressure for a unified group with a strategic overview. See UK

Sets Up Human Genetics Commission, CLINIC A July 1996, at 1 (describing the commission
,

as a nonstatutory body consisting of eminent, independent experts who will report to both
health and industry ministers); Michael J. Malinowski, Globalization of Biotechnology and
the Public Health Challenges Accompanying It, 60 ALB. L. REV. 1 19, 123-33 ( 1 99 6). In the
United Kingdom, the Medical Research Council is deciding whether it will publicly fund a
search for genes that influence IQ-test results. See David King, Editorial, Business Gets the
Upper Hand; David King Calls for Democratic Decision-Making, GUARDIAN, May 2 3

1996, at 19.

,
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genotechnology3° industry has just begun to recognize the need to
address

ethical

concerns

regarding

the

responsible applications of its work.31

commercialization

and

As a result, the regulatory

infrastructure necessary for responsible commercialization of genetic
technology

is

being

developed

in response to,

anticipation of, its commercialization.

rather

than

in

The following is an overview

of present genetic testing capabilities, existing regulations, and dangers
arising from the premature commercialization of genetic testing.

A.

Overview of Genetic Testing Capabilities
Today

the

scientific

community

is

experiencing

a

nature

movement as forceful as the nurture movement that took force in the
1960s and that set the priorities in science for the decades to follow.32
Behavioral genetics, the nature extreme in genetic medicine, is a
burgeoning field grounded in the belief that molecular genetics even

30. Genotechnology is the subset of biotechnology cons1stmg of scientific
discoveries associated with human genetics and the HGP. See Malinowski & O'Rourke,
supra note 20, at 1 9 1 & n. 1 65. "Genomics" is another descriptive term, used routinely by
industry for this category of technology. See generally B IO '96, INTERNATIONAL
B IOTECHNOLOGY MEETING & EXHIBITION, GENOMICS: IMPACT ON HEALTH CARE (1 996)
[hereinafter Bio '96] (on file with authors) (discussing the impact of genomics on health
care).
3 1 . The Biotechnology Industry Organization (BIO) recently formed an ethics
committee to deal with privacy and research issues. See Kathleen Day, Genetics Research
Begets Questions; Biotech Industry Seeks Ethics Advice to Deal with Complex Issues,
WASH. POST, May 8, 1 996, at Al . This committee

will focus on [the) issue of privacy and on what types of research should and
should not be performed, said BIO President Carl Feldbaum. He said executives
from American Home Products Corp., Genentech Inc. and Genzyme are heading
committees on these and other topics and that the organization is trying to hire a
PhD [sic] in philosophy to become its full-time staff member on ethics issues.
Id.

Perhaps even more impressive, Novartis, one of the world's largest life-sciences
companies (formed through the merger of Ciba-Geigy and Sandoz in December 1 996), will
voluntarily label its genetically-engineered food products as part of a campaign to educate
the public about the advantages of these products-e.g. , a significant reduction in the use of
pesticides and pesticide residues. See Scott Allen, Genetically Altered Food to be Labeled,
BOSTON GLOBE, Feb. 25, 1 997, at D2.
32. See Saltus, Sounding the Alarm, supra note 1 4, at 14 (stating,
If "nurture" was the rallying cry of the 1 960s, when changing the social
environment through Great Society-style programs seemed the surest way to
better lives, the pendulum has swung back i n the last 25 years toward "nature"
and the belief that genes are decisive components of what and who we are and
how we behave.
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Recent discoveries

linking genes to complex behavior such as depression34 and nurturing35
are reinforcing this belief. 36
Generally, when a gene or biological marker linked to a physical
or mental condition is discovered, the basic scientific capability to test
for the presence of that marker is a given. Thousands of such linkages
have been made subsequent to the commencement of the HGP,37 and
at a rate accelerating with the passage of time, to the point that
linkages are being identified almost on a weekly (if not daily) basis.38
Now that a critical mass of the human genome map has been

33. Erik Parens, Taking Behavioral Genetics Seriously, HASTINGS CENTER REP.,
July-Aug. 1996, at 1 3 (citing U.S. CONGRESS, OFFICE OF TEcHNOLOGY ASSESSMENT,
MENTAL DISORDERS AND GENETICS: BRIDGING THE GAP BElWEEN REsEARCH AND S OCIETY
(1994)) (although emphasizing the danger of straying away from appreciation for
environmental factors, recognizing that "much research suggests that genetics may help to
explain a partial but significant component of some fonns of, for example, schizophrenia,
bipolar disorder, and depression"); see also Richard A. Knox, Study of Mice Links a Gene to
Nurturing, BOSTON GLOBE, July 26, 1996, at A l (reporting that the objective of scientists
working in the field is to identify "molecular handle[s] to try to unravel some of the
neuronal circuitry involved in mediating behavior"); Rick Weiss, Discovery May be Brewing
in Search for Genetic Link to Alcoholism, WASH. POST, July 1 , 1996, at A3 (reporting new
breakthroughs in discovering genes relating to alcoholism); Anxiety Linked to Genetics, N.Y.
TIMES NEWS SERVICE, Nov. 29, 1 996 (reporting that "[s]cientists have discovered a modest
but measurable link between anxiety-related behavior and the gene that controls the brain's
ability to use serotonin"); Parens, supra, at 1 3- 1 8 ("As information about the genetic
component of human behavior increases, so, of course, does the number of opportunities for
its abuse.").
34. During the spring of 1996, scientists in Edinburgh, Scotland identified a gene
linked to depression that could lead to much more effective treatment. See Nigel Hawkes,
Scientists Identify Gene Linked to Depression; Discovery Prompts Study of Families, TIMES
LoNDON, Mar. 1 5 , 1996, available in Westlaw, 1996 WL 648 1 302.

35. See Knox, supra note 33, at Al (reporting that a team consisting of researchers
from Harvard Medical School and Tufts University, through manipulation of a gene called
fosB, have created a strain of mice that seem normal in every way except that they ignore
their newborn offspring).
36. At the present time, "research suggests that genetics may help to explain a partial
but significant component of some forms of, for example, schizophrenia, bipolar disorder,
and depression." Parens, supra note 33, at 1 3 .
37. For listings of such discoveries over the past several years, see Malinowski,
supra note 2 1 , at 1443-44. See also Saltus, Sounding the Alann, supra note 1 4, at 1 4 ("In
recent years, researchers have claimed that homosexuality, schizophrenia, alcoholism, risk
taking, violent behavior, and even basic temperamental traits like shyness are governed by
genetic variations.").
38. Recent genetic-linkage discoveries have been made both for the tendency to
nurture and the tendency to have strokes. See Peter J. Howe, Gains Reported Toward
Identifying Stroke-Related Genes, BOSTON GLOBE, July 30, 1 996, at A6 (reporting on Nature
Genetics article and stating that the discovery may create novel opportunities for diagnosis
of potential strokes); Knox, supra note 33, at A l (noting a gene, FosB, which is linked to
nurturing).
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completed,39 the pace of such discoveries is likely to increase
exponentially. In fact, although the impact of environmental factors on
the function of genes and physical and mental health must not be

underestimated, an age governed by molecular medicine, i n which a

patient's actual and future health can be diagnosed primarily through
deciphering genes, is a conceivable possibility.40

Biotech companies are using such discoveries to develop and
commercialize predictive screening tests for an abundance of health
conditions in addition to breast and ovarian cancer. Recent discoveries
include genetic links to Alzheimer's,41 bladder cancer,42 cervical
39.
See Human Physical Map, supra note 2 1 , at 5 ('The new map, which contains
more than 1 5,000 STS DNA markers spaced an average of 1 99 kb apart, covers almost 95%
of the entire genome . . . . Although originally slated for 1998, map completion by
Whitehead-MIT and other groups is expected by the end of this year.").
40. See Annas, supra note 14, at 20 ("Molecular medicine, based on deciphering the
genes of a patient i nstead of diagnosing the patient based on signs and symptoms, is said to
be just around the comer."); Bio '96, supra note 30, at 5 C"lnhe study of genetic variation
will enable the identification of patient sub-populations that may respond particularly well
or poorly to currently-marketed drugs."); id. at 9 ("Drugs developed using genomics
technology can be expected to offer advantages i n specificity that will result in therapeutics
with fewer side effects."); id. at 16 ("The ability to eliminate ineffective therapies due to
individual therapeutic response will be another way in which genomics will contribute to the
reduction in healthcare costs. . . . Genomic diagnosis will provide physicians with a sound
basis upon which to prescribe appropriate therapies.").
41.
See Eric M . Reiman et al., Preclinical Evidence of Alzheimer's Disease in
Persons Homozygous for the e4 Allele for Apolipoprotein E, 334 NEW ENG. J. MED. 752,
752 ( 1 996) (stating that variants of the apolipoprotein E allele appear to account for most
cases of late-onset Alzheimer's disease, and that persons with two copies of one variation
appear to have an especially high risk of dementia); Stephenson, supra note 1 5, at 1 66 1 -62
("One such test detects APOE-4 (also frequently denoted as APOE4), a form of the gene
that directs the production of cholesterol-carrying protein called apolipoprotein E.
Individuals who possess the APOE-4 gene have an elevated risk for developing Alzheimer's
disease, particularly those who have two copies of the allele."). Athena Diagnostics, a
biotech company located in Worcester, Massachusetts, developed the first specific laboratory
test for Alzheimer's disease, a disorder which affects four million Americans. See Richard
Saltus, Worcester Firm Touts First Lab Tests for A lzheimer 's, BOSTON GLOBE, Mar. 27,
1996; at 47. According to Athena officials, the company is making the test available as a
service under an investigatory protocol, meaning that, like OncorMed and Myriad, Athena
will perform the test in-house for samples (blood and cerebrospinal fluid, obtained by a
spinal tap) submitted by providers for a fee of $ 1 95. See id. ; see also Jerry E. Bishop, Test
Improves Detection ofA lzheimer's, WALL ST. J., July 1 2, 1 996, at B3 (discussing genetic test
that may improve the accuracy of diagnosing Alzheimer's disease). The clinical utility of
the test, as defined by Athena, is that it may be used to distinguish Alzheimer's from other
forms of dementia, some of which can be treated. See id. ; see also Saltus, Early
Alzheimer's, supra note 1 4, at 39 ("With the discovery last week of a gene that causes an
aggressive inherited form of Alzheimer's disease, it will soon be possible to offer a test to
people in at-risk families, where, on average, half the children of any affected parent will get
the gene."); Saltus, supra, at 47.
42. See Rosenberg, supra note 15, at 80. In comparison with the traditional bladder
test now on the market, this test (1) is performed on a simple urine sample, thereby avoiding
·
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caricer,43 colon cancer,44 obesity,45 prostate cancer,46 and tumor growth
associated with a spectrum of common cancers.47

Researchers are

even developing an "Ides of March" genetic test to serve

as

a crude

indicator of a person's life span.48 By conservative estimates, "some

50,000 gene markers will be developed as a result of molecular
biology and translated in not easy-to-employ biochemical assays,
genetic tests, new drugs, and genetic therapies."49
Unfortunately, the discovery of genetic alterations linked to many
health conditions comes well before those discoveries can be turned
into therapeutics

and reliable predictors of disease

in

specific

the painful cystoscopy-the insertion of a fiber-optic rod through the urethra and into the
bladder-which is required for the current test; (2) costs $50 rather than $300; and (3) is
much more accurate and, therefore, can detect the earliest signs of cancer. See id.
43. Matritech , a biotech company located in Worcester, Massachusetts, i s working
on a test for cervical cancer that would be an improvement to the Pap smear procedure. See
Ttna Cassidy, Matritech Says It Will Begin Trials on a More Accurate Colon Cancer Test,
BOSTON GLOBE, Apr. 20, 1996, at 25.
44. Trials are being conducted on a colon cancer test that allegedly is more than
twice as sensitive (70% compared to 33%) as the current leading diagnostic test for early
stage colorectal cancer. See Cassidy, supra note 43, at 25.
45. A gene-signaling system has been discovered through the independent work of
two biotech companies, Amgen and Millennium Phannaceuticals. Amgen discovered a
gene that makes leptin, an enzyme linked to obesity in rats; Millennium has identified a
genetic receptor for leptin. See Richard Saltus, Piece of Obesity Puzzle Found in
Cambridge: Drug Researchers Locate Key Receptor, BOSTON GLOBE, Dec. 29, 1 995, at I .
The work of these companies has pushed their competitors, and "researchers have now
found five genes involved in regulating food intake and weight." Id.
46. At least one biotech company is working on an improved test for prostate cancer.
See Cassidy, supra note 43, at 25.
47. Through research in an extended family with a high incidence of kidney cancer,
scientists have discovered a gene known as FHIT. See Richard Saltus, Gene Eyed in Many
Cancers, BosroN GLOBE, Feb. 25, 1996, at 9. This gene is believed to make a protein that
helps to keep the body's cells dividing in an orderly, regulated way. Control over cell
growth is lost when the gene is damaged by environmental pollutants, diet, or other factors.
See id. The FHIT gene may prove to be an invaluable lead for understanding how normal
cells become malignant in a variety of common cancers, including those of the esophagus,
stomach, and colon; and possibly including ovarian, cervical, lung, and bone cancers. See
id.; see also Cancer Research Yields 'Time Bomb' for Tumors, BOSTON GLOBE, Apr. 24,
1 996, at 8 ("Cancer researchers have engineered what they call the first genetic time bomb,
set to go off inside tumor cells when they blow their cover by producing telltale proteins.").
48. Research involving APOE variations indicates linkages to general susceptibility
to diseases of aging. See Jerry E. Bishop, A Gene Gives a Hint of How Long a Person
Might Hope to Live, WALL ST. J., Oct. 19, 1995, at A l ("If some scientists are correct, the
test may be the forerunner of what could be called the Ides of March tests, a panel of blood
tests that might predict, as the onlooker foretold for Julius Caesar, when one might die-but
not how."). The researchers responsible for this discovery admit that APOE is, for any one
individual, a "sloppy indicator." Id. Nevertheless, there is the possibility that such a test
could be used by insurers who engage in grouping. See infra note 1 1 3 and accompanying
text.
49. Boyle, supra note 13, supp. at S2.
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Although the availability of therapeutics to offset

predispositions

will

make

genetic

testing

much

less

controversial, that time is years away for most conditions.51 Similarly,
for families other than those with high occurrence of disease and well

documented pedigrees, determining predictability is a l aborious,

subject-intensive process that may take more than a decade to
complete. 52
50. See Mclean, supra note 19, at 1 1 6. As recognized by the U.K. House of
Commons Science and Technology Committee, "(w]hile a knowledge of how the gene
works, when established, should, in time, lead to new drug development, through rational
drug design, at present it can take 1 5 years to develop and gain approval for a new
pharmaceutical product." Id. (citing 1 SCIENCE AND TEcHNOLOGY COMMrITEE, HOUSE OF
COMMONS, HUMAN GENETICS: THE SCIENCE AND ITS CONSEQUENCES xxxvi ( l 995)); see also
Boyle, supra note 1 3, supp. at S2 (
People will be tested for conditions that might never fully express themselves as a
disease, or only express themselves in a mild form. For example, nearly 20
percent of persons who carry the gene for fragile-X, the most common form of
inherited mental retardation (affecting one in every 2,500 live births), will never
express any fonn of mental retardation. Yet if parents knew their children's
genetic status, they might treat unaffected children as if they were mentally
disabled.
); Saltus, Sounding the Alarm, supra note 1 4, at 1 4 ("But today, 1 5 or 20 years after the
first predictions that gene technology would greatly improve health, scientists have been
far more successful in finding defective genes than in fixing or replacing them."); infra
Part 11.C. Examples o f the practical effect of this gap between the discovery of a genetic
linkage to a health condition and treatment derived from that discovery are plentiful:
Genetic researchers, in their quest to understand a terrifying disease, have
once again delivered the means to predict a person's future, but not yet to alter it.
With the discovery last week of a gene that causes an aggressive inherited
form of Alzheimer's disease, it will soon be possible to offer a test to people in at
risk families, where, on average, half the children of any affected parent will get
the gene.
Recently developed gene tests for Huntington's disease and for inherited
predispositions to breast cancer and other cancers have raised this issue for an
increasing number of families . . . .
The test for familial, early-onset Alzheimer's might be relevant for 500,000
or more Americans who are at risk for having the gene . . . .
Unlike the more common type of Alzheimer's disease, which affects an
estimated 4 million people in the United States and generally appears in the late
60s, the 70s or 80s, the early-onset form can show up even among people in their
30s.
Saltus, Early Alzheimer's, supra note 14, at 39.
5 1 . See Malinowski & O' Rourke, supra note 20, at 174-77 (discussing status of
gene therapy). Dr. Ruth Hubbard and Jonathan Beckwith recognize that, even for conditions
such as Huntington's and multiple sclerosis, which are known to be caused by a single
genetic variation that is responsible for the failure of the cell to make a single protein,
science has not been successful in turning genetic discoveries into treatments. Multifactorial
conditions multiply this complexity. See Saltus, Sounding the Alarm, supra note 1 4, at 14.
52. See ELSI TASK FORCE ON GENETIC TEsTING, supra note 1; infra Part II. C.
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Nevertheless, a deluge of fully commercialized genetic testing
services and kits is well within sight.53 Even by conservative
estimates,54 expectations are that the DNA testing market ( 1) for
neoplastic (tissue growth) diseases will reach $340 million in 1 998�
(2) for infectious diseases will exceed $300 million by 1 998; and
(3) for genetic diseases will exceed $65 million by 1 998.55 This
market could experience a several-fold increase with the availability of
probes for polygenic (multifactorial) diseases.56 To build these
markets, the developers and manufacturers of genetic tests need patient
data both ( 1) to establish clinical predictability, and (2) to sequence
and better understand the most fundamental intricacies of specific
genes. The latter will enhance the predictive capabilities of resulting
tests and perhaps lead to other products, including therapeutics and
even gene therapies. The commercial possibilities, including patient
care possibilities, create a powerful incentive to make research-stage
genetic tests available to the public.
Many developers and manufacturers of genetic tests now are
making investigatory, predictive genetic testing available to the public.
The commercial interests developing genetic technologies are nearly as diverse
53.
and plentiful as the u nderlying discoveries:
Major diagnostic companies (Abbots, Boehringer Mannheim, Miles, B axter,
Beckman, Becton Dickenson, Ciba-Geigy, Johnson & Johnson, Eastman Kodak,
Bio Rad, etc.) are developing a variety of technologies by inhouse invention and
through alliances and acquisitions. . . .
In addition to the established major commercial players, hundreds o f start
up companies have been formed to exploit various niche diagnostic capabilities
generated in academic research laboratories.
Silverman, supra note 1 5, supp. at SIS; see id. supp. at S 1 7 ("Regardless of the numerous
unknowns in the development of DNA diagnostics, the potential demand for these services
will continue to grow. Attractive financial rewards assure that DNA diagnostics will become
a significant commercial enterprise.").
These estimates, generated during the Spring/Summer of 1995, are conservative
54.
because they predate ( 1 ) the precedent for commercialization of genetic testing services
without FDA oversight now being set by OncorMed and Myriad, (2) the advancement of
pending FDA reforms to streamline the FDA review process for biotechnology products,
(3) growth in consumer demand for genetic tests due to both increased media coverage and
marketing efforts o n the part of biotechnology companies, and (4) a globalization of
biotechnology and expansion of worldwide markets. See Malinowski, supra note 29, at
123-33.
55. See Silverman, supra note 1 5, supp. at S l6 ; see also BLATT, s upra note 2 1
(noting that the revenues presently being generated are from biogenetic analysis for prenatal
testing of chromosome conditions). But see Vicki Glaser, Myriad Pulls /PO from
Inhospitable Market, 1 5 NATURE BIOTECHNOLOGY 14 (1 997) (reporting that Myriad pulled
its follow-on public offering, and speculating that lack of investor interest may have been
attributable to below lower-than-anticipated sales figures for its BRCAl and BRCA2 tests).
56. See Silverman, supra note 15, supp. at S 1 6.
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Although IVF, Myriad, and OncorMed are commercializing their tests,
other companies and research laboratories are making research-stage
genetic tests available in a more discreet manner.

In 1 994, the

Committee on Assessing Genetic Risks assembled by the Institutes of
Medicine documented pervasive informal genetic testing by research

laboratories,57 and the ELSI Task Force on Genetic Testing has reached
similar

conclusions

regarding

both

research

and

commercial

laboratories that report results to patients. 58
The emergence of predictive genetic tests with implications for
broad segments of the population, such as the APOE-4 (Alzheimer's)
test, is raising c oncern among public health officials and providers

57. See generally ASSESSING GENETIC RISKS, supra note 15.
See ELSI TASK FORCE ON GENETIC TESTING, supra note 1 , at 2-4; see also
58.
Richard Saltus, Survey of Labs New Tests Concerns Genetics Specialists, BOSTON GLOBE,
Oct. 28, 1995, at 14 ("Commercial and academic labs are moving so quickly to offer gene
tests predicting future health risks that some are bypassing regulatory and ethical quality
controls, specialists in genetics say."). According to a survey conducted by Dr. Neil
Holtzman's office at John Hopkins University:
Although any lab perfonning clinical genetic tests must register with HCFA under
the Clinical Laboratory Improvement Amendments of 1 988 (CLIA) [ 42 C.F.R.
§ 493. 1 ( 1 996) ] , the study found that about 10% of responding labs failed to do
so. Several labs (8%) did not use external review (including proficiency testing)
to help assure quality. Many labs intended to market genetic tests to non
geneticist providers, even though most respondents were of the opinion that such
providers knew little about these tests. Responding labs also tended to view the
current regulatory scheme as inappropriate.
Dr. Stephen Hilgartner described the highlights of his follow-up interviews
of selected respondents to Holtzman's survey. He found a variety of commercial
genetic testing activity, ranging from large companies seeking to offer
comprehensive test services to smaller firms developing specific tests for
particular market niches.
Meeting Minutes, supra note 1 , at 1 -2. Other studies, including a study undertaken by the
Genetic Screening Study Group in the spring of 1 992, have reached similar conclusions
about the pervasiveness of genetic discrimination. See, e.g. , Carol I . Barash & Joseph S.
Alper, A Study on Genetic Discrimination, 8 GENETIC RESOURCE 43, 43 ( 1 994) ('The study
found that a wide variety of social institutions engage in genetic discrimination. People
reported discriminatory practices by insurance companies (life, health, disability, and
mortgage), in employment (hiring and promotion), by the military, schools and universitie s,
adoption agencies, and health care providers."); Lisa N. Geller et al., Individual, Family, and
Societal Dimensions of Genetic Discrimination: A Case Study Analysis, 2 SCIENCE &
ENGINEERING Ennes 7 1 , 75 ( 1 996) (concluding that, of the 9 1 7 questionnaire respondents,
455 indicated instances of genetic information discrimination). For anecdotes of genetic
information discrimination, see generally id.
In contrast with the United States's incremental approach to protection against genetic
discrimination by insurers, see, e.g., Health Care Portability and Accountability Act, Pub. L.
No. 104- 1 9 1 , 1 1 0 Stat. 1 936 ( 1 996), European countries are considering an outright ban on
the use of genetic testing information by insurance in the absence of comprehensive self
regulation. See Insurers Risk Ban, supra note 8.
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who understand the limitations of this technology and are sensitive to
its potential impact on the lives of patients and their families. 59
However, with

such understanding

comes appreciation

for the

difficulty of introducing a satisfactory regulatory response to the
multitude

of
0
6
cornmerce.

B.

genetic

technologies

approaching

and

entering

Existing Regulations
Predictive genetic testing services, perfonned in-house by the

tests' developers and manufacturers, are square pegs in the rubric of
federal regulation.

The FDA regulates the production of reagents,

probes, or test kits manufactured for use by others in laboratories and,
therefore, genetic tests manufactured and sold for others to perform.61
59. See Stephenson, supra note 15, at 1661 -62 ("Concerns about genetic testing
have escalated with the recent emergence of tests that may have implications for large
segments of the population.").
60. See Boyle, supra note 13, supp. at S2 ("Genetic technologies are by no means a
homogenous lot; they have varied medical and social effects, and are intended for diverse
populations with distinct severity of illnesses, both actual and potential.").
61.
Such tests constitute "diagnostic kits" subject to regulation under the Medical
Device Amendments of 1 976 (MDA), 2 1 U.S.C. § 360k(a) (1 994), and the FDA has
exercised some considerable discretion in the area of home testing. See, e.g., Daniel J.
Murphy, FDA Ridiculed for B locking At-Home Drug Testing, INVESTORS Bus. DAILY, Oct.
1, 1994, at A4 (reporting FDA's prohibition of the sale of drug-testing kits to parents).
Pursuant to the MDA, the FDA regulates medical devices in the context of a classification
scheme that distinguishes among devices based upon the concerns they raise about safety
and effectiveness. The FDA i s required to classify each medical device intended for human
use into Class I, II, or III. See 21 U.S.C. § 360(C)(a) ( l ). Class I devices pose no
unreasonable health risk (general controls that ensure, among other things, safe labeling and
that the produce is safe when used as directed), while Class II devices carry special controls,
such as performance standards necessary to ensure safety and effectiveness. See id. Class
III devices are those represented to be life-sustaining or life-supporting and those presenting
potentially unreasonable risk of illness or injury, and they require premarket approval to
assure safety and effectiveness. The premarket-approval process requires submission of a
premarket-approval application (PMA), which the FDA must review before it authorizes
marketing. However, there is an exception for diagnostics that are the substantial equivalent
of others already approved. See id. § 360k. Still, additional review is required for any
change in a device's design. See 21 C.F.R. § 807.8 l (a)(3)(i) ( 1996). There also are
regulations for device construction and manufacture, known as good manufacturing practice
(GMP) requirements, that establish detailed requirements for all stages of the manufacturing
process. To monitor compliance, the MDA require factory inspections at least once every
two years for Class III products and post-marketing reporting. See 2 1 U.S.C. § 360(h); 2 1
C.F.R. § 803 . 1-.58.
Because of their complexity, when genetics-based diagnostics are subjected to review,
they generally are labeled Class III devices. See Malinowski & O'Rourke, supra note 20, at
206. Before developers make these products available to the public, they must apply for an
Investigational Device Exemption (IDE), which is analogous to the Investigational New
Drug Application (IND) required for new drugs. See id. Device manufacturers can
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However, manufacturers and private laboratories may avoid the
routine FDA review process

for

diagnostics

and comply

with

applicable federal regulations by manufacturing and using their own
reagents in-house and selling testing services through primary care
physicians. 62 Such reagents are called "home brews" because they are
manufactured and used within the same facility, and a number of such
tests are being developed and made available to the public. 63
Home brews may be marketed

as

e stablished products or, to limit

product liability w here clinical efficacy is not yet established, labeled
investigatory.64

Although the developers of investigatory tests are

circumvent the IDE requirement by establishing that there is an independent means by
which to confirm the validity of their test.
This may be accomplished ( 1 ) through the 5 IO(k) clearance process, by establishing
that the product is the substantial equivalence of a previously marketed product or (2) by
obtaining premarket approval (PMA), which requires a full documentation of safety and
effectiveness and an advisory conunittee review. However, the general absence of approved
genetic diagnostics on the market makes these exceptions unlikely for predictive genetic
tests. In fact, the manufacturers of such kits should expect added requirements, such as a
requirement that counseling accompany test results. The FDA imposed such a requirement
when approving a home AIDS test in May of 1 996. See Weiss, supra note 2, at A I .
62. See Medical Devices, Classification/Reclassification; Restricted Devices;
Analyte Specific Reagents, 6 1 Fed. Reg. 1 0,484 ( 1 996) (to be codified at 21 C.F.R. pts. 809
& 864) (proposed Mar. 1 4, 1 996) ("FDA currently regulates the safety and effectiveness of
diagnostic tests that are traditionally manufactured and commercially marketed as finished
products. However, in-house developed tests have not been actively regulated by the
Agency and the ingredients used in them generally are not produced under FDA assured
manufacturing quality control."); see also OncorMed BRCA J Testing Service, supra note 8,
at 7 (reporting on the FDA statement that it has the authority to regulate but not the needed
resources and expertise to actually do so).
63.
See FDA Needs to Regulate Genetic "Home Brews, " 1 4 NATURE
BIOTECHNOLOGY 1 627 (1996) [hereinafter FDA Needs to Regulate]; Stephenson, supra note
15, at 1 662. The ELSI Task Force, in its investigation of genetic testing practices, found
that "at least some companies appear to be circumventing this process by offering genetic
testing services themselves-using the very probes and other products that would be subject
to FDA regulation i f these products were sold to others as part of a kit for the purpose of
genetic testing." Stephenson, supra note 15, at 1 662. The distinction is that, if a developer
performs an assay in its own laboratory, that laboratory may be designated a reference
laboratory, and uncertainty regarding how reliably a third party will perform the test is
removed. See id. ; see also ELSI TASK FORCE ON GENETIC TESTING, supra note 1 , at 1 2
("Often [laboratories developing new tests] use home brews as well as reagents purchased
'for research use only' in clinical tests, although neither have been approved for clinical
use."). Still, as discussed in Part II.C., the results of predictive genetic tests are prone to
misinterpretation by both providers and patients and, therefore, may be misused clinically.
64. As discussed above, a BRCA test is being marketed without self-restraint by
IVF, while OncorMed i s limiting its potential liability by restricting access to its testing
service. See Weiss, supra note 2, at A l . There are two main labeling options for products
without established clinical efficacy:
For research use only and not for use in diagnostic procedures. The
manufacturers of such tests are not permitted to make claims regarding the test
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allowed to charge consumers only enough to recapture costs,
commercialization of these tests enables them to generate a revenue
stream, gather needed patient data, and build standard-care acceptance
of their technologies. Standard-care acceptance means enhanced
acceptability among physicians and the public, limits on product
liability, and perhaps insurance coverage.65 Also, the costs of
investigatory tests may be considerable, depending upon the stated
research objective.66
Private laboratories performing genetic testing services also are
essentially immune to federal laboratory-quality assurances imposed
by the Health Care Finance Administration (HCFA) through the
Clinical Laboratory Improvement Amendments (CLIA).67 Under
beyond statements that identify and explain its research purpose, and such tests
are not supposed to be used clinically (the results are not supposed to be reported
to subjects); and

For investigational use only. Infonned consent must be obtained before
the test is perfonned, and those tested must be apprised of the facts that
performance characteri stics are not yet established and data is being collected (the
test is being offered) for that purpose.

See id. ; see also BLATT, supra note 2 1 . However, off-label uses of tests, where a test
approved by the FDA for one purpose is used for another, are commonplace. See ELS I
TASK FORCE ON GENETIC TE.sTING, supra note I , at 1 1 ('The Task Force opposes off label
use of genetic tests without independent validation and is exploring new policies to deal
with this problem."). A prime example of widespread, off-label testing is the use of the
maternal serum alphafetoprotein (MSAFP) screening for the presence of Down 's syndrome.
Although the test was initially designed to screen for the presence of neural tube disorders in
the unborn, researchers and labs noticed a correlation between low MSAFP results and

Down's syndrome, thereby creating a new application for its use. See BLATT, supra note 2 1 .
The shortcomings o f this labeling system include the following:
( 1 ) despite these
requirements, it is not uncommon for laboratories to offer testing labeled "for research
purposes only" to patients and report the results to them; (2) off-label uses are common;
(3) the FDA, although aware of compliance problems in laboratory genetic medicine, lacks
the resources to bring laboratories into compliance and is hesitant about removing products
from the marketplace out of fear of causing disruption and arousing public and political
opposition; (4) compounding this problem, the FDA is presently in a state of flux and there

is a moratorium on new regulations; and (5) although laboratories are required to be aware
of the regulatory status of the products they use and are expected to use them appropriately,
consumers and medical practitioners are frequently unaware of the regulatory status of the
laboratory tests being performed. See id.
See The First BRCA J Test Hits the Market; A re Oncologists, Patients Ready?,
65.
CANCER LETIER, Jan. 26, 1 996, at 1, 1-5 [hereinafter Firs t BRCAI Tes t Hits the Market].
66.

For example, if the stated objective of providing a genetic testing service is gene

sequencing, the cost may increase tenfold.
67.

See 42 C.F.R

See id. at 2.

§ 493. l (1996); Proposed Recommendations of the Task Force on

Genetic Testing, Meeting Notice, 62 Fed. Reg. 4545 (Nat'! Insts. Health 1997) ("Many tests
currently on the market have not been systematically validated nor subject to external
review. . . .

The Task Force is concerned about the lack of Federal law or regulation

covering genetic tests . . . . "). As enacted, CLIA prescribed general regulations for medical
laboratories, but it applied only to (I) laboratories involved in testing specimens originating
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CLIA, a laboratory must demonstrate analytical validity of its tests and
their components, but there is no clinical validity requirement.68 In
other words, the CLIA validity requirement is satisfied when a genetic
test to detennine the presence of a specific genetic alteration does so
accurately, even though the test may offer no clinical predictability.69
There is no required express showing that the alteration tested for has
any bearing on the subject's health. The only CLIA patient-care
safeguard on clinical quality is the requirement that the proposed
clinical protocol receive institutional review board (IRB) approval
when an investigatory test enters the human-trial phase.70 Academic
laboratories are required to report to their standing IRBs, but "[t]he
situation with respect to IRBs is murkier for biotechnology companies
and commercial laboratories. They also may consult an IRB of an
academic institution with whom they have ties, or they may form their
own IRB-a practice that has the potential for a conflict of interest."71
(2) laboratories processing specimens from individuals on Medicare and
CUA 88 set forth revised regulations that more unifonnly govern laboratory

out-of-state and
Medicaid.

testing involving human samples by establi shing general laboratory standards for personnel,

See generally Summary of
(research memorandum prepared by

proficiency testing, quality control, and quality assurance.
United States Product Liability Law (May

24, 1 996)

Kirkpatrick & Lockhart LLP, Boston, MA) (on file with authors).

68.

See ELSI TASK FORCE ON GENETIC TESTING, supra note 1, at 14-15.

69.

The ELSI Task Force's Subcommittee on Laboratory Quality's "main theme [is]

that genetic testing is unique and better assurance of its quality is needed."
Minutes,

supra

note

Meeting

1, at 5; see also id. at 6- 7, 8 (stating that even the "high complexity"

category under CUA does not adequately address the unique nature of genetic tests). The
failure of CLIA to address the impact of genetic tests on patient care is addressed in Boyle,
note 13, supp. at S7 ("[T]he FDA's standards would consider a test to screen infants

supra

for a genetic anomaly 'effective' if it yields an accurate diagnosis, even if no treatment exists
. . . . Accepting such narrow judgments of effectiveness may . . . create substantial harm by
providing

information

that

can

cause

anxiety,

stigmatize,

and

promote

invidious

discrimination.").

70.

See

Stephenson,

supra

15,

note

at

1 662.

An organization planning clinical

validation studies is supposed to file its protocol with a properly constituted IRB competent
to review clinical validation protocols.

Net Too Thin,

See

Joseph Palca,

HASTINGS CENTER REP., May-June

1 996,

at

Institutional Review Boards: A
4. This requirement reflects the

original purpose of IRBs, to protect the autonomy of human subjects participating in
research.

See id.

For discussion of the increased dependence on IRBs to resolve genetics

issues due to proposed disbandment of the Recombinant DNA Advisory Committee (RAC),
see infra note

71.

257

and accompanying text.

Stephenson,

supra note 15, at 1 662; see infra

notes

245-247

and accompanying

text (proposing national IRB standards); Proposed Recommendations of the Task Force on
Genetic Testing, Meetin g Notice,

62

Fed. Reg. at

4544

("The Task Force is concerned that

the high workload of IRBs, their variability i n community representation, in evaluating
protocols, and in expertise germane to the review of genetic tests, as well as the conflicts of
interest that can arise i n local review, impairs current review of genetic tests that warrant
stringent scrutiny.").

See generally

PHARMACEUTICAL INDUSTRY :

JOHN

ABRAHAM,

SCIENCE,

Pouncs

AND THE
( 1995)

CONTROVERSY AND B IAS IN DRUG REGULATION
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The general lack of regulatory quality control on genetic tests,
which raises questions about their fundamental reliability,72 is
exacerbated by the fact that very few specific guidelines for these tests
have been formally developed an d introduced by the medical
profession.73 "[L]ack of consensus about what type of screening
should be offered means that there is also no clear guidance for state
policy makers adopting mandatory screening plans" even on issues
such as the testing of fetuses for BRCA 1 and BRCA2 variations.74
Also, reliance on state regulation to monitor (in the ongoing manner
necessitated by the research nature of the technology) the quality of
genetic testing services is misplaced for, there too, "the field of
laboratory licensure and monitoring remains in a state of flux."75
(exploring the capture theory in the context of IRBs, and suggesting that those from the
medical profession who serve on IRBs reap tremendous financial rewards and, due to
revolving-door staffing of IRBs, may even receive R&D funding from the manufacturer
whose products they are reviewing); ELSI TASK FORCE ON GENETIC TEsTING, s upra note 1 ,
at 1 1 ("The Task Force recognizes that IRBs differ widely in their approach to clinical
protocols and in their policies regarding what constitutes research in their purview.");
Advisory Committee on Human Radiation Experiments, Research Ethics and the Medical
Profession, 276 JAMA 403, 403-09 (1996) (callin g for alterations in the IRB component of
the federal system to protect human subjects).
72. See Medical Devices; Classification/Reclassification; Restricted Devices;
Analyte Specific Reagents , 61 Fed. Reg. 10,484 ( 1 996) (to be codified at 2 1 C.F.R. pts. 809
& 864) (proposed Mar. 1 4 , 1 996); FDA Needs to Regulate, " supra note 63, at 1 627 (
As a resul t , neither patients nor practitioners have assurance that all ingredients in
the laboratory developed tests are of high quality and capable of producing
consistent results.
[The] FDA is concerned that the present situation with respect to in-house
developed tests, in which these ingredients are essentially unregulated and
therefore of unpredictable quality, may create a risk to the public health.

); see also The Hazards ofGenetic Testing, supra note 24, at 6 (reporting on Dr. Holtzman's
survey).
But see infra notes 245-246 and accompanying text (addressing how
73 .
professional opposition to BRCA testing outside research centers is resulting in initiatives to
develop such guidelines).
Andrews, supra note 22, at 99 1 .
74.
Bl.Arr, s upra note 2 1 (
75 .
While almost every state public health department has a laboratory licensing
bureau that is supposed to monitor the quality of laboratory services, many do not
have standards designed specifically for genetic laboratory studies (i.e., DNA
analysis) and performance requirements are not always enforced.
Some
laboratories have gone for years without an on-site visit.
). An exception is the State of New York , which has some meaningful laboratory quality
_ enforceable and has regulatory language addressing the use of
.
that 1s
authonty
investigational genetic testing. See Meeting Minutes, supra note 1 , at 7 (
New York cannot impose "cease and desist" orders on labs failing to meet
voluntary PT [proficiency testing] standards , and for this reason the state does not
recognize the voluntary lab standards promulgated by the College of American
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Perhaps most importantly, circumvention of the FDA review
process also may avoid the FDA's tight control on advertising.76
Advertising carte blanche is a troubling proposition in the context of
providers

dealing

directly

with

b iotechnology

companies

and

Pathologists [CAP]. However, New York i s empowered to revoke a lab's license
for ignoring the reconunendations of lab surveyors.

); see also Proposed Reconunendations of the Task Force on Genetic Testing, Meeting
Notice, 62 Fed. Reg. at 4545 (discussing how New York requires certification of all
laboratories performing clinical genetic tests on state residents).

76.

According to some accounts, FDA officials have all the power and discretion of

tax collectors----discretion enhanced by the ambiguity of the regulations they enforce. See,

e.g., James G. Dickinson, W ill Anybody Sue FDA?, MED. MARKETING & MEDIA, Oct. 1 993,
at 1 00, 102 ('The Food, Drug and Cosmetic Act's failure to address pharmaceutical
marketing activities that are neither 'advertisements' nor 'labeling' created the gray zone in
which both industry and FDA take liberties.

Congress simply failed to foresee the

innovations that modem communication technologies [advertising] could spawn.").

As

explained by Dr. Dickinson:
Adverti sing alone is defined as "commercial speech" and is thus subject to
less First Amendment protection than labeling or non-commercial speech.

But

FDA has been able to tie advertising's statutory dependence on the content of
approved labeling to a broad array of "labeling" materials in such a way that
companies "have no freedom of speech rights when it comes to advertising
prescription drugs, compared to the way in which those rights are conunonly
understood and i nterpreted by the courts for other industries."

Id. (quoting Richard T. Kaplar, Vice President of the Washington-based Media Institute).
Dr. Dickinson alleges that, "[b]ecause FDA has excessive coercive power in its ability to
approve an advertiser's products for market, and Congress has shown no interest in
balancing FDA' s First Amendment incursions, the regulation of drug advertising and

promotion should be handed over to the Federal Trade Conunission." Id. at 103-04. Dr.
Dickinson, citing other authority, contends that the FDA's definition of "deception" is '"the

basis for the mischief created by the FDA' s regulation of advertising'" because the FDA
declares ads or promotional materials "deceptive" unless they contain a "fair balance." Id. at

104 (quoting Kaplar). In practice, according to Dr. Dickinson, '"any message promoting
some pharmaceutical

must also present virtually all negative information about the

product. "' Id. (quoting Kaplar).

Citing a book by Paul H. Rubin, an Emory University

economics professor, Dickinson sets forth the following proposals for reform:
FDA should ( l ) cancel all recent initiatives restricting promotion of off-label uses;

(2) allow manufacturers to advertise any reasonable claim for which reliable
scientific evidence exists; (3) abolish the "brief sununary" requirement for
consumer adverti sing; and (4) allow unrestricted advertising of drugs, subject only
to regulation for "falsity" but not for "deception" as currently defined.

Id.

Nevertheless, the hyping of health-care product features by their manufacturers is a

pervasive problem:
So endemic is the practice of hyping product features the facts clearly don't
support that FDA deputy commissioner Mary K. Pendergast, speaking in October

1994 before the House Subcornmittee on Regulation, Business Opportunities, and
Technology,

was

moved

to

uncharacteri stically

straightforward

language.

"Promotion of unapproved uses by company sales representatives," she stated, "is
a major problem."
Greg Critser, Oh, How Happy We Will Be, HARPER'S MAG., June 1996, at 39, 47.
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institutional laboratories to run extraordinarily novel tests on patient
samples. These are tests that, without predictability defined through
scientifically

reliable

clinical

data,

are

highly

subject

to

misinterpretation. The dependence of both providers and their patients
on the developers of genetic tests for information-information test
developers are compiling on an ongoing basis from patient data
could not be greater. Ironically, because test developers are the entities
with the most information about their evolving technology, advertising
restrictions that are too intrusive could exacerbate rather than lessen
misinterpretation by cutting providers and their patients off from the
most up-to-date data. 77
The FDA, in response to the actions taken by IVF, Myriad, and
OncorMed, has proposed regulations to bring genetic testing services
(and home brews in general) more directly within its purview.78
Specifically, the FDA would like to regulate the active ingredients
used in genetic tests.

The FDA's proposal is to classify "active

ingredients," chemicals or antibodies that are useful only in testing for
one specific disease or condition, as analyte specific reagents (ASRs),
which are subject to controls.79 This l abeling would require suppliers
77.
Historically, advertising of health products accompanied the spread of
journalism during the Civil War and was targeted to reach consumers. See ABRAHAM, supra
note 7 1 , at 42. However, this was followed very quickly by dependence by doctors on the
"pharmacopoeias" for knowledge about specific drugs and their measured doses. Soon,
drug manufacturers began to make standard preparations available, and

a close relationship based on mutual interest evolved between the big
pharmaceutical companies in the U.S. and American physicians; the latter could
extend their professional power since only they had the knowledge to prescribe
the new science-based drugs, while the large high technology finns create a
unique prescription market, in which they had a clear advantage over other
medicine makers.
Id. In an age of burgeoning medical science, of a deluge of genetics products, and of
competition to attract and retain patients under managed care (by, among other things,
offering them the latest treatments), providers' need for infonnation could not be greater.
Where products are being made available under investigatory protocols, their developers and
manufacturers may be the only entities with such information.
78.
See Medical Devices; Classification/Reclassification; Restricted Devices;
Analyte Specific Reagents, 61 Fed. Reg. 10,484 ( 1 996) (to be codified at 21 C.F.R pts. 809
& 864) (proposed Mar. 1 4 , 1 996). But see Weiss, supra note 2, at Al ('The Food and Drug
Administration, already on the defensive amid corporate claims of over-regulation, has
declared it has the authority to regulate genetic tests but hastens to add that it has no plans to
do so."); ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 , at 15 ('The Task Force has
requested a legal opinion from FDA as to whether, if it has the authority to regulate the
development of genetic test services, it can limit the duration of the investigational stage.").
79.
Although ASRs generally are subjected to general Class I controls, those
detennined to carry a high risk may be designated for Class III controls, which i nclude a
premarket approval requirement, or they may be regulated by the Center for Biologics
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of such active ingredients to register with the FDA and provide lists of
the ASRs they are supplying to laboratories for use in developing tests.
These suppliers then would be held to good manufacturing standards,
which

require

FDA

reporting

of

all

adverse

events

possibly

attributable to products.80 The FDA also has left open the possibility
of directly regulating in-house genetic testing services at a later date.8 1
Ironically, h owever, the advent of commercialization of genetic
testing by OncorMed and Myriad is juxtaposed against weighty
political and public pressures on the FDA to streamline, expedite, and
privatize its review process. 82

Despite recent self-reforms,8 3 this

Evaluation and Research (CBER) because their use presents particularly high risks. See
Medical Devices; Classification/Reclassification; Restricted Devices; Analyte Specific
Reagents, 61 Fed. Reg. at 1 0,484-86.
See id. ; 2 1 C.F.R §§ 803 . 1 -.58, 820. 1 -. 1 98 ( 1996).
80.
In the Proposed Rules, the FDA states:
81.
However, at a future date, the agency may reevaluate whether additional controls
. . . . may be especially relevant as testing for the presence of genes associated
with cancer or dementing diseases becomes more widely available. Additional
controls might include a broad array of approaches, ranging from full premarket
review by FDA to use of third parties to evaluate analytical or clinical
performance of the tests.
Medical Devices; Classification/Reclassification; Restricted Devices; Analyte Specific
Reagents, 61 Fed. Reg. at 1 0,486.
82. See John Schwartz, FDA Often Blamed for Problems that Aren 't Agencys Fault,
WASH. PosT . July 1 5 , 1 996, at Al 7 (reporting how the pharmaceutical industry's trade
organization brought 1 40 disease victims to Washington to lobby for reform); cf. Matthew
Rees, What Makes David Kessler Run?, WKLY STANDARD, June 3, 1996, at 25 (stating that,
rather than a political victim, "the Commissioner of the [FDA] is an amazingly resourceful
political animal"). The most dramatic features of the proposed FDA reform legislation are
privatization of the review process (using private companies to help review clinical data)
and a six-month ( 1 80-day) time limit on the review of all drugs by 1 998-a dramatic
reduction compared to the average of 12 months. See The Food and Drug Administration
and Accountability Act of 1 995, S. 1477, 1 04th Cong. ( 1 995) (bill introduced by Sen.
Nancy Kassebaum); Malinowski & O'Rourke, supra note 20, at 2 1 0-23 ; Robert Pear,
LLlwyers and Lobbyists Help Guide Effort by Republicans to Speed Drug Approvals, N.Y.
TIMES, Mar. 4, 1 996, at A l 5 ("Republicans on the Senate Committee on Labor and Human
Resources and the House Commerce Committee, joined by some Democrats, have
concluded that Congress must revise the F.D.A. laws to give patients swifter access to new
drugs and devices."); Ronald Rosenberg, Biotech Group Hits Kennedy s FDA Stance,
BOSTON GLOBE, Apr. 26, 1 996, at 90 ("Citing scientific advances over the past 50 years, the
biotech industry wants to abolish the two-track approval process for biology-based drugs.
That process now requires separate approvals for a biological drug, its manufacturing
process and for every lot or batch produced."); see also Jeffrey L. Fox, "Nitty-Gritty " FDA
Guidelines Wanted Sooner Not LLlter, 14 NATURE B IOTECHNOLOGY 698, 698 ( 1 996) (stating
that reforms are expected by late summer which will lessen the burdens on biologics
manufacturing).
( 1 ) mandatory review of all
Other proposed reforms include:
"breakthrough" drugs for killer or untreatable diseases in four months. two months faster
than today; (2) a requirement that the FDA farm out its work to private companies if it does
not meet the proposed review deadlines by 1 998; and (3) the opportunity for companies to
,
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pressure has been mounting, especially for cancer and AIDS-<liseases
that affect millions of people and, not coincidentally, major research
and development (R&D) areas for biotechnology companies. 84
petition for automatic approval for sale in the United States of any therapy that is approved
in certain foreign countries if the FDA misses its deadline (the FDA then would have 30
days to block the sale, by declaring the treatment u nsafe or unproven). See Lauran
Neergaard, FDA Resists Claiming Potential for Dangerous Errors, BOSTON GLOBE, Feb. 22,
1996, at 3. The public pressures on the FDA also have been profound. See, e.g., Editorial,
The FDA and Shannon McDermott, BOSTON GLOBE, Apr. 15, 1996, at 1 0 ("Janet
McDennott[, who was brought to Washington by pharmaceutical trade groups,] is waging a
valiant struggle to get medication that will prevent the seizures suffered by her daughter
Shannon. But Shannon's plight should not encourage support for a bill in Congress that
would force the [FDA] to speed up the approval process for new drugs."). These forces
have joined, for drug companies have learned the power of teaming up with patients. See
Pear, supra ("Drug companies contribute substantial sums of money to patient-advocacy
groups, but those groups insist that they are not unduly influenced by the money."). The
FDA reform movement is the culmination of a general trend to deregulate the
commercialization of pharmaceuticals. See Critser, supra note 76, at 40 ('Today, the
American patient is inexorably being transformed into his own pharmacist. The trend is
most apparent in the pages of magazines, with their weirdly text-heavy ads. Less obvious
are the marketing fests taking place in the nation's doctors' offices and emergency rooms.").
83. See BILL CLINTON & AL GoRE, REINVENTING DRUG AND MEDICAL DEVICE
REGULATIONS 4-5 ( 1 995) (executive branch/FDA proposals for self-reform); KENNETH B .
LEE, JR. & G . STEVEN BURRILL, BIOTECH 97: ALIGNMENT , THE ELEVENTH INDUSTRY
ANNUAL REPORT 34-36 ( 1 996); For Biotech Firms, FDA Rules H ave Much to Please,
BOSTON GLOBE, Nov. 23, 1 996, at 90 ("[B]iotechnology executives are breathing a lot easier
these days about such big up-front investments now that the [FDA] has revamped a host of
regulations governing the industry."). These proposed reforms, many of which now are in
the process of allegedly being implemented, were referred to by some in the industry as "the
most significant and sweeping in 50 years." CLINTON & GORE, supra, at 4-5. The reforms
included proposals to ( l ) eliminate requirements that each company seek a separate license
for each facility where it plans to manufacture a drug, (2) eliminate the requirement that each
batch of a biotech-developed drug be sent to the FDA to test, and (3) impose a 30-day
deadline for the FDA to respond to a company that has submitted additional information
requested after the FDA has put a clinical trial on hold. See id. Many of these proposals
have been incorporated into Senator Kassebaum's FDA reform bill. See supra note 82 and
accompanying text; see also Pear, supra note 82, at A l 5 (reporting that industry experts
helped write an FDA bill regarding speeding up approval for new drugs).
84. See generally Elizabeth C. Price, Teaching the Elephant to Dance: P rivatizing
the FDA Review Process, 5 1 FOOD & DRUG L.J. 65 1 (1 996); Cancer Diagnostics , MED.
TECH. STOCK LETTER (Piedmont Venture Group, Berkeley, CA), Apr. 18, 1 996. "Within
days after the Republicans won control of Congress in 1 994, some gay rights groups saw an
opportunity to win speedier access to new, unapproved treatments for AIDS by rewriting
Federal drug Jaws." Pear, supra note 82, at A I 5 (discussing new FDA regulations regarding
new drug approval process); see also Tanya E. Karwaki, Note & Comment, The FDA and
the Biotechnology Industry: A Symbiotic Relationship?, 7 1 WASH. L. REV. 8 2 1 , 8 2 1 -22,
834-37 (1996) (addressing reform). This strategy appears to be working, for in response to
the political and public pressure, the FDA already has expedited approval of drugs that fight
AIDS and cancer. See Pear, supra note 82, at Al5; Laurie McGinley, FDA to Quickly Clear
Merck AIDS Drug, after Approving Abbott's Treatment, WALL ST. J., Mar. 4, 1 996, at B 3
("On �riday . . . the [FDA) approved Norvir, known generically as ritonavir. That approval
came JUSt 72 days after Abbott filed its application-the fastest drug approval in the
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Moreover, the manufacturers of medical devices and diagnostics are
pressuring the FDA by organizing and calling for reforms favorable to
their products. 85 The drive to reform the FDA does, however, have its
agency's modem history.

And it came just one day after the advisory panel backed its

approval."). It i s i mportant to note, however, that many consumer advocacy groups oppose
the "premature" commercialization of genetic testing:
The National Breast Cancer Coalition, for example, a patients' rights group,
opposes open marketing of a test for the so-called breast cancer gene, BRCA 1 . At
the risk of sounding as paternalistic as the doctors they often fight against,
members said the test's general ambiguous results may trigger unnecessary panic
in many women while reassuring others who should remain vigilant.
Weiss, supra note 2, at A l .
85.

According to the General Accounting Office (Congress's investigator), the

average time required for the approval of new drugs has fallen in the last decade from 33 to
1 9 months.

However, acceleration of FDA review of drugs has not been matched for

diagnostics.

See 1 42

CONG. REC. S3203 (daily ed. Mar. 29, 1996) (statement of Sen.

Edward Kennedy acknowledging that the review process is slower for medical devices and
various animal vaccines); Neergaard, supra note 82, at 3 ("Today, the FDA spends six
months reviewing breakthrough drugs and 1 6 months reviewing nonessential medicines.
Medical devices take much longer."); Pear, supra note 82, at A l 5 ('The agency has
accelerated the process of reviewing AIDS drugs, but patients with other life-threatening
conditions contend that those drugs recei ve preferential treatment," and the FDA has not had
similar success i n accelerating approval of devices and food additives.).
Delays Approval ofNew Test for Diabetics,

See, e.g., FDA

BOSTON GLOBE, Feb. 27, 1996, at 1 2 ("Diabetics

pleaded with the government yesterday to approve the first pain-free way to measure blood
sugar, but a panel of specialists said there was no proof the machine works well enough to
keep their disease at bay."); id. ('"I can't tell you how frustrating it is to know this device
exists but is just out of reach of Bonnie,' said Glenn Sklar of Columbia, Md., who draws
blood from his 3-year-old's finger six times a day."). Some argue that the FDA's approval of
Olestra, a fat substitute, reflects organization of the Grocery Manufacturers of America, see
Pear, supra note 82, at A l 5, and that the FDA's recent approval of Intemeuron's antiobesity

drug, the first obesity drug approval in over 20 years, reflects the FDA's responsiveness to
biotechnology. See Ronald Rosenberg, Antiobesity Drug Cleared by FDA; Available Soon,

BOSTON GLOBE, Apr. 30, 1 996, at 3 (reporting that Redux, developed by Intemeuron
Pharmaceuticals Inc., was the first new obesity drug approved in 22 years).

To create a

counterpart to BIO and the Pharmaceutical Research and Manufacturers of America
(PHARMA) and a voice for device manufacturers in the FDA refonn movement, the device
manufacturers are organizing. Specifically,
[a)fter years of being lumped with the biotechnology industry, Massachusetts'
medical device companies yesterday announced the formation of their own trade
association.

Known as the Massachusetts Medical Device Industry Council, or

MassMEDIC, the group intends to have a voice in pending reforms at the Food
and Drug Administration and in local business and government issues that affect
the industry.
Ronald Rosenberg, Medical Device Firms Form Trade Association,

BOSTON GLOBE, May 7,

1 996, at 43 (defining the industry as 200 member companies that employ more than 1 5 ,000
people in Massachusetts, create more than three percent of all manufacturing jobs, and
generate collective revenues of $3.5 billion). The formation of MassMEDJC coincides with
enhanced FDA responsi veness to the manufacturers' industry.

According to former

Commissioner Kessler, the FDA has shortened the time it takes to review a device from 1 34
days in 1 994 to 90 days. See id. Presently, the FDA is modifying rules that govern export
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opponents, most notably fonner Commissioner David Kessler86 and
Senator Edward Kennedy.87

licenses for medical device products that have not been approved by the agency, that govern

pilot testing private-industry review of some low-risk medical devices, and modification of
safety and inspection procedures for devices. See id. ; see also Kate C. Beardsley, Medical

Devices·Regulation and Refonn, in ALl·ABA COURSE OF STUDY MATERIALS:

BIOTECH '95

BUSINESS, !Aw, AND REGULATION, Nov. 2-3, 1995, at 255; FDA lays Out Plan to Reduce

Delays, Costs in Approval Procedures, BOSTON GLOBE, Apr. 4, 1996, at 6 (reporting that

FDA has launched a pilot test to determine if outside groups could assume some of the

reviews of routine medical devices now handled by FDA scientists for low and moderate
risk devices like electronic thermometers and surgical gloves).
manufacturers' industry supports proposals that include:

More specifically, the

(I) exempting

(by moving from

Class II to Class I) an additional 1 25 medical device categories from premarket notification
requirements, thereby exempting a total of 570 categories (about one-third) from this

requirement; (2) allowing the export of devices without an IND exemption; and (3) adopting

"an approach similar to that used in the European Community in which device firms have

their device applications reviewed by a third-party scientific organization accredited by the

government." Id. ; see also Malinowski, supra note 29, at 1 34-42. Under this approach, "a
manufacturer pays a third-party organization for its review, the third-party organization
notifies the government of the results, the device i s marketed without government review,

and the government monitors the device after it is on the market for subsequent safety

problems." Beardsley, supra, at 280.

FDA responsiveness to the device manufacturers'

industry has, however, accompanied new reporting requirements:

The FDA has issued final regulations specifying new requirements for reporting
serious problems with medical devices, as required under the Safe Medical

Devices Act of 1 990. . . . It will also provide the necessary assurance of product
safety to enable the FDA to clear innovative devices for marketing more quickly.

Under the new requirements, medical facilities must report all serious

device-related injuries or illnesses within 10 days . . . .

Manufacturers have been given 5 days to report to the FDA any device

related incident that requires immediate action to protect the public health.

The

time limit for the rest of the manufacturers' reports to FDA on device-related

deaths and serious injuries or illness is 30 days. This gives manufacturers time to

investigate incidents and provide the FDA with detailed information on adverse
events.

Stuart L. Nightingale, From the Food and Drug Administration, 275 JAMA 585, 585
( 1996).

86.
According to former Commissioner Kessler, the proposed reforms could
endanger the health o f Americans. See Neergaard, supra note 82, at 3; Legislation Puts
Public Health at Risk, FDA Chief Tells Panel, BOSTON GLOBE, May 2, 1996, at 9 . For a
detailed discussion of former Commissioner Kessler's position on this i s sue see
'
Malinowski, supra note 29.

87.
See 1 42 CONG. REC. S3203 (daily ed. Mar. 29, 1 996) (statement of Sen. Edward
Kennedy regarding the FDA Reform Markup); Rosenberg, supra note 82, at 90. In the
words of Senator Kennedy:
Most recently, we reduced the delays in approving prescription drugs with
user fees.

�ngdom.

As a result, we are now approving drugs faster than the United

We have fixed the drug lag. In fact, the United States approves more

important new drugs faster than any other country in the world.
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The FDA review process significantly impacts the economy of
the United States, for "[t]he products regulated by the ED.A. account
for

25 percent of the nation's economic output."88 Nevertheless, the

biotechnology aspect of the FDA reform movement is grounded in
more than the profit motives of biotech companies.
exception
products

of predictive
have

been

pharmaceuticals. 89

genetic

more

Biotech

testing

highly

drugs

services,

regulated

and

With the

biotechnology

than

traditional

therapeutics generally are

classified as biologics and, as such, are subject to requirements
imposed by both the Federal Food, Drug, and Cosmetic Act (FDCA)90
and the Public Health and Services Act (PHSA).91

Because of

fundamental differences in the regulatory approaches taken under
these statutes, an entire dimension of added regulation is imposed
upon biologics. Specifically, "[t]he primary objective of the FDCA is
to ensure the s afety and effectiveness of the final product, with
controlling the manufacturing process a secondary concern.

In

contrast, biologics regulation under the PHSA is focused on 'rigid
control of the manufacturing process . . . . "'92 The practical effect on
biologics has been

that,

to reach

the

market, developers and

manufacturers have had to negotiate an entanglement of licensing and
other requirements that front-load their financial investment.93

Self-

. . . The [proposed] legislation says you have to examine all of them, a11 of
the drugs within the 6 months . . . .
So now instead of bringing focus and attention of the gifted and able
scientists out at FDA on those drugs that could be breakthrough drugs in cancer,
in AIDS, in hepatitis, in all kinds of diseases, we are going to divert their attention
to looking after the "me-too" drugs that can make extra bucks for the
pharmaceutical companies.
142 CONG. REC. S3203-04 (daily ed. Mar. 29, 1 996).
88.
Pear, supra note 82, at A 1 5.
89.
See JAMES T. O'REILLY, FOOD AND DRUG ADMINISTRATION §§ 1 3- 1 5 (2d ed.
1993) (detailing drug regulation, specifically the approval process, safety and qua1ity issues,
and economic and labeling issues); Gary E. Gammennan, Regulation of Biologics
Manufacturing: Questioning the Premise, 49 FOOD & DRUG L.J. 213, 2 1 3 ( 1 994) (arguing
that, in retrospect, the divergent regulatory emphasis of the Biologics Act and the FDCA
were appropriate when biologics were crude mixtures or biological extracts); Malinowski &
O'Rourke, supra note 20, at 205.
21 U.S.C. § 360k(a) (1994).
90.
9 1 . 42 u.s.c. § 262.
92.
Malinowski & O' Rourke, supra note 20, at 205-06 (quoting Gammerman, supra
note 89, at 2 1 3); see also Gammerman, supra note 89, at 220-26 (analyzing the utility of the
Biologics Act).
93. See Gammerman, supra note 89, at 230-33; Malinowski & O' Rourke, supra
note 20, at 205- 1 3 , 21 5-24. Establishment licensure requirements have mandated that
products used in Phase III trials produced in the intended commercial-scale manufacturing
facility and that only the company that manufactures the biologic may obtain and hold the
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refonns by the FDA to eliminate some of the most unduly burdensome
licensing and other requirements imposed upon biologics have come
too late to quell the organization of the biotechnology industry and
frustrated consumers awaiting products.
stemming from

the

establishment

International competition

of the European

Medicines

Evaluation Agency (EMEA) should inspire more self-reform by the
FDA and perhaps produce a new commitment to international
collaboration in drug review and approval.94
The impact of regulatory uncertainty on the biotech industry has
provided an incentive to "Coase around"95 and reform the existing
FDA review process.96 Moreover, the reform movement is fueled by
genuine concern that, "'[i]n this increasingly complex scientific world,
where the half-life of knowledge is growing shorter and shorter every
day, it's going to be impossible for the ED.A. to maintain in-house the
full range of expertise and experience that will be needed.' "97 Despite
marketing licenses. Accordingly, in comparison with traditional drug developers, CBER has
forced biotech developers to commit more financial resources to manufacturing before they

See Gammerman, supra note 89, at 230-3 1 .
Development of the European Biotechnology
Industry, 33 CAL. W.L. REv. 83 ( 1 996); Malinowski, supra note 29.
95. See Ronald H. Coase, The Problem of Social Cost, in THE FIRM, THE MARKET
know if they have an approvable product.

94.

See generally

John Ashworth,

AND THE LAW 95, 99 ( 1 988) (arguing that parties will be driven to overcome market

interferences, whether caused by regulations or contractual provisions, to reach maximum
efficiencies).

96.

FDA actions have had, and continue to have, a profound impact on the market

appeal of biotechnology.

See

Malinowski

&

O'Rourke,

supra

note 20, at 2 1 5-24.

This is

true even for relati vely "mature" biotech companies with diverse technology, such as
Genzyme

Corp.,

Massachusetts.

See

an

established

Steve Bailey

&

biotechnology
Steven Syre,

company

After the Fall,

located

in

Cambridge,

BOSTON GLOBE, Mar. 28,

1996, at 41 (reporting that vote by FDA advisory commi ttee reconunending approval for

limited

uses of Seprafi lm, a membrane product designed to prevent the adhesion of organs

and tissue after some operations, caused a two-day fal l in Genzyme stock).

97.

Pear,

supra

note 82, at Al5 (quoting Sen. Bill Frist, who is a heart surgeon). A

prime example of the innovative products at issue is Olestra, a fat-based substitute for

conventional fats manu factured by Procter & Gamble. See Nightingale, supra note 85, at
585. In a flourish of controversy, the FDA approved this drug but imposed enhanced post
mariceting obligations. See Henry Blackbum, Sounding Board: Olestra and the FDA , 334
NEW ENG. J. MED. 984, 984 ( 1 996) ("Procter & Gamble will be required to conduct studies
that monitor consumption and examine Olestra's long-term effects.

The FDA's Food

Advisory Committee will review these studies in a public meeting within

30 months.").

This decision may be an indication that the FDA is beginning to recognize that truly
innovative products may require more than the FDA's li mited resources:
Clearly, the FDA is becoming more aware of the need for epiderniologic
studies and clinical trials with adequate statistical power to detect effects and
monitor human safety. The agency apparently also has the fortitude to stick to its

guns, as it has done, for example, in the cigarette controversy by maintaining that
nicotine is an addictive drug. But the FDA does not have the statutory authority,
the staff, or the funding to examine adequately the benefit and safety of food
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the short "half-life" of its underlying science, the work necessary to
fully assess clinical applications takes years.

These problems are

exacerbated by the FDA's resistance to accept scientific evaluations of
technology by the rest of the industrialized first world, a resistance
presumably due to a belief in the superiority of United States science
and scientific capability.98 The success of the HGP, the globalization
of

the

science

community

and

revolution,

the

responsible

for

of

realization

biotechnology

the

meaningful

global

telecommunications support the introduction of uniform, international
scientific standards for compiling and evaluating clinical data.99
The strength of the FDA reform movement reduces, but does not
make impossible, 100 the likelihood that a comprehensive regulatory
response to the commercialization of genetic testing services will be
introduced in the immediate future. Without such FDA reform, other
biotechnology companies will follow the precedent set by IVF,
Myriad, and OncorMed.

Dangers

arising from the widespread

availability of investigatory, predictive genetic testing services must,
additives

generated

technology.

by

the

powerful

food

industry

and

its

sophisticated

Moreover, there are now serious political pressures on the FDA,

including informal proposals that it become a rubber-stamp certifying body for
industry.

There are even threats to abolish the agency.

In this climate, it is

understandable, i f unfortunate, that the FDA has to set priorities and choose
carefully where to do battle.

Id. at 986.
In the words of Senator Barbara Mikulski, a Maryland Democrat, '"If we can
98.
use NATO weapons, why can't we use drugs from NAm countries?"' Neergaard, supra
note 82, at 3. Despite former Commissioner Kessler's assertions to the contrary, gaps in
approval between the United States and Europe do exist and, at times, are extreme.

For

example, although the FDA only recently approved dexfenfluramine, "in Europe, where it
has been used for l 0 years, an estimated 1 0 million patients have been treated with no
epidemiological signal indicating any behavioral problem in clinical usage."

Ronald

Rosenberg, "Take a Pill, " Lose Some Weight, BOSTON GLOBE, Apr. 15, 1 996, at 9 1 (noting
that three fat-fighting drugs are entering the United States market:

dexfenfluramine by

Interneuron Pharmaceuticals, Inc., known as Redux; sibutramine, with the trade name
Meridia, by Knoll Pharmaceutical, Inc., a unit of BASF Corp; and orlistat, with the trade
name Xenical , by Hoffmann-La Roche, Inc.).

99. See generally Malinowski, supra note 29. See also Malinowski & O'Rourke,
supra note 20, at 2 1 8 (noting that the FDA standards should be harmonized with
international medical standards).
I 00.

A personal observation is that the ongoing work of the ELSI Task Force and

consumer groups such as the National Breast Cancer Coalition and the Jewish Women 's
Coalition on Breast Cancer could make this issue a priority on Congress's agenda.

See

Richard Saltus, Jewish Women s Group Warns of Risks of Cancer-Gene Testing, BOSTON
GLOBE, Jan. 1 7 , 1 997, at B2 (reporting on formation of a coalition that includes the
Combined Jewish

Philanthropies, National

Council

of Jewish Women,

Beth

Israel

Deaconness Medical Center, and Jewish Community Centers of Greater Boston to challenge
testing for inherited breast cancer genes).
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therefore, be identified,

thoughtfully

considered, and

addressed

without further delay.

C.

Dangers Arising from the Premature Use of Genetic Testing

Predictive genetic testing services are, in the aggregate, biological
tarot cards subject to misinterpretation by both patients and their
physicians.101 The predictive capability of many genetic tests remains
scientifically undefined for the general population.102

This type of

testing must be conclusively distinguished from presymptomatic
genetic testing.

The latter constitutes a reliable and meaningful

predictor only for a small number of conditions-conditions usually
3
Only these few conditions,
caused by a single genetic mutation. 1 0
such

as

Huntington's and Tay Sachs disease, can be diagnosed

conclusively through genetic testing.104
101 .

Even when such conditions

See ELSI TASK FoRCE ON GENETIC TESTING, supra note 1, at 14 (reporting that a

test is ready for routine use only when it has been carefully assessed for ( l ) sensitivity,

(2) positive PPV, and (3) clinical utility). The ELSI Task Force has identified the following
aspects of genetic testing as bases for special consideration by public health officials and
other policy makers:
predictability seldom approaches certainty; often no independent test is available
to confirm the prediction of a genetic test (only appearance confirms the
prediction); no i nterventions are yet available; those tested may be subject to
psychological distress, discrimination, and stigmatization; ethnicity may influence
genetic makeup ; [and] most health providers have received little training in
genetics.

Id. at 3; see also Wei ss, supra note 2, at Al ("Genetic tests differ from many medical tests
because they often provide very vague answers, such as, 'You have a gene that gives you

a

70 percent chance of getting breast cancer in the next 20 years."').
102.

See supra note 25 and accompanying text.

1 03. See supra note 25; see also ELSI TASK FORCE ON GENETIC TESTING, supra note
1 , at 8 ("In only a small proportion of patients with common disorders, such as breast cancer
or malignant melanoma, do inherited mutations at a single gene locus contribute
significantly to the occurrence of the disease.").

Examples of the clinical limitations of

modern genetic science are almost as plentiful as the genetic linkage discoveries that so
captivate the media and the public. Consider the APOE-4 discovery:
Two-thirds of people who develop Alzheimer's later in life have ApoE4.
Having just one copy confers three times the average risk of developing the
disease; having two copies raises the risk to beyond 90% (The risk of developing
Alzheimer's disease is 2% at age 65, but about 1 0% at age 85.) However, many
people with Alzheimer's do not carry even one copy of ApoE4, and some who
have two copies of ApoE4 do not develop the disease.

The Hazards of Genetic Testing, supra note 24, at 6; see Bishop, supra note 48, at Al
(describing blood tests identifying the gene Apoe, which will eventually help determine how
long a person lives).
104. See Stephenson, supra note 15 , at 1 66 1 (
The Task Force investigators discovered that while academic laboratories were
more likely than the biotechnology companies to offer tests for single gene
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can be diagnosed through genetic testing, the rate of expression may
vary; with many

genetic

conditions,

severity remains

open

an

question. 1 05 Most often there is no available treatment,1 06 or treatment
exists but is price-prohibitive. 1 07 In addition, in the absence of unifonn
federal regulatory oversight, the quality of laboratory performance is
questionable. 108

disorders, such as cystic fibrosis, fragile X syndrome, and muscular dystrophy, the
latter are far likelier to be engaged in developing or offering tests for complex
genetic disorders, such as Alzheimer's disease, breast cancer, and hereditary
nonpolyposis colon cancer, and in conducting population testing for such
disorders.
105.

See,

e.g. ,

COOK-DEEGAN, supra

note

20,

at

242

(discussing

clinical

heterogeneity i n the context of cystic fibrosis).
1 06. In the absence of therapeutics and gene therapies, most predictive genetic tests
offer few options:
For example, the only options now available to a woman who learns that
she is predisposed to breast cancer are prophylactic mastectomy (in hopes that
cancer would not develop in the residual amount of breast tissue) or frequent
clinical breast exams and mammograms. Physicians have little to offer in terms of
preventive strategies to patients who discover that they have a markedly increased
risk of developing Alzheimer's disease by virtue of having two copies of the
APOE-4 allele.
Stephenson, supra note 1 5 , at 1 662; see Hilzenrath, supra note 4, at D 1 4 ("Should the
patient have her breasts or ovaries removed as purely preventive measures, when there is no
guarantee that the surgery would prevent the disease, and no assurance that cancer would
develop in the absence of the surgery?"); Richard Saltus, Genetic Clairvoyance, BOSTON
GWBE, Jan. 8, 1 995, (Magazine), at 14 ("One of the lessons patients and counselors have
learned from this experience is that knowing one's genetic fate is not for everyone
especially when, as is the case with Huntington's, knowing what's ahead doesn 't help one to
avoid it.").
1 07.

A prime example is the treatment for Gaucher Disease. See Gaucher Disease:

Current Issues in Diagnosis and Treatment, 275 JAMA 548, 548 ( 1 996) (

Despite the success of enzyme therapy, treatment is limited by the cost of
the agent.
[This) makes it imperative to determine the lowest effective initial and
maintenance dosages and the most cost-effective dosage for clinical response, to
define the appropriate clinical indications for treatment, and to establish uniform
methods to optimize outcome assessment.
108.

See Proposed Recommendations of the Task Force on Genetic Testing, Meeting

Notice, 62 Fed. Reg. 4539, 4545-46 ( 1 997) (expressing concern over the absence of federal
law and regulation to ensure the laboratory quality o f genetic tests). Due to the novelty of
widespread commercialization of predictive genetic testing services, those scrutinizing them
tend to rely heavily on anecdotal evidence. According to one account:
Citing case studies reported to the Task Force, Dr. Holtzman pointed out other
problems:
I) laboratory error in performing and interpreting genetic tests;

2) ordering of genetic tests for inappropriate reasons; 3) restriction by managed
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More troubling, due to the absence of adequate clinical data,
health care providers cannot interpret the results of predictiv e genetic
tests for most of their patients with any reliability even when they are
knowledgeable about genetics. 109
This interpretation problem is
exacerbated because the current generation of health care providers
1 10
does not possess such knowledge.
Their lack of genetics education

care organizations of the labs in which tests o n their subscribers can be perfonned;
and 4) maintaining confidentiality of genetic test results.
Meeting Minutes, supra note 1 , at 2.
109. See Stephenson, supra note 15, at 1 66 1 ("Interpreting the results of such tests is
difficult, in part because the rate of false negatives is unknown."); Brom, supra note 27, at
1 26. Fully assessing the PPV of existing genetic testing capability for individual patients
could take a decade or more.

Moreover, it may be that, in the aggregate, environmental

factors control approximately 50% of physical characteristics, and that each of us carries
multiple genetic predispositions for disease.

See id. ; cf ELSI TASK FORCE ON GENETIC

TESTING, supra note 1 .
1 1 0.

See The First BCAJ Test Hits the Market, supra note 65, at 2 ('"Available data

suggest that many primary care providers lack the knowledge about genetics that's necessary
to educate their patients and ensure informed consent for genetic testing . . . . "' (quoting
Caryn Lennan, associate professor of medicine and psychiatry at the Georgetown University
Lombardi Cancer Center)); Proposed Recommendations of the Task Force on Genetic
Testing, Meeting Notice, 62 Fed. Reg. at 4546 ("A provider's need for knowledge is
particularly keen when tests are in transition from research to clinical use and when clinical
utility is still under i nvestigation and there are no established practice guidelines."); see also
William C. Felch & Donald M . Scanlon, Bridging the Gap Between Research and Practice,
277 JAMA 1 55 ( 1 997) (arguing that the research and provider communities must work
together to bring medical technology into patient care). At the meeting of the National Task
Force on Genetic Testing held in April 1 996, representatives of the biotechnology industry
placed the responsibility of informed consumption of genetic testing services o n physicians.
In response, "Doctors said they were still getting up to speed in genetics and would be
unable to stem the tide of patient demand if testing were not subject to regulatory
restrictions." Weiss, supra note 2, at A l 5 ; see also ELSI TASK FORCE ON GENETIC TESTING,
supra note 1 , at 24 (
Several studies have documented the deficiencies in health care providers' level of
knowledge about genetics and genetic tests. As opposed to the results of a serum
sodium or a complete blood count, which the referring physician is competent to
interpret and convey to the patient, genetic test results raise unfamiliar problems
about probabilities, psychological impact, and reproductive implications.
). Concern about the ability of physicians to interpret such tests for their p atients is well
founded:
Even though both commercial and academic laboratories are marketing the
tests to physicians who lack any expertise in medical genetics, i n cluding
obstetricians and primary care providers, only a minority of the laboratory
directors who responded to the survey said they felt that most physicians can
interpret genetic tests adequately for their patients.
Stephenson, supra note 1 5, at 1 661 (confirming by study of 4,210 Ohio family physicians).
As reported in The Boston Globe, based upon a survey of laboratories:
"A lot of people are getting into genetic testing now who haven' t been
through human genetics training," said Dr. Mi chael S. Watson of Washington
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and the novelty of the technology makes providers dependent upon the
developers and manufacturers of these tests (both commercial and
academic laboratories) for information. This dependency suggests that
neither consumers nor their health care providers can reasonably
evaluate the technology.
Accordingly, until this informational
asymmetry between providers/patients and biotechnology companies
is decreased through the compilation of clinical data and education,
heavy reliance upon market forces like consumer and provider demand
is misplaced. In fact, the premature commercialization of genetic
testing services may create a general climate of uncertainty that skews
incentives for all market participants:

Biotech companies ' decisions about what technologies to
develop are subject to being inflated by dependence upon them
for information, consumer demand, and the influence of
consumer advocacy groups; 1 11
public demand is subject to being bloated by the aggressive
marketing efforts of biotechnology companies that play off of the
cultural icon status of DNA, 1 1 2 the fact that the public is
accustomed to undergoing testing for reliable health evaluation
and diagnosis, and
providers' lack of adequate genetic
education; 1 1 3 and
University in St. Louis [an official of the American College of Medical Genetics].

'This used to be an unprofitable and esoteric field" when the only genes scientists
had identified were those that caused rare disorders. "Now that we are getting
into common diseases" influenced by genes-including cancer, heart disease and
diabetes- "people are jumping into it."

Saltus, supra note 5 8 , at 14. This problem will be exacerbated with the proliferation of
genetic testing services. See ELSI TASK FORCE ON GENETIC TEsrING, supra note 1 , at 23
("As the number of genetic tests proliferate and their usage expands, primary health care
providers and other non-genetics specialists (e.g., [sic] oncologists, neurologists) will play a
major role in the provision of genetic tests.").
1 1 1.

Advocacy groups (e.g. , for those afflicted by breast cancer and AIDS) may

influence what products are brought to market based upon what they treat rather than their
relative quality. See Boyle, supra note 1 3 , supp. at S5.
1 1 2.

See Annas, supra note 14, at 25.

1 1 3. FDA enforcement of its advertising restrictions has had a profound impact on
the availability of genetic testing within the United States:
While a number of blood tests have been used in other countries, they have been
much less common in the United States. P art of this is the result of Centocor's
experience with their test for CA 1 5.3, a marker for breast cancer.

In 1 99 1 , the

FDA forced Centocor to stop selling this test as a research product in the United
States and the rest of the world.
Cancer Diagnostics, supra note 84, at 2.

As explained above, the precedent set by

OncorMed and Myriad is revitalizing this industry.

FDA controls on advertising are
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providers ' decisions to make the technology available may be
of legal liability,

skewed by fears

the

desire to

appear

knowledgeable about and receptive to health care technology,
pressure from consumers anned with newspaper and magazine
stories on genetic discoveries, and care managers who place
severe limits on physicians' time and pressure to maintain patient
enrollment.1 14
Many of the concerns about the commercialization of genetic
testing services are familiar and apply to other medical technologies.
Nevertheless,

(I) the

fact that research-stage genetic testing available

to the general public is being conducted by private companies rather
than by major research institutions, (2) the absence of reliable quality
controls on

in-house

testing

services,

and

(3) perceptions

and

uncertainties about the predictive capabilities of genetic testing make

circumvented when laboratories and biotech companies sell investigatory services rather
than kits.

See supra

note 76 and accompanying text.

The relationship between providers

and the entities perfonning these testing services i s one-on-one enough to be difficult to
regulate.

See

Boyle,

supra

note 13, supp. at

SS.

Moreover, at least one study has

challenged the accuracy of the information provided by genetic laboratories and biotech
companies about their tests. According to Dr. Holtzman' s study, as interpreted b y one of his
colleagues who reached preliminary conclusions based upon a sampling of consent forms
collected,
several grossly overstate the test's accuracy or represent it in a way that is likely to
be misleading. For example, some tests for a single gene did not specify that they

only detected a few of the known mutations and therefore would yield an
underestimate of the false negative rate. . . . (O] nl y half the materi als mentioned
the availability of genetic counseling to accompany test results. Victoria Odesina
and Nancy Press questioned whether recipients even understood the information
they did receive.

Meeting Minutes,

s upra

note 1 , at 2. Some public health officials are also monitoring

and documenting the marketing efforts of biotech companies.

According to one such

account, "[p]rivate companies are performing sophisticated market research studies in order
to determine what kinds of new genetic technologies will sell and reap large profits . . . .
There are numerou s reports being issued to generate investment in prenatal genetic tests."
BLATI, supra note 2 1 .

1 1 4. .Providers are especially prone to overuse genetic testing technology in the
prenatal context in states recognizing the common-law doctrines of wrongful birth and

See generally Belinda L. Kimble, Wrongful Birth: A Pr actitioner s Guide to
a New Arrival, 55 ALA. L. REV. 84 ( 1994) (recognizing a cause of action for wrongful
birth); Malinowski, s upra note 2 1 , at 1497- 1 5 1 3 (demonstrating the need for minimum
bioethics standards); Timothy J. Dawe, Note, Wrongful Life: Time of a "Day in Court", 5 1
OHIO Sr. L.J. 473 ( l 990) (discussing the elements for these causes of action, their
application, and relevant state statutes, and providing case citations); see also CooK
DEEGAN, supr a note 20, at 243 (addressing this potential problem in the context of cystic
fibrosis screening); Ellen Wright Clayton, The Dispersion of Genetic Technologies and the
law, HASTINGS CENTER REP., May-June 1995, supp. at s 1 3- 1 4.

wrongful life.
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these concerns profound enough to stand alone. 1 1 5 Specifically, lack of
regulatory quality control and the perceived ability of predictive
genetic tests to penetrate well into the future despite the absence of
PPV makes this testing different. Many consumers and providers are
more in awe of the "miracles of modem genetics" than appreciative of
its clinical limitations.

The demand for predictive genetic testing

services may reflect this faith in genetic medicine, a tendency to equate
investigational genetic tests with reliable, standard-care diagnostic
tests, and the influence of entrepreneurial and academic interests . 1 16 It
also may reflect intolerance for health c onditions that deviate from the
majority. 1 1 7
The information generated by predictive genetic tests, regardless
of its clinical reliability, will deeply impact people's lives. 1 1 8 Some of

1 1 5. See Silverman, supra note 1 5, supp. at S 1 7 ("While the concerns about
developing new medical technologies are not unique to DNA diagnostics, genetic analysis
has the potential for particularly potent impact on society because of its predictive
capacities.").
1 16. See BLATT, supra note 2 1 .
1 17. Advocates for the disabled who challenge the availability o f genetic testing
argue that the concept of "disease" is a social construct. See Marsha Saxton, Cost
Benefit/Cost-Effectiveness Analysis in Genetics, Presentation at the Whitehead Inst. for
Biomolecular Research (Mar. 30, 1996) (on file with authors). There is concern that
genetics testing capabilities could result in less tolerance for deviation from the majority, less
appreciation for life, and a general submission to the prejudices of society. Society could be
cheated of all that can be learned from those born with disabilities, and genetic testing
capabilities will reduce the freedom of choice of prospective parents by putting more
pressure on them to abort. See id. ; see also John Seabrook, All in the Genes, NEW YORKER,
Feb. 12, 1996, at 80 (reviewing PIIDJP KITCHER, THE LIVES TO COME ( 1 996)) ("Eugenics is
to the science of biology what the A-bomb was to physics."); Malinowski, supra note 21, at
1478-89 (describing how prenatal genetic testing may cause some parents to abort anything
less than a "perfect" baby).
1 1 8. See generally Andrews, supra note 22, at 974-91 (discussing how genetic
infonnation, including carrier status, may have a multifaceted impact on people's lives). As
stated by one observer:
Knowing your genetic makeup can also create profound emotional and
financial problems. For example, a spouse might use this information in a
custody dispute. Or a woman might decide not to have children, for fear of
passing on the gene. But if she decides to adopt, will she be approved by an
agency? And should a 9-year old girl be tested for the mutation?
Koenig, supra note 24, at A23. Similarly, another stated:
The ability to predict late-onset diseases, both common (for example, cancer) and
unusual (for example, Huntington's) can result in dramatic changes in life-style.
Premarital genetic analysis can affect the selection of prospective marriage
partners, or even whether one will choose to marry. Genetic analysis is already
being used for decisions on childbearing or adoption. And in prenatal genetic
analysis the prospect of pregnancy termination is confronted directly.
Silverman, supra note 1 5 , supp. at S l 7.
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those who have opted to undergo the presymptomatic test for
Huntington's, a clinically valid test that conclusively determines future
onset, have experienced detrimental psychological reactions to the
results even when they are negative. 1 19 For those whose results are
positive, the suicide rate is approximately thirty-five percent higher
than among the general population.12° Further, it appears that genetic
infonnation already is disrupting the lives of individuals and their
families by subj ecting them to discrimination from employers and
insurers.121
Although adequate genetic counseling could, perhaps, enable
people to cope better with genetic information, genetic counseling is
1 19. See Andrews, supra note 22, at 976; Silverman, supra note 1 5, supp. at S 1 7
(discussing market influences o n genetic testing); Koenig, supra note 24, a t A23; Saltus,
supra note 106, at 1 4 ("[P]eople who receive good news from a genetic test can be as
seriously troubled as those who discover the worst."); see also COOK-DEEGAN, supra note
20, at 235-36 (discussing the experience of Dr. Nancy Wexler, codiscoverer of the allele
responsible for Huntington's, and her family). Although reliable figures are unavailable, in
January 1995 it was estimated that several hundred people in the United States and more
than 500 in Canada had been tested for the genetic predisposition to H untington's.
Although the psychological angst condition following testing experienced by those who test
positive has not yet been adequately researched, it appears to include the following:
(I) "[l]ike lottery winners, people who receive the gift of unexpected genetic health face the
quandary of what to do with it"; (2) the results completely disturb conscious and
subconscious views of the future which have shaped their lives; (3) though each sibling has
an equal chance of carrying a parent's genetic su sceptibility to Huntington ' s, people
misinterpret their good fortune as their sibling's doom, and vice versa; (4) having lived their
lives anticipating the worst, individuals may experience an identity crisis and mourn
opportunities they did not pursue; and (5) all emotional problems blamed on the disease
now must be dealt with and family members and friends no longer will make special
allowances. See Saltus, supra note 106, at 14. As stated by one who underwent this testing:
I don't know who I am or what my goals are . . . . The whole world is open to me
now. Before, I li ved a year at a time; I always had short-range goals. I got my
associate's degree, then my bachelor's, then a master's, and I switched careers so I
would be working for an employer where I would have good benefits and be
protected by federal laws. Now, I don't know what I am going to do-I just know
that I'm restless.

Id. To decide whether to take the Huntington's test, Dr. Nancy Wexler asked herself:
"Would I change my job? No, I love what I ' m doing. Would I work any less?
No. Would I work any more? I am not sure I can. Would I be any less frantic
and obsessional? Probably not. Would it change personal relationships and
friendships? No. There's an awful lot it would n ' t change. . . . I'm already h appy,
how much happier am I going to be? Part of me realized how happy I am, being
part of this whole research process that's going to make a difference in the future."
COOK-DEEGAN, supra note 20, at 236.

1 20. See Communication between Robin J.R. Blatt and Dr. Patricia Murphy),
(January 1997); see also Andrews, supra note 22, at 9 7 6 (stating rate is four times higher).
1 2 1 . See Andrews, supra note 20, at 984-9 1 ; B arash & Alper, supra note 5 8 , at 43;
Geller et al., supra note 58, at 72.
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expensive and not necessarily covered by insurance; 1 22 the United
States does not have enough certified, practicing genetic counselors;123
and health care providers are not knowledgeable enough about
genetics to help stretch these limited resources. 1 24 Because of poor
insurance coverage, costs for investigatory genetic testing are likely to
be paid out of the pockets of consumers, and adequate counseling
could increase the costs of testing tenfold. 125 But without mandatory
provisions for pre- and post-genetic counseling, the United States is in
danger of repeating its sickle-cell screening mistake, multiplied for a
whole spectrum of conditions. 126
Moreover, absent a legal infrastructure to comprehensively
protect the public from discrimination by insurers, people may be
paying out of their pockets for tests to generate genetic inforrnation
that gets into their medical records and damages their insurability. 127
1 22. Even when counseling is covered, the time constraints placed on genetic
counselors under managed care may be responsible for the profession's high rate of burnout.
1 23. See ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 , at 4 ('The number of
medical geneticists and genetic counselors to whom patients can be referred is likely to
remain too small to cope with the potential volume of testing."). At the present time, the
National Society of Genetic Counselors has an enrollment of only 1 ,450 members. See
McCormack, supra note 1 8, at 3. Note, however, that some biotech companies are
employing counselors to act as a resource for providers. For example, Genzyme Genetics,
which has 1 6 testing labs across the country, employs three counselors. See id.
124. See supra note 1 1 0 and accompanying text.
1 25. See Michael J. Malinowski , Capitation, Advances in Medical Technology, and
the Advent of a New Era in Medical Ethics, 22 AM . J.L. & MED. 335, 35 1 & n. 1 06 ( 1996).
1 26. The United States's sick.le cell screening program was launched in the early
1970s with good intentions and lots of shortsightedness:
[G]enetic counseling of the individuals tested, and restrictions on the use of
the genetic information obtained from the tests, were not made priorities. As a
result, the screening generated confusion and anxiety among the population.
Many identified as carri ers of sickle cell mistakenly thought they were afflicted
with the disease. Often, confidentiality was breached, and in some instances,
carriers, not actually possessing the disease, were denied health insurance. In
addition, because no prenatal test was available, some carriers were told the only
prevention for the disease was to avoid having children.
Brom, supra note 27, at 1 29 (footnotes omitted).
1 27. The EEOC has issued a comment in its Enforcement Manual that prohibits
employers from discriminating on the basis of genetic information. See EEOC COMPLIANCE
MANUAL § 902.8 ( 1 995); see also infra note 263. President Clinton recently signed into law
legislation that includes a prohibition against denying a person, previously insured, coverage
on the basis of genetic information during a change in insurance. See Health Insurance
Portability and Accountability Act, Pub. L. No. I 04- 1 9 1 , 1 10 Stat. 1 936 (1996)
(nonetheless, not protecting those presently without insurance against genetic discrimination
and denial of coverage based upon preexisting conditions); see also Senate Passes Bill on
Portable Health Insurance, BOSTON GLOBE, Aug. 3 , 1 996, at A4. Moreover, approximately
1 1 states have enacted protective legislation, and there presently is a flurry of activity at the
state level. See Neil A. Lewis, 2 Marines Who Refused to Comply with Genetic-Testing
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Investigatory predictive genetic tests also may endanger the physical
health of patients by creating the possibility of over-treatment . 1 28 The
Order Face a Court-Martial,

N.Y. TIMES, Apr. 13, 1 996, at 7 (reporting that "[o]nly 1 1

states forbid discrimination based on a person's genetic makeup" and mentioning that bills
are pending in 20 other states).

Nevertheless, the danger of genetic discrimination is

expanding with the generation of genetic infonnation from the availability of genetic testing.

See Genetic Screening by Ins urance Carriers, 267

JAMA 1 207, 1207-09 ( 1 992) ("Insurers

may apply genetic information inappropriately. Individual risk will be overestimated if the
concepts of penetrance and variable expressivity are not considered."); Susan O' Hara,

The Use of Genetic Testing in the Health Insurance Industry: The C reation of a
"Biologic Underclass ", 22 Sw. U. L. REV. 1 2 1 1 , 1 21 9-24 ( 1993) (exploring the potential
for discrimination by the health insurance industry arising from genetic testing); Geneticist
Calls for Privacy in Test Res ults , BOSTON GLOBE, Sept. 30, 1995, at 3 ("One study found

Comment,

1 00 people who were denied insurance benefits because of genetic risks, and a survey of
families with inherited diseases found 31 percent had been denied coverage even if they
weren't actually ill . . . . "); Koenig,

supra note 24.

In April 1996, representatives of the insurance industry stated publicly at a meeting of
the National Task Force on Genetic Testing that they "would go out of business if they were
restricted from having access to genetic information." Weiss,

supra

note 2.

According to

some accounts, 'Though insurance industry representatives often state that their companies
are not likely to use genetic screening now or in the foreseeable future, they demand access
to this information concerning their applicants if it is available at professionals' offices,
employment settings, or governmental agencies." O'Hara,

s upra,

at 1220. The insurance

industry already has organized to maximize its access to underwriting i nformation.
"Currently, seven hundred insurance companies have formed an organization called the
Medical Information Bureau (MIB), sharing information about policy holders in an effort to

Id.
See generally

prevent concealment of underwriting information."

at 122 1 . Insurance companies may

already be demandin g genetic testing.

Geller et al.,

(discussing reports of genetic discrimination); Lee Bowman,

Privacy Issue,

supra note 58, at 72
Genetic Inheritance Seen as

WASH. TIMES, Apr. 1 5, 1996, at A 10 (According to Dr. Paul Billings of

Stanford Medical School, co-author of a study on genetic di scrimination,
[m]ore than 900 people known to have a genetic predisposition for certain
diseases but without any symptoms themselves said they had experienced some
form of discrimin ation on the job or from insurers, according to the study. . . .
Many more people also have been denied life or health insurance for refusing to
submit tissue for genetic testing . . . .
One response is to flatly exclude genetic information from the insurance process, see
Genetic Screening by Insurance Carriers, supra, at 1 207-08, a position supported by the
biotechnology industry. See Lisa Piercey, Kennedy Alleges HIAA Seeks to Undennine
Genetic "Nondiscrimination " Provision, B10WORLD TODAY, May 15, 1 996, at I . The
industry perceives fear of genetic discrimination as an impediment to consumptio n . See id.

Such an approach is prudent in the context of health insurance for predictive conditions. We
all carry genetic predispositions for disease and, i n light of the frequency of which

individuals change jobs and health insurance coverage, the genetic predisposition factor i s
"a wash" fo r all practical purposes. However, such an approach i n the context of l i fe and
disability policies (life-long contracts) could price those policies off of the market due to the

problem of adverse selection-individuals with genetic information may use it to "cheat" the
health insurance market by buying added coverage.
Genetic Screening by Insurance
Carriers , supra, at 1 208.

128. The importance of specificity (this term is defined at supra note 25) in the
context of genetic screening tests for cancers is underscored by the fact that the human body
can be thought of as "one giant precancer":
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United Kingdom has explored the impact of predictive genetic testing
information on the lives of children and concluded that children should
not have genetic diagnoses for late-onset disorders.129
The precedent set by IVF, Myriad, and OncorMed could carry
significant implications for the commercialization of predictive genetic
testing

services,

including

widespread

investigatory genetic testing services.

commercialization

of

The BRCA testing services

offered by these companies may shape standards used to evaluate this
technology.

If a test has no predecessor, it becomes the governing

standard; the most definitive method or test in existence becomes the
"gold standard" against which analytical validation is measured.

1 30

The availability of BRCA testing services should enable IVF,
Myriad, OncorMed, and their research allies to compile enough
clinical data to determine predictability in a greatly accelerated
fashion.

These

advantages

will

pressure

other

biotechnology

companies to make genetic testing available to the public. All of the
related science, including sequencing, could be pushed forward,
thereby making more therapeutics and treatments a viable possibility.
Although such benefits to public health may be considerable, the
financial and emotional costs to those who undergo predictive genetic

As it turns out, virtually all of us have precancerous lesions in our bodies.
Autopsy studies of women who died of something other than cancer reveal that 39
percent of women between the ages of 40 and 50 have hidden precancer lesions in
their breasts-but only 1 percent of women in this age group are clinically
diagnosed with breast cancer. Likewise, more than 40 percent of men between 60
and 70 have cellular evidence of prostate cancer that can be found when their
tissue is scrutinized under a microscope, though only 1 percent are actually
diagnosed with the disease.
Madeline Drexler, Malignant Predictions, BOSTON GLOBE, Feb. 18, 1 996, (Magazine), at 9.

1 29.

This conclusion was reached by the Science and Technology Committee of the

House of Commons and the

U.K. Working Party of the Clinical Genetics Society. See
U.K. Working Party of the

Mclean, supra note 1 9, at 1 20 (discussing recent report of the

Clinical Genetics Society) (citing 1 SCIENCE AND TECHNOLOGY CoMMTITEE , supra note 50,
at xxxviii). The findings of these entities have been summarized as follows:
Where the diagnosis has no direct impact on the health of the child, they suggest
that testing,

and

knowledge of test

results,

have

a number

of negative

implications. For example, they may lead to the loss of sel f-esteem, affect the way
in which the child is treated in the family or the wider community, prevent a later
exercise of autonomy by taking the decision about testing out of the hands of the
potential adult, and breach current

U.K. policies on the need for counseling before

or in the tandem with screening.

Id.
1 30.

See ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 , at 4-6.
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testing during the interim will be significant. At what point does this
cost become too high?
The four cornerstone principles of health care are "autonomy,
beneficence, nonmalfeasance, and justice or equity."131

These are

inherently individualized concepts, meaning that they lead providers to
"focus on the specific patient to the exclusion of other actual or
potential patients."132

Applying these principles to widespread

investigatory, predictive genetic testing raises many questions. One of
the most fundamental is, what should patients be told before they
decide to undergo such testing? The danger is that the answer to this
question is left to the provider and to the protocol established by the
test's developer, who has every incentive to encourage use to gather
both patient data and revenue to cover the costs of research.
The following

is

a more

comprehensive

analysis · of the

commercialization of testing services for BRCA mutations linked to
breast and ovarian cancers. First, the prevalence of breast cancer and
the approaches taken by the companies marketing these tests are
addressed in more detail.

Next, the regulatory and general health

policy implications of BRCA testing services are explored through the
technique of legal storytelling, which is applied to identify important
public health issues ("issue spot").

The varying stories presented

embody the perspectives-cancer survivor, genetic counselor, health
consumer advocate, and corporate representative-of individuals with
personal experiences dealing with breast cancer, BRCA genetic
testing, and the R&D, marketing, and regulation of medical products.

ill.

THE SEMINAL CASE: BRCA TEsTING SERVICES
As stated by Dr. Francis Collins, head of the HGP, "[b] reast

cancer is the most common cancer among women in the Western
world, with a cumulative lifetime risk of 1 in 8."133 This year alone,
1 84,300 women will be diagnosed as having breast cancer. 134

Some

1 3 1 . Mclean, supra note 1 9, at 1 17.
1 32. Id. ; see also Malinowski , supra note 1 25, at 334-47 (discussing the
deontological tradition of medical ethics).
1 33. Collins, supra note 2, at 1 86; see also Hon Fong Louie Mark et al., Clinical and
Research Issues in Breast Cancer Genetics, 26 ANNALS CLINICAL & LABORATORY SCI. 396,
396 (1996) ("Breast Cancer is the most common form of cancer in women in the U.S.").
1 34. See From the CDC: Breast Cancer Incidence and Mortality-United States, 276
JAMA 1293, 1 293-94 (1 996) [hereinafter Breast Cancer Incidence] ; David Plotkin, Good
News and Bad News About Breast Cancer, ATLANTIC MONTHLY, June 1996, at 53, 55-58
(relying upon data provided by the American Cancer Society); see also Dolores Kong,
Mammogram Wars, BOSTON GLOB E, May 27, 1 996, at 34 (stating that, overall, 1 80,000
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44,300 women will die from the disease. 135 Of the women in whom
cancer is diagnosed,

9,200 will not have reached their fortieth birthday,

nearly twice the number of women under forty who were found to
have breast cancer in
forties.137

1 970, 136 and another 33,000 will be in their

Breast cancer "is now the leading cause of death for

American women aged forty to fifty-five, and causes women to lose
more years of productive life than any other disease."138
BRCA testing is available through three schemes, two of which
reflect the labeling options under present regulations. 1 39

The third

entails direct marketing without FDA oversight and restrictions:

For research use only and not for use in diagnostic procedures.
NIH is conducting a BRCA testing study in the Washin
1
area that involves 5,000 Ashkenazi Jewish volunteers.

�on-Baltimore
Pursuant to

this labeling, 141 those participating in the study are not given their test
142

results.

For investigational use only.

OncorMed has labeled its genetic

testing service accordingly. To comply with the accompanying federal
restrictions:

( 1 ) women

must be referred for counseling before and

after the test is performed; (2) results must be given by the physician in
person;

(3) the

physician must follow up with the patient about three

months later; (4) the test developer must compile data on an ongoing
basis to determine which aspects of the gene-testing process need

cases of breast cancer are diagnosed in the United States each year); Richard Saltus, Breast
Cancer Testing: Do You Want to Know?, BOSTON GLOBE, Mar. 1 1 , 1996, at 25 ("Each year,
about 185,000 new cases (4,600 in Massachusetts), and 44,000 deaths are reported."). For
more information, contact the National Cancer Institute, Cancer Information Service, 9000
Rockville Pike, EPN 300, Bethesda, MD 20892. The Institute may be reached by telephone
at (800) 4-CANCER (422-6237).
1 35. See Plotkin, supra note 1 34, at 55, 58 (relying upon data provided by the
American Cancer Society); see also Kong, supra note 1 34, at 34; Saltus, supra note 1 34, at
25.
1 36. See Plotkin, supra note 134, at 55, 5 8 . The significance of these numbers is
underscored by the fact that malignancy generally grows faster in younger women. Kong,
supra note 1 34, at 34. Despite advances in detection through mammography, surgical
technique, radiation therapy, and chemotherapy, these advances have not lessened the
likelihood that women will die of breast cancer. See Plotkin, supra note 1 34, at 76. "In
1935, 26.2 out of every 1 00,000 women died of breast cancer. . . . In 1 992, the latest year
for which figures are available, the adjusted rate of mortality was 26.2 women per
1 00,000-h
-t e same as 1 935." Id.
1 37. See Kong, supra note 134, at 34.
138. Plotkin, supra note 1 34, at 58.
1 39. See supra note 64.
1 40. The recruitment target of 5,000 volunteers was surpassed in just two months.
See Wadman, supra note 5.
1 4 1 . See supra note 64 (addressing "research" labeling).
142. See Wadman, supra note 5, at C3; Weiss, supra note 2, at A l .
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improvement� and (5) the developer only may charge an amount
necessary to recapture the costs incurred for the stated research
143
Many of these restrictions were developed through an

objective.

IRB assembled by OncorMed. The IRB was staffed with experts paid

consulting fees

1

44

to develop a protocol for investigational marketing in
145
The sum effect of the work of OncorMed's

compliance with CLIA.

IRB is that physicians are given a well-developed protocol for their

interactions with patients regarding the test, and they

are

instructed to

make the testing service available only to patients with breast cancer or
146
at a high risk of getting the disease.
The costs charged for the test
fluctuate significantly according to the stated research objective and
the testing undertaken.

If the company is attempting to locate a

specific mutation, the cost may be as low as $ 1 50; if the data is used
147
for sequencing, that cost may reach $ 1 ,650.
Independent

of FDA Regulations. A B RCA test also is being made

available entirely independent of FDA oversight by IVF Institute. IVF
Institute offers its BRCA test and the results to any woman willing to
148
pay $295 .
Similarly, two of Canada's most respected universities
McGill University and the University of Toronto-are offering open
149
access to BRCA testing.

143. See Weiss, supra note 2, at A2. OncorMed continues to revisit and revise its
protocol. As of January 1997, OncorMed also requires physicians to call in or fax patients'
family histories to the company before testing. See OncorMed, Hereditary Breast Cancer
Education and Testing Packet (Jan. 15, 1997).
144. See First BRCAJ Test Hits the Market, supra note 65, at 1-5.
145. See id. at 3-5. A summary of the OncorMed protocol is attached as Appendix I.
146. OncorMed is instructing physicians that its BRCA test is available only to
certain at-risk patients. See App. I.
147. See id. OncorMed offers testing in stages I to III for BRCAI alterations and
stages I and II for BRCA2 mutations. Each stage tests for different BRCA alterations and
carries a separate cost-from $420 for a Stage I BRCA 1 test to $800 for a Stage III BRCA 1
test, and $800 for a Stage II BRCAI and BRCA2 multiplex test (the tests are done together).
See Hereditary Breast Cancer: Questions and Answers for Patients 3, in OncorMed, supra
note 143 .
148. See Wadman, supra note 5 , at C3 (discussing a genetic test fo r breast and
ovarian cancer); Weiss, supra note 2, at A2. Dr. Schulman, who is working i n conjunction
with IVF Institute, is making the test available to all Jewish women who have been referred
by a physician. See Wadman, supra note 5, at C3. One of Dr. Schulman's first clients was
his wife, who underwent the test at the age of 38, tested positive and had both of her breasts
removed. See id.
149. See Wadman, supra note 5, at C3 ("In last week's New England Journal of
Medicine, they report that they are offering on-demand testing for the Jewish mutation.");
David S. Rosenblatt et al., Genetic Screening for Breast Cancer, 334 NEW ENG. J. MED.
1 199, 1 199-1200 ( 1 996) (testing for 185delAG is being offered at the University of Toronto
and McGill University).
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Although the occurrence of breast cancer is epidemic, 150 the fear
of breast cancer and the potential market for genetic testing services is
exponentially larger.151 Even according to Myriad's own marketing
materials, current data suggests that, of all the women with breast or
ovarian cancer, only approximately five percent carry a BRCAl
mutation.152 Of the approximately 1 85,000 people diagnosed with
breast cancer annually, only five to ten percent inherit the disease.153
Nevertheless, OncorMed, IVF, and Myriad envision multimillion
dollar markets for their BRCA tests, and their expectations are well
grounded. The market for cancer diagnostics is big business, that
business is growing quickly, 154 and "surveys of women have revealed
1 50. See AMERICAN CANCER SOCIETY, CANCER FACTS AND FIGURES ( 1 995). Women
in the United States have an estimated 1 0% lifetime risk of getting the disease, and the
median onset age is 64.
1 5 1 . See Koenig, supra note 24, at A23 (after the discovery that l % of Ashkenazi
Jewish women carry genetic predisposition to breast and ovarian cancer, "a surgeon who
operates on women with breast cancer told me that a day rarely passes when a patient does
not ask about 'the gene test"'); Weiss, supra note 2, at Al ("Most important, many women
seem not to realize that it is only if a woman has a clear family history of breast cancer
usually identified as two or more close relatives with the disease-that the BRCAI mutation
confers 85% odds of getting breast cancer."). But see Alison Bass, Ethnicity Called Factor
in Patients' Decisions, BOSTON GLOBE, Sept. 14, 1 995, at 3 ("For example, a majority of
elderly people of Korean and Mexican descent would prefer not to be told that they suffer
from metastatic cancer, while European-Americans and African-Americans would rather
know the bad news, the study of 800 nursing home residents found."); Saltus, supra note
106, at 14 ("Before the HD test became available, people who were at risk showed strong
interest in a predictive test. But when the test appeared, fewer people than expected actually
stepped forward.").
152. See MYRIAD LABORATORIES, INC., supra note 7, at 2; Saltus, supra note 1 34, at
25 (stating that inherited mutant genes probably account for 5 to I 0 percent of breast cancer
cases, but this inherited type "seems to be more aggressive; it may also appear earlier than in
noninherited cases, sometimes when the woman i s in her 20s or 30s"). "About I in 200
women in the United States are thought to carry a mutant BRCAI gene. BRCAI accounts
for about 50 percent of inherited breast cancers, BRCA2, may cause 35 percent, and the
remainder are due to undiscovered genes." Id.
153. See The Scientific Questions, supra note 4, at 4 (stating that it is estimated that
1 0% of breast cancers are due to gennline mutations); Hilzenrath, supra note 4, at D24
(discussing a news service to detect predisposition to breast and ovarian cancer); Saltus,
supra note 2, at A 1 8 .
1 54. "Today, the cancer diagnostic business alone i s a $1 billion industry attracting
some major corporate players and small companies," and the demand for more reliable ways
of detecting and monitoring cancer is growing with an aging American population. See
Rosenberg, supra note 1 5 , at 80. As stated by a market analyst:
Genetic tests for susceptibility to cancer are a hot area currently, as there
have been many announcements of the discovery of genes which predispose some
people to specific types of cancer. While genetic tests are done using blood, they
are more expensive and difficult than traditional blood tests. Myriad Genetics,
one of the genomic companies, has made a decision to enter this business. They
are one of the discoveries of the BRCAI gene, which identifies one form of the
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an overwhelming interest in being tested to learn their gene status."155
As stated by the National Cancer Coalition, "ready or not, genetic tests
are on the threshold of entering everyday practice of medicine." 1 56

Meaningfu,l Assessment of the Commercialization ofBRCA
Testing Services

A.

Understanding the full implications of commercialization of
predictive BRCA testing services is a necessary prerequisite for
defining resulting health-policy issues and constructing a regulatory
response that maximizes public health benefits. Especially in light of
the novelty of this technology, there must be meaningful assessment
in other words, appreciation of innumerable issues and perspectives,
many of them contradictory.
individual lives,

The potential impact of such law on

society in general,

and the commercial

sector

responsible for producing health care technology mandates such an
approach.
"Legal storytelling" has been defined by some scholars as a
license to describe personal experiences without the constraints of
traditional
extensive

legal

scholarship,

footnoting,

and

which

reliance

include
upon

an objective

empirical

tone,

research. 1 57

Extremists contend that only those excluded by the legal academy,

hereditary risk of breast cancer. OncorMed is a genetic testing company which
also sees an opportunity in cancer testing, and is acquiring diagnostic rights to
discoveries made by others. Additional cancer genes will be discovered over the
next few years, but the acceptance of such tests will be controversial. Unless the
patient will gain some benefit from the knowledge, there is no justification for an
expensive test.

In some cases, the knowledge that a patient has a high risk of

cancer could be devastating.
Cancer Diagnostics, supra note 84, at 3.

155. Saltus, supra note 1 34, at 25.
1 56. First BRCA J Test Hits the Market, supra note 65, at 4.
1 57. See Arthur Austin, Evaluating Storytelling as a Type of Nontraditional
Scholarship, 74 NEB. L. REv. 479, 485-88, 521 (1995) (stating that feminists and members
of the racial critique theory movement profess to speak in a different voice derived from
their gender and race experiences, and that they make no pretense of balance or objectivity);
Mary I. Coombs, Outsider Scholarship: The lAw Review Stories, 63 U. COLO. L. REV. 683,

685 (l 992) (discussing the rejection of dispassionate objectivity in favor of narrative
discourse). For a general and thoughtful discussion of the deontological aspect of the legal
storytelling technique, see Toni M. Massaro, Empathy, Legal Storytelling, and the Rule of
lAw:

New Words, Old Wounds?, 87 MICH.

L. REV. 2099 ( 1989).

See also Anne M .

Coughlin, Regulating the Self: Autobiographical Perfonnances in Outsider Scholarship, 8 1

VA. L. REV. 1 229, 1 23 1 ( 1 995) (applying autobiographical narrative to legal discourse);
Angela P. Harris, Foreword: The Jurisprudence of Reconstruction, 82 CAL. L . REV. 741 ,
750-54 (1 994) (discussing how critical race theory utilizes modem narratives in its
optimistic moments).
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people of color and women, have stories to tell.158 They also

argue that reversion to elements of traditional scholarship, such

as

extensive footnoting, weakens resulting scholarship.159 Critics of this
genre of legal storytelling (the extremist perimeter of "outsider
jurisprudence"160)

dismiss

such

scholarship

as

anecdotal

self

absorption. 161 Many pages have been consumed debating whether this
scholarship is more or less "real" and meaningful than its more
traditional counterparts.162
In this Article, the technique of legal storytelling is used to
complement traditional-style scholarship.

Absent the extensive

clinical data necessary to comprehensively evaluate the impact of
genetic testing capability on the lives of those who undergo it, legal
storytelling is a technique used to thoughtfully assess both the need for
and the potential impact of changes in regulatory law.

These stories

are offered to illustrate the practical effects of the commercialization of
predictive genetic testing services. The objective is to engage in legal
analysis that is more responsive to the underlying facts and, therefore,

more intellectually rigorous and meaningful. Accordingly, rather than
a substitute for comprehensive empirical data and with full recognition
that its utility is l imited by the perspectives of the stories presented, the
158. See Austin, supra note 157, at 487 (stating that both feminists and Racial
Critique Theory people "claim to get special insights from status as victims or outsiders").
1 59. See id. at 5 2 1 ('The presence of footnotes should not distract from the plot or
create static in the flow of the narrative.").
160. See Mari J. Matsuda, looking to the Bottom: Critical Legal Studies and
Reparations, 22 H ARV. C.R.-C.L. L. REV. 323, 325 (1 987) (recommending a "new
epistemological source for critical scholars: the actual experience, history, culture, and
intellectual tradition of people of color in America"); Deborah L. Rhode, Feminist Critical
Theories, 42 STAN. L. REV. 6 17, 622 ( 1990) (discussing the experience of women's actual
circumstances, such as being dominated, as a way of understanding feminism). The
"outsider" group "encompass[es] various outgroups, including women, people of color, poor
people, gays and lesbians, indigenous Americans, and other oppressed people who have
suffered historical under-representation and silencing in the law schools." Mari Matsuda,
Affinnative Action and Legal Knowledge: Planting Seeds in Plowed- Up Ground, 1 1 HARV.
WOMEN's L.J. 1 , 1 n.2 ( 1988).
1 6 1 . See Austin, supra note 157, at 49 1 ("Serious scholars revere analysis and
objectivity. To them, subjective advocacy posturing is best left to the National Enquirer.
Bias is a form of fraud." (footnote omitted)); see also Daniel A Farber & Suzanna Sherry,
Telling Stories Out ofSchool: An Essay on Legal Narratives, 45 STAN. L. REV. 807, 853-54
( 1 993) (discussing the importance of reason and analysis in legal scholarship).
162. See, e.g., Kathryn Abrams, Hearing the Call of Stories, 79 CAL. L. REV. 97 1,
1021-27 (199 1 ); Austin, supra note 157, at 523-27; Richard Delgado, On Telling Stories in
School: A Reply to Farber and Sherry, 46 V AND. L. REV. 665, 668-75 ( 1 993); Farber &
Sherry, supra note 1 6 1 , at 832-38; Daniel J. Solove, Book Note, Fictions About Fictions,
105 YALE L.J. 1 439, 1 439-40 ( 1 996) (reviewing L.H. LARUE, CONSTITU TIONAL LAW AS
FICTION: NARRATIVE IN THE RHETORJC OF AtrrHORITY ( 1995)).
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technique of legal storytelling i s used as a means t o illustrate
underlying

facts,

identify

issues,

and

analyze

public

health

implications and regulatory considerations.163

B.

Some Stories
The effectiveness of the legal storytelling technique is dependent

upon the selection of stories and the manner in which they are
presented. The following narratives are in the words of the subjects
who relayed them. They illustrate many of the patient, provider, and
regulatory issues identified above in more objective prose.

Varying

perspectives, both complementary and contradictory, are juxtaposed to
stimulate issue identification.
Many prospective subjects were considered, and representative
subjects were

selected.

Interviews

with

these

subjects

were

audiotaped, transcribed, edited, reviewed by the subjects for accuracy,
and revised accordingly.

In content, we have selected perspectives

resulting from first-hand experience with the issue of BRCA genetic
testing.

We also have selected arguably contradictory perspectives,

such as those of a consumer advocate and a corporate executive from
the biotechnology industry.

The overall objective was to solicit

opinions, based upon personal and professional experiences, on the
adequacy or inadequacy of the existing regulatory scheme for
predictive genetic testing, with a particular focus on BRCA testing
services.

1.

A Cancer Survivor's Story164
In January

cancer.

1 993, at age forty-eight, I was diagnosed with breast

I had a routine mammogram that had a density on it. A six

month follow-up visit was recommended. I elected to ask for a second
opinion because I was on honnone replacement therapy, and I knew
that this therapy could potentially affect the growth of a tumor if one
was there. I went ahead and had a biopsy, and it was positive.
had a lumpectomy,

auxiliary dissection,

and radiation

So

I

therapy.

Meanwhile, a decision was made to biopsy the other side. I h ad some

163. The use of legal storytelling in this Article parallels the storytelling of outsiders.
See Austin, supra note 1 57, at 505 ("Descriptions by people like Derrick Bell, Richard
Delgado, and Patricia Williams convey the common theme that stories raise consciousness
and serve as a vehicle to educate insiders." (footnotes omitted)).

1 64. This story is based upon an interview with a breast and colon cancer survivor
who also is a health care professional.
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calcifications which normally wouldn't be of concern but, because I
had a primary tumor on the left, a biopsy of my right breast was
suggested. In fact, I had a precancer on that side. This was treated
with a wide excision. Seven weeks after I finished radiation, I had a
colonoscopy and was diagnosed with advanced colon cancer. I had
four positive lymph nodes, so I went on to do a year of chemotherapy
after that.
I have a very strong history of cancer on my father's side of the
family. My father, aunt, uncle, and grandfather had multiple cancers. I
have three first cousins who have had cancer, and my brother also has
had two primaries. Having grown up with cancer in my family, I have
always thought about what's at work in our genetic background. I
guess it was always an expectation that some day, eventually, I would
probably get cancer. I just never thought I'd get it as young as I did. I
certainly never thought I would get two at once. You do think about
this when you grow up and are surrounded by it. In a way, it gives you
a chance to sort things through and ask yourself, "What would I do if
this type of scenario happens to me?"
One of the reasons I remain optimistic despite the likelihood of
my having a genetic predisposition is that I believe we are more than
our genetic inheritance-lifestyle, diet, and environment all come into
play in varying degrees . If you looked at my family pedigree, you
would see that all the family members who had cancer lived in or near
a paper mill town. Those who lived on the coast were cancer-free.
There are also large quartz deposits and, consequently, high radon
levels in the paper mill area . . . another carcinogen, along with the
dioxin and other byproducts of the paper-making process. So I guess I
believe that the bottom-line isn't in yet and that, while genetics are
important, there is more to the story.
I had really never thought to myself, "I wish there were a genetic
test available so I could find out whether I' m going to get cancer." But
I will say that, back in 1989, I became much more aware of genetic
testing. I remember saying to my colleagues, "You know this is what
my family history looks like . . . don't you think this is a lot of
cancer?"
Since my breast cancer diagnosis, I have thought about whether I
would want BRCA 1 testing-if I would want to know whether I carry
the alterations in the gene linked to cancer. I don't know that I would
want to be tested for BRCAl , and the reason is that my daughter is
twenty-five and my son is twenty-four. As far as I'm concerned, for
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me personally, the die is cast. I've had cancer twice. This is clearly
my heritage. I know I could possibly have it again. I am probably also
at elevated risk for both ovarian and uterine cancer. But I don't know
what I would gain if I found out I have an altered BRCA I gene
because I know I would not have a prophylactic mastectomy. I've had
my children, and I don't know that my daughter would gain anything
by knowing either.

Her awareness i s already heightened.

She will

certainly go through pretty rigorous surveillance, seeing the doctor
frequently for breast exams, and there's not a lot else she can do in
terms of prevention.
Both my kids have asked whether it's possible that they have
inherited a gene for cancer. We talk about it a lot. We tend to discuss
the colon cancer more than the breast cancer. We have talked about it
and, again, I think BRCAI for my family is probably not as big an
issue as the colon cancer gene.

I do think I would feel differently

about genetic testing for the colon cancer gene for several reasons. If I
do have that particular gene, I would then have the option to think
about taking an action-such as having a hysterectomy. If I actually
had the gene, once again, I don't know that anybody can put numbers
on this, but I would be at elevated risk for ovarian and uterine cancers.
So for me, personally, that would be something I could do with that
infonnation. I can't think of anything I could do with the breast cancer
infonnation that would be any different from what I'm doing now.
I think risk is a lot like beauty. It is in the eyes of the beholder.
Perhaps because I've grown up in a family with various, multiple
cancers, and my family members have dealt with it and gotten on with
their lives, my perception of risk is maybe a little different than
someone else's might be. I don't know that I could say how I would
feel if I had a strong family history of breast cancer. If my mom or
sister had breast cancer, I suspect I' d feel a lot more threatened than I
do now. I would probably also feel more threatened in terms of my
daughter.

In my opinion, undergoing this type of testing is a very

personal decision.
I think the whole area of predictive genetic testing is something
that we need to address, because we're going to have a lot more genes
coming down the pike. There are going to be many people who are
going to be affected by earlier diagnosis, and all these discoveries that
are coming . . . it just means that there are that many more people at
risk who are going to face these issues and be anxious.

I also think

one of the unfortunate down sides of genetic testing is that, for the
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average person, it is extremely difficult to sort out where you fit into
. this picture . . . i f you fit in at all.

While there are high-risk cancer

clinics at some major teaching hospitals and research institutions, not
everybody has access to these kinds of services. Not everybody lives
in a metropolitan area.
It's interesting that, although the BRCAl testing is still relatively
new, independent labs are giving out results.

I think it's potentially

dangerous to offer predictive genetic tests without stringent quality
control and regulation. Giving out results that aren't accurate isn't the
whole problem.

Based on my experience working with researchers

who are extremely careful, even when they set up programs with many
safeguards, the issues that arise for people are still traumatic. This type
of genetic testing is not something to be taken lightly.

My personal

bias is that this kind of testing must be set up by the medical
profession, ordered by the medical profession, and that members of the
medical profession should be the ones responsible for giving out the
results-not independent labs or companies developing the tests.

I

mean, if you go to your physician and you have your annual physical
exam, and you have a chest x-ray or a blood test, the lab doesn't call
you and give you your results.

I really feel that there should be the

same kind of o versight and development of medical standards for
genetic tests that there are for other types of medical tests, perhaps
even more so.

A lab shouldn' t be doing genetic testing if it hasn't

gone through an approval process for that particular test.
There are s o many things that one needs to know before
undergoing genetic testing. I think one of the biggest challenges of the
genetic revolution is the dissemination of infonnation and education of
both the primary care providers and the patients themselves. It's very
tough to sort out all this infonnation. I think it has created a great deal
of concern and a lot of anguish for women who probably aren 't even at
risk for the inherited fonn of breast cancer.

Women almost always

overestimate their risk.
From a cancer patient's perspective, what I believe is most
needed for an individual prior to this type of genetic testing is time,
especially time for genetic counseling.

There also needs to be

coordinated peer support so that when an individual is diagnosed with
cancer, no matter what type it is, they can, through their physician,
nurse, or social worker, say, "I would really like to speak with
The

someone who has been through this decision-making process."

other issue that concerns me is the point in time that genetic testing is
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discussed. If it's close to diagnosis, you are concentrating on how you
are going to get through the surgery, whether you are going to live
through the treatment, who's going to take care of your kids for five
days a week during seven weeks of radiation, and what's going to
happen with your job. That's enough for the average person. There's
a limit to how much you can deal with at one time. We need to think
more about when people are mentally ready to hear the information on
genetic testing and its implications.

I have spoken with many people with cancer .over the last few
years.

I also have had the advantage, if you want to call it an

advantage, of not only talking with people and growing up in a family
with a lot of cancer, but also working in this research area. And even
having dealt with this every day, the decision to undergo genetic
testing still takes a lot of thought.

You have to know what the

ramifications of that decision are and, let's face it, there are a lot of
potential

ramifications.

How

one

perceives

the

risk

of the

ramifications i s as important as how you perceive your risk of the
disease. For example, the thought of being without health insurance,
particularly if you have children, or the thought of being denied
employment because of something like this is frightening to most
people, and right now these are very real potential ramifications.
One of the issues I came up
gynecologist for my annual exam

against when I visited my
after I'd been through both

diagnoses was insurance coverage. We discussed the fact that I might
be at elevated risk for both uterine and ovarian cancer, and what
strategy we would take on this.
transvaginal ultrasound.

He suggested my having a baseline

I agreed that I would have the baseline

ultrasound and the other baseline test recommended, which was a
blood test called

CA 125. My insurance carrier refused to pay for the

blood test. Just on general principles, I decided I was going to argue
about it.

So I called my doctor and told him what the insurance

company said.

Essentially, they said it would not affect patient care,

and that's why they wouldn't cover it. S o my doctor wrote a blistering
letter saying it absolutely would affect patient care, explaining how I
was at risk and that very positive action would be taken if this value
was elevated. They covered it but made it clear that they were going to
pay for this once and only once. Since then, I do go for a visit every
six months and have a pelvic exam, but I'm not doing routine
ultrasounds or blood tests. I could do it if I wanted to, and pay for it
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out of pocket, but I just don 't feel that i s something I choose to do right
now.
What it boils down to for me is, "Am I going to go and ask for a
hysterectomy if I have this colon c ancer gene?" I don't know about
that answer today. I've had a long time to think about this. I know a
lot, and it's still very difficult for me.

So can you imagine the

confusion for the average person who, out of the blue, develops cancer
or learns someone in their family has it? Right now, the colon cancer
gene testing is at a stage where they' re verifying their results to be sure
that they have completely reproducible results.

Results are not yet

being reported to patients. I have had my blood drawn and provided
tissue samples as well.

I will be notified when a clinical testing

program for colon cancer is available, and I will make a decision about
testing at that time.

In general, I support all the research taking place on gene

susceptibility testing. I think that the quality of most of the research is

good, and those researchers working in the area don't take any of these
issues lightly. But I do think that this type of testing must initially take
place in a research setting, to see what the ramifications are, to work
out the kinks, before opening it up to the general public. It will be
interesting to see who hops on this particular bandwagon. I've heard
about the marketing of predictive genetic testing for breast cancer
second-han�, and I think that's pretty unconscionable.

I know how

volatile it is for people to think about genetic testing. If it takes place

outside a settin g with a lot of education and counseling, well, I just
think it's unconscionable to do the test and give out the results. I don't
know that there will be any way to keep track of what the results and
the outcome will be.

I think that's the other very bad part about

genetic testing for breast cancer.

Are companies going to keep any

kind of records? Are they going to do any kind of reporting? What
about doing further testing on samples? Who will have access to the
test results?

Who will be there to help individuals deal with the

information they receive? There is no doubt that safeguards need to be
put in place, immediately, before it's too late.

2.

A Genetic Counselor's Story165
Our center is involved in a number of clinical research projects to

offer general predictive genetic testing to anybody in the local area

165. This source is a genetic counselor at a major medical research institution.
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who may have a mutation in a cancer susceptibility gene, BRCA l .
One is a general research protocol that allows us to draw blood on
anybody who has cancer to look for an inherited factor. We consider it
a fishing expedition, and it has a pretty low yield. In another program,
one of our predictive genetic testing programs for breast c ancer, we
only test people who already have a known mutation in their family, so
we're starting with knowing exactly where in their genome to focus.

In this program, we use a three-visit model with extensive counseling
because it is too much to give all of the infonnation necessary in one
visit. We do not do counseling by phone, so individuals who are out
of state are referred elsewhere for counseling and testing.

We use a

networked group of counselors that are trained and specialize in cancer
genetics.
I'm not aware of any of our researchers having financial ties with
the laboratories performing BRCA 1 testing. I really do not think there
are any financial
institution.

incentives among

the

researchers

within

our

However, since our laboratory does not have CLIA

approval to perform testing at this time, we have agreements with
other laboratories that are certified to c onfirm all results independently.
So everyone who comes to our program has two independent tests
done on their samples. Two samples of blood are drawn, and one tube
is immediately sent out to the other laboratory. This offsets concern
about a coding error or contamination at the beginning of the process.

In addition, in a separate testing protocol, we have an agreement
with a specific biotechnology company. They will perform the entire
sequence of BRC A l free of charge and we will provide the pre- and
post-counseling.

We are one of nine centers with whom this

laboratory is collaborating on this

proj ect.

It is with the understanding

that they will be allowed to use that data to determine the sensitivity
and specificity of their test assay.

Before a lab can offer a test for

clinical use and charge for it, and before developers can do clinical
marketing, they have to prove that their analyses reach a level of
specificity and sensitivity that's acceptable.
them do that, basically. This is

a

And so we' re helping

time-l imited study. Right now, all the

people who undergo BRCAl testing through our program receive it
free of charge since it is part of a research protocol.

Very soon, the

commercial labs will be offering testing, and there will be a charge for
the laboratory costs.
The women who come to our BRCA 1 program are either
concerned about getting breast cancer or actually have breast cancer.
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A lot of those concerned have a family history of the disease.

As a

result of the publicity about BRCAI testing in lay press j ournals or
. newspaper articles, we have recently received a flurry of phone calls.
We also have a cancer risk and prevention clinic at our hospital that
attracts a lot of inquiries. Many of the women who decide to be tested
do so because this is an area of uncertainty that they' ve been living
under. A lot of these women see this

as

a way of getting control-they

really want to know, and that's a lot of what it comes down to.

We

also see people for second opinions.
The maj ority of patient referrals come from outside providers,
such as doctors and genetic counselors. Although we have the ability
to search medical records here at the hospital to find people who might

be at risk, we don't. In fact, even for people who come into the cancer
risk and prevention clinic or who are at the hospital, special permission

is necessary for us to obtain their records.

The oncologists at the

hospital know about us so, if they have a breast cancer patient who
says, "Yes, my sister also had breast cancer at the age of forty," then

it's very common that the oncologist will suggest to the patient that
they contact us.

Whether an individual with breast cancer follows

through on this depends on the person themselves. Some people want

to talk soon after diagnosis, others really have no interest in doing that
at that point.

The people who are eligible for genetic testing are those with
significant histories of breast or ovarian cancer, meaning that they have
three or more people in their family with the disease. It is i mportant

for the family history to include more than one generation and
premenopausal cases of breast cancer. And they need to have a living
affected family member that we can test first because, following the
classic genetic model, we need to start with somebody who we assume
has the disease.

Otherwise, if the results are negative in the healthy

person you're testing, you don't know if you've even looked at the

right gene or the right place on the right gene. So we make a very big

deal about needing to first test somebody who is affected with the
disease and has had their diagnosis confirmed with medical records.
The only exception to that now are Jewish women who have
significant histories of breast or ovarian cancer. For these women, we
offer testing for the three known mutations without testing an affected

relative first. Part of what we are currently doing is mutation testing
for the three common mutations in the BRCA gene that occur within
the Ashkenazi Jewish population. I

am

familiar with the controversy
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surrounding the notion of a "Jewish gene for breast cancer."

I think

that, if there is malice in targeting a racial group, it's very wrong. But I
don't think that's the case with

BRCA 1 . This is not the first time that

ethnic backgrounds have been important to think about in genetic
research.
What has struck me most in thinking about our predictive testing
program is that we' re starting with people who themselves have had
cancer . . . they are the entry point into the family.

These people

understand that, really, their daughters and sisters are the ones who
potentially have the most to benefit from this. These
have already had their cancer.

are

people who

We began offering testing with the

assumption that an important reason why people who had the disease
would want to be tested would be to get the explanation of why they
got cancer, and that they already would be assuming that they carry an
altered gene. What w e found is that cancer patients we have seen are
really much more tortured about the possibility of being a gene carrier
and the possibility that they might in fact have higher chances of
getting a second cancer. I've talked with several people now that have
ultimately made the decision not to go forward with testing because
the idea was so distressing to them that, despite the fact that their sister
was really pushing them and wanted to know. When this happens, I
tell the person "Look, you're the one that has to decide because it has
direct implications for you. It's okay to make the decision that is best
for you."

So this has been eye-opening.

BRCAl testing does not

provide benign information even for somebody who's had cancer. It is
not an easy decision to make.
You can appreciate then that getting other family members to
provide samples for

BRCA 1 testing can be complicated. When you

deal with families, you encounter all kinds of different situations.
There have been situations where the person in front of you says,
"There's no way that my aunt with cancer will agree to do this . . . I
can't even ask her." In this case, you are really stuck. You can't offer
anything.

So there are certain instances where a person is the

gatekeeper for the family, and, if that person does not want to
participate at any time, we can't offer anything further.

There have

been other situations where somebody will initially be interested in
participating but then change her mind.

We honor that.

There's

another situation that doesn't come up as often, but it has happened.
The person sitting in front of you says, "My cousin has had cancer,"
we're put in touch with that person and she becomes very enthusiastic
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about participating, and then the person you have been directly dealing
with says, "I don't want to hear any more about this." But, by that
time, we're already working with other people in the family and will
continue to work with them.
Incidentally, we don't tend to see many husbands or fathers
coming to the counseling sessions with the women considering
BRCA l testing. We see a lot of friends, sometimes family members,
but that gets complicated because family members may also be at risk.
You wonder how much they are acting as a companion and how much
they are focusing on their own stuff. Mainly, women come by
themselves. We do encourage women to try to bring somebody when
the results are given.
All participants receive a patient information sheet that we've put
together about the genetic testing program itself and another just about
the BRCA I gene and what we know about it. Because our program is
a research program, there are three consent forms: one to enroll in the
program, a second to have blood drawn and analyzed, and a third to
receive results. The initial consent form is mailed to patients before
they come in for their first visit, and they are asked to bring it with
them. There's a lot of information in the consent form that can be
looked at beforehand. Women are asked to sign the first consent form
during the first visit, and then at the end of the first visit we'll show
them the blood drawing and analysis consent form. They can either
sign it that day, or they can take it home and think about it. The
informed consent process is integral to our research. All patients that
participate in our testing program are told that this is part of a research
protocol, and that they must sign an informed consent document.
Much of the same information is reiterated for all three of the
consent forms. We talk about the implications of results. We talk
about the fact that, if there is no mutation, the person's risk i s lowered
down to that of the general population. Having a gene alteration
would substantially increase the risks of cancer. We also mention the
pros and cons of testing, including the possible stigmatization of
knowing that you have an altered gene. fusurance concerns are
something that are heavily emphasized. We discuss the possible strain
on family relationships, and we talk about the fact that there is no
known medical benefit to being tested.
For some people, there are other definite benefits. It may be that
the person needs this extra information to put them into gear to have
surveillance done. People have told us that they think knowing they
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have an alteration would motivate them to plan better, to take better
care of themselves.

Now we're looking at the outcome in terms of

behavior. I'm not sure anything changes human behavior, but there are
people who think it will motivate them. Also, a lot of the women who
want testing have daughters-that is a big reason for wanting to be
tested. They say "For myself, I don' t really care, but I really am so
anxious about my daughters. I really want to know for their sake." If
the woman has the altered gene, then her daughters have the option of
being tested. If the woman doesn't have it, then her daughters are not
at risk for inheriting it.
Providing the results of BRCA 1 testing is one of the most
difficult aspects of my job. It is very powerful infonnation. There has
to be a lot of thought put into it beforehand, and a lot of follow-up and

TLC (tender, loving care) afterwards. Giving the results can really be
very involved, depending, of course, on the person being tested. For
some people, it takes twenty minutes. That's all the time they want to
give us. They just want to go home and let it sink in. Some people are
very

private

and,

whether

they

are

devastatingly

sad

or

overwhelmingly happy, they don 't choose to share that with u s . That's
why there is a third follow-up visit. Other people have a million and
one questions or they want and need to express their emotions and, for
them, it can be an hour-and-a-half to a two-hour session. We have set
up our protocol to call in a couple days after giving the test results. If
we're really worried, we'll call them that night.

If we are not so

worried, we' ll wait a couple days and then we'll check on them. There
have been instances where a husband or other companion has come in
with the woman when it is time to receive results.

Some are very

supportive, others are not as helpful.
The results are given to the person verbally along with a letter
that addresses all the things that we mentioned-the implications of
the results, what it means and doesn't mean, what the concerns are,
and the letter stresses that they

can

always contact us again.

Even if

they can't remember what we told them, they have the letter to refer to.
And I tell them that they can either throw it away if they are worried
about having something with their name and results on it, or show it to
their health care provider, or stick it in a file somewhere in their house.
The control is up to them.

We don' t document results in medical

records. The results will be told to the other providers in our high risk
clinic who know not to write it anywhere. Outside our little close-knit
group, the providers are not told. We are more than happy to disclose
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the results if we get written permission to do so, but otherwise it
doesn't go anywhere. It is unlikely that

an

insurance company would

learn about the result because it is completely done in a research
setting.
Because this is powerful information, we have to consider
whether someone will be suicidal after hearing the news. We had one
case where the woman was very upset that she got a normal result (not
in the BRCA l gene, but in a different cancer gene). She was hoping
for abnormal results as her way out of her horrible life-being able to
get cancer and just die.

Us telling her, "No, that's not going to

happen," was not good news for her, so for her we were worried. But I
think, in general , we are more concerned about the people who get an
altered gene result. They have filled out some psychiatric assessments
and had a lengthy discussion before the day results are given.

So

hopefully we have an idea of their stability and emotional well being
before they even get to this point.

It i s an important reason why we

have a clinical psychologist working on the project.
I generally do feel comfortable giving out the predictions of
breast cancer risk because of the way that we do it. We' re deliberately
vague. I am amazed when I hear that s omebody says, "Okay you' re
forty. By age forty-five, you will have this risk, and at age fifty your
risk will be that."

We just don't know that for certain .

ranges, but often we downplay the numbers.
people, numbers don't mean anything.

We' ll give

Remember, for most

You could give the same

number to four people and they w il l all perceive it in a very different
way. For many women in the breast cancer clinic, they are living with
so much feeling of doom and fear that they already know they have a
higher risk of cancer.

In fact, for a lot of people, they' ve over

estimated what their lifetime cancer risk is. So I'm not sure that they
even hear me when I say, "Look, your highest risk is fifty percent."
Now, for me or you, that sounds l ike an incredibly high risk, but for
these people, that's quite a drop in what they already think their risks
are.
Sometimes I think that being part of this research is a scary place
to be because there are not a lot of models for what we're doing. We
see other institutions doing things in ways that we don't agree with so
we can see what it is we don't want to do, but it's very hard to know
how best to do things.

For example , I hear from other centers that

have just gone ahead and started doing this type of testing more freely.
I know that there are a few labs that are offering predictive genetic
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testing for breast cancer without a required counseling component.
There are a few labs where you can just send money and a blood
sample and the test will be done. There' s at least one site that will take
anyone's blood, regardless of whether they have cancer or a striking
family history. A couple of these sites strongly encourage counseling,
but I don't know if it's required.
Whenever you work with families, what works for one family
doesn't always

work

for

another,

reevaluating how you're doing things.

and

so

you are

constantly

The first step in our testing

program is to send an invitation letter to families saying "You know,
this altered gene may be in your family. Do you want to know about
it?" Well, one person is going to call and be upset that we didn't give
more infonnation i n the letter-"As you know, I've been seen in your
center for five years. This is all you can tell me? What do you mean
that I have to have another blood test? You already have my blood."
And then a second person will get the letter and be devastated by what
they are reading into it. So it's hard to know how much information
people really want, and it's hard to be able to predict that.

If there's

one thing we've learned, it is that you can't predict how people are
going to react to this information or what people are going to want to
hear.
I have confidence in our approach to predictive genetic testing for
breast cancer because we do everything within a group process. We
have people with specialties in oncology, psychology, and genetic
counseling.

We also have set up an outside ethics group for our

research protocol composed of people not affiliated with the hospital
so that, when we really get stuck or w e ' ve done something and we
want reassurance that it was okay, we can go to them. We meet a few
times a year and go over the case histories and how we've resolved it,
or how we plan to resolve it, and they give us their feedback. I think
it's really useful, because we do a lot of obsessing about things. Also,
you can get to a point where you're convinced that you' re doing the
right thing, and sometimes it's really important for an outside group to
look at it and say, "Well, what about doing it like this instead?" This is
important because people do tend to think alike after working together
for a while.
From a laboratory standpoint, I think there has to be some sort of
standard to ensure accuracy of the results.
whenever the word "regulation" is raised.

Still, it worries me

Are we going to make it

difficult, actually i mpede our ability, to do genetic testing?

I think
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there is a fine line sometimes when i t comes to regulations.

Do we

regulate each genetic test that comes along? Do we just regulate the
labs? There are a lot of things to consider . . . .

3.

A Consumer Advocate's Story1 66
As a statewide consumer advocacy organization, our mission is

to increase breast cancer research funding, improve access to breast
cancer care and treatment, and foster consumer participation in
research decisions.

Although we are always pleased to see that

researchers are looking for the causes of breast cancer, we are seriously
concerned with the trends in genetic research. There has always been
some concern in our organization about the genetic factors at play in
high-risk families. However, only five to ten percent of women who
get breast cancer have a strong family history; most have no
identifiable risk factors. The way in which Jewish women are being
recruited for predictive genetic testing is alarming.

BRCA 1 is now

being referred to as the "Jewish gene," an d this incredible focu s on one
particular ethnic group, especially without education and the support
of the community, is appalling.
The way in which genetic research is being portrayed is very
distorted. There seems to be this implication that if you have a test,
and it shows that you have an altered BRCA 1 gene, you can do
something about it. That is not the case; there is still no known proven
intervention for breast cancer.

Our organization has received many

calls about breast cancer genetic testing over the past year. There have
been many people who are initially very excited about it, and say that
they want to go out and get tested.

But when they learn a little more

about what this type of testing can and cannot tell them, they realize it
may not be so great.

First of all, it may not tell them anything that

would be actually useful to them.

And, psychologically, it can be

extremely distressing to them and their families. Furthermore, there is
no protection from discrimination.

I think, these days, everybody

understands how precarious health insurance is and that if you were to
be diagnosed with breast cancer, or found to carry an altered BRCAI
gene, you run the risk of losing your insurance, even your job. There
are many people in our group who make serious life decisions based

1 66. This story is based upon an interview with Jan Platner, J.D., who is the
Executive Director of the Massachusetts Breast Cancer Coalition (MBC). MBC is located
at 85 Merrimac St., Boston, M A 021 14. Ms. Platner may be contacted by telephone at 800649-6222 or 6 1 7-624-01 80, or by facsimile at 6 1 7-624-01 76.
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on the fear of discrimination. The other concern is that most causes of
breast cancer are not inherited, but occur sporadically, possibly as a
result of environmental influences. We are very concerned about the
focus shifting from the environment almost entirely to genes.
All that really exists now is data.

I think that we are in an age

where people place a high value on information.
knowledge; it's just information.

I'm not sure it's

We are a culture that reveres

knowledge and that thinks that science has far more answers than it
probably does.

It is our position that predictive genetic testing for breast c ancer is
still experimental and academic.

Whether a woman wants to have

such testing is an extremely complex decision that needs to be made
by the woman herself and her family.

It's a very personal decision.

But we believe that no one should even contemplate this unless they
have up-to-date

information and appropriate counseling.

Also,

nondiscrimination and confidentiality protections are needed for
people who decide to be tested.

It is our position that no genetic

testing should take place whether in clinical trials or commercially
without these protections in place. But this is not happening.

Right

now, for example, anyone could walk into some of the local hospitals
and get tested for BRCA I . All they need is to be able to pay for the
test. It concerns me that this type of testing is being offered in some
settings without professional counseling .
testing will

be made available.

Very soon, wide-scale

The majority of health

care

professionals have little knowledge about the research status and
ramifications of this type of testing and little, if any, experience in
genetic counseling.

It also concerns me that, through commercially available testing,
people are getting information from the companies who administer the
tests. There have been some pretty aggressive marketing campaigns
and literature sent out to recruit people in a way that is problematic.
For example, there is marketing to encourage all Jewish women to get
tested.

You can even do it by mail order-by sending in a blood

sample and

$295 to one lab in the country.

The bottom line is that the

companies have a tremendous financial interest in creating a new
market for this product. And some researchers involved in this area
have personal financial interests in the companies.

Because I'm a

lawyer, I may be more sensitive to the notion of conflict of interest. At
the very least, there should be some rules regarding disclosure.

We

also know that one of the companies is marketing its testing service to
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disease management facilities and insurance companies that would
benefit from information about a person's risk for breast cancer. With
the facilitation of computerized access to medical records and the lack
of consumer protections, this is incredibly problematic.
The other major concern of our organization is that gene testing
for BRCA I seems to not be regulated at all.
State Attorney

General 's Office

We have met with the

and their Consumer

Protection

Division and Civil Rights Division to talk about these issues.

It's

problematic, because the resolution of this kind of issue usually occurs
at the federal level. It is my understanding that the FDA could regulate
this, but they don't since it's not a pharmaceutical and not a medical
device. Although the FDA is not a perfect agency and its regulatory
powers are being cut back, I think it i s critical that they have strong
jurisdiction over this.
themselves.

I don't think industries should ever regulate

This information has the potential to impact individual

· lives in so many ways . Inadequate regul ation is a serious public health
issue that needs to be addressed.
The issue of informed consent for participating in these studies
also is a great concern. I have reviewed a number of informed consent
documents that are being given to women.

The majority of these

documents are inadequate, even the ones developed for clinical trials
in large, well-respected institutions with people who are sensitive and
knowledgeable about these issues. We have no idea what h appens to
people when they get test results, be they positive or negative results,
or if they have any understanding of what this means to them or for
their family members. We have talked with a few people who have
been tested who entered the process understanding the issues and who
were surprised at how they were emotionally impacted by the test.
They thought they were prepared but later admitted they really were
not.

And the family issues created by this type of testing

are

overwhelming. One woman was tested within a clinical protocol and
wanted the test to be blind; she didn' t want to know the results. But
after she was tested she received a letter from the facility basically
saying, "We have some bad news fo r you . . . you are at high risk."
She was strictly doing this because she thought it would be a
contribution to science.

Then she was faced with the decision of

whether to tell her daughter. Although some of the research programs
have a psychologist and psychiatrist on board and apparently make an
attempt to help sort through the issues, it sounds like it's just an
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attempt. Many women considering testing feel that these programs
still have a long way to go.
Ruth Hubbard1 67 has a great analogy-she says that if you want
to build a skyscraper you tum that task over to architects. But if you
want to decide whether to build the skyscraper, those are not the
people who should make the decision because you will get the
skyscraper no matter what. Consumers really need to be part of the
dialogue before genetic tests are developed.

4.

A Corporate Representative's Story168
I work as the education and corporate communications manager

for a national genetic testing company with a very large research and
development arm, genomics group, and clinical trials lab. At our
company we do prenatal testing as well as molecular and biochemical
testing. We also do cancer cytogenetics and provide a number of other
genetic laboratory services.
Within our clinical trials lab, we are currently working with a
number of collaborators in the area of BRCA testing. We were not
involved in the cloning of the BRCAl gene. However, we do develop
tests for certain genetically inherited diseases, and we h ave the
capability with some new technology that we developed to run c linical
trials for academic partners. We also are very much involved in the
development of protocols for the delivery of this type of predictive
genetic testing service, including genetic counseling, which has to be
part of BRCA testing. Although protocols for testing are generally
developed by professional medical organizations, we believe that we
have the experience and the data to help these organizations as the
BRCA test becomes available. We develop the protocols for use in
conjunction with our academic collaborators who will be the ones who
actually make them available within the physician community.
There's a lot of information that comes forward during a clinical trial
. . . it's not just the mechanics of putting something through the testing
process. We address the many ethical and social implications that
arise from the testing process itself prior to introducing a new genetic
test.
Our laboratory does not accept specimens from physicians or
consumers interested in BRCA testing. The specimens that come
1 67. Ruth Hubbard is Professor Emerita of B iology at Harvard University.
1 68. This story is based upon an interview with an executive at a major biotechnology
company.
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through our lab come only from our collaborators, and they are all
research studies. We have chosen not to make this test commercially
available at this time because there
questions.

are too many unanswered

The protocols for the use of this test have not yet been

established, and we believe that its entry must be done carefully. The
development of a predictive genetic test i s a very touchy issue, one that
needs a lot of examination and care in the thought process prior to its
entry into the market.
As an example, an important part of any genetic test is the
protocol for providing test results.

The findings and report process

have to be explained very carefully to a physician.

We do not just

provide physicians with a written report that states that the patient has
tested negatively or positively.

With genetic disease, there can be

familial and psychological impact, and a lab cannot just print out a
report and send it off.

The interpretive process is one of the most

important things on any report that comes out of a genetic diagnostics
laboratory. As part of our work, we are examining the way in which

BRCA test results ought to be provided and the type of counseling that
may be necessary to deal with the impact of the information.

An illustration of how well the genetic diagnostics community
works together i s what happened when the genetic test, by linkage
analysis, for Huntington Disease (HD) first became available in the
early 1 980s.

A consortium was formed of academic and commercial

geneticists and others who got together expressly to carefully map out
the process for the manner in which testing should be offered. When
the gene was
intensified.

uncovered in

1 993,

these

guidelines

were

only

HD still is not offered to anyone except through a

carefully controlled clinical protocol.

All of our patient samples, for

all genetic tests, come from referring physicians-not directly from
consumers.

I have seen one package of marketing literature on BRCA testing
from one company offering the test. The materials do not appear to be
very unusual.

In fact, I was delighted to see how responsibly and

sensitively they

have been

handled.

The companies

that are

announcing and marketing this test, I believe, are now working
through IRBs that have been established within their own companies.
There is still much to be determined before this test is made widely
available.

I think, as a whole, the genetics diagnostic industry is very
cautious about what tests it offers and how they are offered.

In my
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view, the commercial industry is equally as cautious and conscientious
I think the genetic testing industry does a

as the academic centers.

very good job of regulating itself. We have a number of organizations
that inspect and license our laboratories.

These inspection and

licensing procedures involve a wide range of quality control and
assurance issues and standards that we are required to meet. CLIA, the
College of American Pathologists (CAP), the Association of Certified
Medical Geneticists (ACMG), and state licensing agencies have
stringent rules and regulations, and our labs are licensed by all of these
organizations. I do not think it is necessary for the genetic diagnostics
industry to be regulated by the FDA.
To my knowledge, no genetic test has to be approved by the
FDA, and there are no FDA guidelines or approval processes on any
genetic diagnostic test.

The labs that develop these tests have very

rigorous programs of their own.

We would not offer any kind of

genetic test without a large amount of data showing efficacy,
sensitivity, and specificity.

I don't think there is a need for any

additional external review.

Any genetic testing company would be

foolish to introduce a test that wasn't technically sound. Think of the
potential for harm, the liability issues, the damage to a lab's reputation,
and so on.
Our president

presented testimony

to the Senate

Committee on the issue of regulation in late 1995.

Cancer

The Executive

Summary states our position on external regulation:
The dawn of a new era of testing for genetically-based disease is
both exciting and challenging. The prospect of being able to identify
individuals at increased risk of cancer and other devastating diseases
and

thereby

facilitate

treatment--could

prevention

reduce human

and

earlier,

more

suffering to an extent

effective
that

is

unprecedented in medical history.
Our collective efforts towards this goal must be conducted with
great care.

The evolution of genetic diagnostics is an interactive

process that needs a high level of flexibility to cope with constant
change.

Test

validation,

laboratory

performance,

and

genetic

infonnation must all be addressed in appropriate ways, but excessive
Federal regulation must be avoided.
Any framework for validating new genetic tests must reflect a
diversity of issues. For instance, testing for a disease that is caused by
a single genetic defect, like Huntington Disease, raises different
validation issues than testing for cancer, which may involve many
genes. Our approach to validating such tests must be flexible or it will
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stifle progress and prevent generations of useful infonnation for
patients.
Placing additional regulatory requirements on the process at this
time could undermine the investment required to make these potential
clinical benefits a timely reality.

Existing voluntary collaborations

between connnercial and academic laboratories and researchers work
well and have successfully moved tests like those for cystic fibrosis
(CF) and Huntington Disease (HD) into general use. Cancer testing is
more complex but can be managed in a similar way.
Genetic testing laboratory performance standards are regulated by
the College of American Pathologists (CAP) and the American College
of Medical

Genetics

(ACMG)

under

the

Clinical

Laboratory

Improvement Amendment (CLIA) of 1 988. Additional regulation of
lab performance is not necessary.

Increased education in genetics for primary care physicians and
other health care providers is crucial to the understanding and
appropriate use of genetic tests, but adequate resources do not
currently exist. This is an area where the Federal government can play
a useful role.
Finally, insurance reform, including elimination of pre-existing
condition exclusions and elimination of lifetime caps, will remove
major limitations to the effective use of genetic diagnostics. Congress
1 69
should address these issues in pending health care reform legislation.

I am not saying that genetic testing should not have any kind of
regulation. But I think it can be imposed upon the community to do
some maj or self-policing. Perhaps certain additional criteria could be
met through the existing regulatory processes (CLIA, CAP, and so on).
But to have the FDA involved i n genetic testing would slow the
process unbelievably.
Our market analysis for BRCA shows that there is certainly a
large potential market. However, an additional reason for not offering
BRCA testin g i s patent ownership.
indication

that

patent

filers

are

To date, there has been no
willing

to

license

out

for

commercialized diagnostic testing.
By the way, the academic institutions charge for their testing. So
there reall y is not much difference between us, except that officially
we are for-profit and they are not, although some of them actually are.
The major difference is in how services are marketed and how the two
entities are perceived out there in the marketplace. One of our larger
competitors is an academic lab that c harges for services and markets
169. Statement of Elliott D. Hillback, Jr., Pres. & CEO of Integrated Genetics
Laboratories, Inc., before the Senate Cancer Caucus (Sept. 29, 1 995).
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their tests much more aggressively and directly to physicians than we
do.

N.

UNIFYING 'fHEMEs AND DIVERGING THEORIES ON REGlJl.ATION
The preceding stories

are

linked by an overarching theme:

the

commercialization of predictive genetic testing services essentially is
being left to market forces, academic interests, and the judgment of
primary care physicians.

Beyond this basic message, however, the

stories raise an entanglement of issues and present disagreement about
what, if anything, constitutes the appropriate regulatory response to the
commercialization

of predictive

genetic

testing services.

The

following is an effort to sort through these conflicting opinions and
draw upon the discussion set forth in Parts II and ill, to present
arguments for and against direct regulation of predictive genetic testing
services.

A

Continued Deference to Market Forces
Advocates of regulatory restraint support maintaining the status

quo. One of the strongest arguments in favor of this position i s that
IRB review coupled with the incentive to avoid product liability is
effective-as

made

evident by

OncorMed's

extensive

protocol

(attached as App. I). The regulatory effect of legal liability must not be
underestimated, for biotechnology executives are well aware that
process sacrifices the liability
limitations associated with the MDA. 170 Under this view, the fact that
circumventing

the

FDA review

170. See First BRCAI Test Hits the Market, supra note 65, at 4 ("Since FDA does not
regulate genetic tests, OncorMed and the companies that will follow it encounter few
regulatory barriers. However, by the same token, their products do not receive the
certification of safety and efficacy that accompanies regulatory approval."). The MDA
preempts claims for negligence and failure to warn. See 21 C.F.R § 808. l (d)( l996); H.R.
REP. No. 853, at 45 ( 1 976) (legislative history). If manufacturers comply with FDA
requirements and do not commit fraud, state law claims generally are preempted. See supra
note 6 1 ; see also Lars Noah, Amplification of Federal Preemption in Medical Device Cases,
49 Fooo & DRUG L.J. 1 83, 2 1 1 ( 1 994) ("By virtue of the express preemption provision in
the MDA, medical devices are unique among products which are subject to regulation by the
FDA."). Bur see Marianne Lavelle, Medical Device Makers ' Liability Shield is Dented,
NAT'L L.J., July 8, 1 996, at A l (reporting on Supreme Court holding in Medtronic, Inc. v.
Lohr, 1 1 6 S. Ct. 2240 ( 1 996), that FDA regulation (MDA) does not necessarily preempt
consumer suits over faulty medical devices); Marianne Lavelle, High Court Medical Devices
Ruling Muddles Matters, NAT'L L.J., Sept. 30, 1 996, at A9 (reporting that "[c]ourts have
split sharply in their readings of a 1996 Supreme Court decision that many had hoped would
clear up the issue of when federal regulatory law preempts actions based on state tort and
other law"). However, liability for clinical trials is raising. See Michael Traynor, As
Manufacturers Seek Approval for More New Pharmaceuticals, Issue Such as the "Learned
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IVF, are marketing research-stage predictive

genetic tests without restraint is a problem of lack of enforcement of
existing labeling and other regulations, namely CLIA and professional
standards, and not a legitimate basis for introducing even more
regulations.

Similarly, to the extent that physicians are straying from

these protocols,

failing to properly

counsel their patients,

and

overusing investigational genetic testing services lacking PPV, they are
guilty of practicing poor medicine
professionally.171

and

should

be

disciplined

Physician malpractice, it may be argued, is not a

legitimate basis for imposing more regulations on biotechnology
companies. Moreover, to the extent that more regulation is needed, it
should come in the form of stronger good-medicine standards imposed
on physicians and enforcement of those standards.172
The status quo offers some significant public health benefits.
First, in addition to developing protocols, industry is addressing ethical
issues associated with the commercialization of genetic technologies,
and perhaps i s doing so more effectively than the government could.
Several multinational pharmaceutical companies have financed ethics
programs to address these issues. 1 73

Similarly, many biotechnology

Intermediary " Rule Will Emerge in Litigation involving Clinical Trials, NAT'L L.J., Nov. 1 8,
1996, at B6.
171.

"About half of people with a family history of breast or ovarian cancer are likely
Breast/Ovarian

to request genetic susceptibility (BRCA I ) testing when available . . . . "

Cancers (Genetics):

Many People Prefer Not to Know if They Have Gene Linked to

Cancers, CANCER RES. WKLY, July 1 5 , 1 996, available in 1996 WL 22863 1 3 (reporting on
study conducted by the Lombardi Cancer Center, Georgetown University, that emphasizes
the importance of relaying information

about genetic tests themselves to patients).

Following the discovery that one percent of Ashkenazi Jewish women carry genetic
predisposition to breast and ovarian cancer and despite consumer demand for the test,
"almost all leading scientists and two major commercial testing laboratories agreed
informally not to offer the test for the mutation to the general public because widespread
testing would do more harm than good."

Koenig, supra note 24, at A23. That consensus

was broken, however, by Dr. Joseph D. Schulman, Director of IVF. Dr. Holtzman, Chair of
the ELSI Task Force, asserts that Dr. Schulman i s "hoodwinking" women by making the
IVF test widely available. See Wadman, supra note 5, at C3. The National Breast Cancer
Coalition and the National Action Plan on Breast Cancer agree that testin g should be
confined to research settings. See id.
172. Consider that the United Kingdom, i n comparison with the United States,
regulates more experimental medical technology through good medicine standards. See
Veronica Henry, Problems with Pharmaceutical Regulation in the United States, 14 J .

LEGAL MED. 6 1 7 , 637-38 ( 1 993) ("In Great Britain, investigational and experimental drug
use requires certification and licensing; however, therapeutic use, by which physicians
administer drugs to their patients, is excluded from the certification requirement." ).

173. For example, in the Fall of 1 995, SmithKline Beecham (London-based) gave
Stanford University $ 1 million to start an ethics program in genetics, and the Hastings
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companies are hiring ethicists and, · at least presumably, taking the
advice for which they are paying top dollar. 174
Second, the FDA traditionally has relied heavily on the private
medical profession when reviewing new products, and legal liability in
the place of FDA involvement (with resulting limitations on liability
for compliance) may result in greater quality control. 175

Conflicts

associated with the case-by-case nature of the FDA review process, the
discretion allotted individual agents, and close ties between members
of the medical profession and individual FDA reviewers support
proposals to rely upon apolitical advisory committees instead of
existing FDA review mechanisms.176

Center has launched a program called "Values and Biotechnology" with the financial
support of Monsanto Co. See Day, supra note 3 1 , at A l .
174. Biotech companies are voluntarily and directly addressing ethics issues arising
from the commercialization of their technologies. See id. Human Genome Sciences, Inc.
has hired former opera diva Beverly Sills, who has two children with birth defects and years
of service as chairman of the March of Dimes. "All over the biotech industry, companies are
hiring ethicists to try to get a jump on these humanistic tangles. Many people in an industry
that has the potential to make reality of science fiction are following the rule of look before
you leap." Id.
175. See, e.g., Claudia MacLachlan, Spine-Tingling Dispute: Bone Screw Suit Places
FDA in 4-Way Squeeze, NAT'L L.J., Jan. 8, 1996, at A l ('"One of the standard defenses is to
wrap your arms and legs around the ankles of some FDA person and say they knew-and a
lot of times that is true. "' (quoting William W. Vodel, head of FDA practice at Washington
D.C.'s Arnold & Porter)). Recently, the FDA was pulled into "a four-way crossfire over the
way it lets medical devices be used without formal approval. . . . The FDA has also been
accused of relying on the advice of doctors allegedly on the take from makers of devices the
doctors had tested." Id. ; see In re Orthopedic Bone Screw Products Liability Litigation, 79
F.3d 46 (7th Cir. 1 996). This case, which involved the use of screws to affix metal plates to
the vertebrae of some 300,000 people despite rejections by the FDA of this use i n 1 984 and
1985, has highlighted the fact that the FDA cannot always be relied upon as an assurance of
quality control. MacLachlan, supra, at A l . The problem is that standard of care acceptance
may be realized without the FDA. On October 4, 1 992, the FDA announced in the Federal
Register that it had discovered that the plate and screw devices were in widespread use and
considered standard of care by surgical community. At that time, the FDA requested a study
by orthopedic professional groups and makers of the spinal implants and, based upon the
reported results, the FDA liberalized use. Accusations that the study was corrupt are now
the subject of a case brought by plaintiffs against the device's manufacturers. Specifically,
attorneys for the plaintiffs i n a products liability case over the device later accused the FDA
of relying "in part on medical reports from doctors who stood to profit from the device."
MacLachlan, supra, at A 1 .
176. See Claire L . Ahem, Drug Approval in the United States and England: A
Question of Medical Safety or Moral Persuasion?-The R U-486 Example, 1 7 SUFFOLK
TRANSNAT'L. L. REV. 93, 93 (1 994) ("Advancements in the pharmaceutical industry have
revealed the magnitude of these dissimilarities and the negative effects that result when
United States drug officials allow nonscientific considerations to affect their analysis of
promising new drugs."); Henry, supra note 172, at 637-38, (comparing the U.S. and U.K.
systems and concluding that "[t]he British system is more objective and expeditious than the
American system. . . . The American system needs to enhance utilization o f apolitical
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Third, even experimental genetic tests may offer clinical benefits
to some patients.

These benefits include clarification of risk status,

more accurate diagnosis of symptomatic individuals, detection of
canier status, and guidance for selecting the most prudent course of
surveillance treatment. 177

For the first time in decades, cancer

advisory committees i n the decisionmaking process, much the same way this has been done
in the British system.").

But see generally ABRAHAM, supra note 7 1 , at 246 ('The close

institutional relationship between the regulators and the pharmaceutical firms in the U.K.
has been associated with a sympathetic view of scientific data from the pharmaceutical
industry on the part of the Government scientists and scientific advisers.").

See also J .

Worth Estes, Book Review, 334 NEW ENG . J. M ED 609, 609 ( 1 996) (reviewing JOHN
.

ABRAHAM, SCIENCE, POl
..ITICS AND THE PHARMACElITICAL INDUSTRY:

CONTROVERSY AND

BIAS IN DRUG REGULATION ( 1 995)) ("Because the B ritish government wishes to ensure the

success of its pharmaceutical industry, its regulatory agencies tend to be protective rather
than adversarial, as they are in the United States, where the government is required to be
more concerned about protecting patients than about protecting the firms that manufacture
medicines.").
177.

See ELSI TASK FORCE ON GENETIC TEsTING, supra note l , at 1 4 ("A test with a

lower sensitivity might have value in certain circumstances, but the organization offering the
test must make clear what the limitations are i n order to enable providers and consumers to
make informed decisions about appropriateness."); Olufunmilayo I. Olopade, Editorial,

Genetics in Clinical Cancer Care-The Future is Now, 335 NEW ENG. J. M ED . 1 455, 1455
("It is no longer unusual for women with newly diagnosed breast cancer to seek genetic
testing before choosing between mastectomy and lumpectomy combined with radiation
therapy."); see also id. at I I ("A direct DNA test can be used to diagnose a genetic disease in
symptomatic individuals, predict future disease in healthy people, detect carriers and also for
prenatal diagnosis."); Saltus, supra note 1 34, at 25 (noting that some women already
diagnosed with breast cancer perhaps could benefit from testing to make decisions regarding
treatment); Wadman, supra note 5, at C3 ('They say negative tests have already allowed
them to tell women scheduled for preventative breast removal that they don't need the
surgery."); Weiss, supra note 2 , at A l (
For some carefully selected women already diagnosed with breast cancer, a

positive test can indicate the need for more aggressive therapy. And for a woman
whose mother or sister had breast cancer from a BRCAl mutation, a negative test
can provide some reassurance. What remains unproved, however, is that the test
has any value for the more than 95% of women who do not fit into those
categories.
).

The breast cancer testing issue has caused division among feminist scholars, some of

whom feel that impeding the accessibility of genetic tests constitutes paternalism.

See

Wadman, supra note 5 , at C3 (discussing the availability to Jewish women of a genetic test
for breast and ovarian cancer); Weiss, supra note 2, at A l . In the words of one woman who
was told that she could not have her BRC A l test results:
Do they reall y believe that women who test positive are going to
inunediately race to the nearest operating room to summarily demand the removal
of both breasts and ovaries-procedures which, in any event, would require the
concurrence of a surgeon?

They are u nderestimating our intelligence to the

millionth degree . . . . Strangely, men considering surgery for prostate cancer don't
seem to receive this kind of counsel, even though the benefits of surgery haven't
been proven and the operation usually leaves men impotent, incontinent or both.
Wadman, supra note 5, at C3.
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mortality rates have fallen and, in addition to better treatment, this has
been attributed to both prevention and improved diagnosis.178 Fourth,
and perhaps most persuasive, medical science eventually will solve the
predictability problem.179 The present scheme, which generates patient
samples and finances research,180 will most rapidly move genetic
medicine to therapeutics and even gene therapies. More regulations
could have the exact opposite effect.

B.

Callfor Direct Regulation
Advocates

for direct regulation

of genetic testing

services

emphasize that, even though these tests are much more likely to be
misinterpreted than traditional diagnostics due to
scientifically valid PPV,
genetics, and
media

(1) the absence of

(2) the lack of physician understanding about

(3) the public's interest and faith in genetics enhanced by

coverage,

biotech

marketing,

and

information

(or

misinformation) from providers, these tests are subject to much less
regulatory oversight. 181 From a mental health perspective, genetic tests
for serious diseases may impact patient lives at least as much as
traditional diagnostics with established PPV This is especially true in
the absence of reliable studies of the impact of genetic information on
patients ' lives182 and the present dearth of trained genetic counselors in
practice.183 In fact, in the absence of coverage, consumers demanding
access to genetic tests may actively avoid genetic counseling due to the

178. See Breast Cancer Incidence, supra note 1 34, at 1 293-94 (reporting that the
overall death rate from cancer fell approximately 3 % between 1991 and 1 995, and the rate
of breast cancer fell 6.3 percent).
179. See Saltus, supra note 134, at 25 (arguing that, with time, the tests will be more
scientifically reliable and easier to interpret, and that there also will be more health care uses
for the information).
180. These research funds are coming out of the pockets of consumers, for most
insurance companies will not cover the costs of such experimental health care. See Boyle,
supra note 13, supp. at SS ("While exact data on private insurance coverage are scarce, most
genetic services-preventive, screening, and counseling-are not covered because the
interventions are considered either 'investigational' or 'not medically necessary."').
1 8 1 . See generally supra Parts 11.B & C.
1 82. See ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 , at 33 ("People at risk
of disease in high risk families may have built up a complex mechanism to deal with the
perception that they are affected. . . . Genetic counseling can be extremely time
consuming."). However, Kaiser Permanente currently is developing a clinical practice
guideline for BRCAl testing and introducing a confidential patient registry to ensure long
term follow up. See BRCA J : Are You Ready for Clinical Testing?, PERSP. GENETIC
COUNSELING, Summer 1 996, at 1 2.
1 83. See Malinowski, supra note 1 25, at 3 5 1 -52 & n . 1 04.
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Over-reliance on negative test results185 and over

treatment based upon positive test results 1 86 are strong possibilities, if
not probabilities.

Also, in the absence of adequate consumer

safeguards to ensure genetic privacy and counseling and awareness of
these dangers

before the decision to undergo genetic testing is made,

those who subject themselves to genetic testing may find that they also
are subjected to discrimination from employers and insurers.187

fu

addition, family members may be subject to discrimination based upon
the results of genetic testing they did not even undergo.188
Advocates for direct regulation also argue that OncorMed's
prudence in developing a thorough protocol cannot be relied upon as
established industry practice. Rather than being representative of long
term industry behavior, these precautions may be a reflection of the
fact that OncorMed is the first biotechnology company to make
predictive genetic testing available outside the major research centers
and, as such, it has been painstakingly careful. Similarly, the influence
that drug developers and manufacturers exercise over scientific
research must not be underestimated.

Industry influence is not only

1 84. Many new predictive genetic tests are investigational and, therefore, often are
paid for out of consumers' pockets. See Bl.Arr, supra note 2 1 ("While genetic counseling is
necessary to make informed decisions about clinical genetic tests, as a sole service, it is often
not covered by insurance."). Accordingly, it is unlikely that consumers are going to seek out
counseling due to the added cost. See Malinowski, supra note 125, at 351 & n. l 06; see also
First BRCA J Test Hits the Market, supra note 65, at 3 ("While it may be difficult to find two
people who agree on all aspects of what is to be done, virtually all the opponents of
immediate commercialization of genetic testing agree that counseling patients before and
after they are tested is anything but a straightforward matter.").
1 85. See Wadman, supra note 5, at C3 ("Scientists argue that testing in nonresearch
settings is fraught with peril. Negative test results, they say, could lull women into a false
sense of security, when in truth 90 to 95 percent of breast and ovarian cancers aren't
inherited but occur spontaneously.").
1 86. The investment in technology to identify breast cancer has not been
accompanied by similar investment to understand its growth and spread. See Plotkin, supra
note 1 34, at 54-55. The failure to appreciate cell growth differences in breast cancer,
coupled with mammography, may have resulted in over-diagnosis and treatment-including
unnecessary mastectomies. See id. at 70. The end result is that breast cancer is twice as
likely to be diagnosed today as it was 60 years ago, but mammography studies show no
overall difference in mortality from breast cancer between treatment and control groups. See
id. at 69 (citing Swedish, Irish, and Canadian studies). Widespread BRCA testing could
greatly exacerbate this problem.
187. See generally supra note 58. See also Barash & Alper, supra note 58, at 43;
Geller, supra note 58, at 7 1 .
1 88. See Act Concerning Genetic Testing and Privacy and Medical Underwriting,
N.J. S.B. 695 & 854, at § 2.d ( 1 996) ("An analysis of an individual's DNA provides
information not only about an individual, but also about the individual's parents, siblings
and children, thereby impacting family privacy, including reproductive decisions.").
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impacting the course of science, 189 but is tainting the safeguard of
scientific peer review. 190

In this modem age of privatized R&D,

academic institutions and their individual researchers are highly
susceptible to the influence of the biotechnology industry and may
even hold royalty interests in the industry's products.191 Accordingly,
1 89. There is fear in the United States that creativity and objectivity in basic science
is being lost due to the privatization of R&D.

Rather than allowing researcher discretion

and the raising of a general floor in science, basic science is being directed by corporate
decisions to pursue and develop research discoveries solely according to their commercial
viability. See, e.g. , ABRAHAM, supra note 7 1 , at 245 ("Since the career structure of academic
medics rewards them for publications, there is an institutional incentive for such medics to
work co-operatively with an industry that can provide the funding for publishable
research."); Christine Gorman, Has Gene Therapy Stalled?, TIME, Oct. 9, 1 995, at 62, 62-63
(noting that, while gene therapy holds extraordinary promise, enthusiasm and financial
pressures may have caused a premature push to market that is sacrificing basic science and
human safety for a quick return on investment). See also Malinowski & O'Rourke, supra
note 20, at 1 87 (discussing the concern that the alliance nature of the biotech industry may
be skewing the course of basic science). This concern has been substantiated in part by a
study published in the New England Journal of Medicine based upon data collected from

2,052 faculty members from October 1994 to April 1 995. According to the study, "faculty
members receiving more than two thirds of their research support from industry were less
academically productive than those receiving a lower level of industrial support" and
"faculty members who have research relationships with industry are more likely to restrict
their communication with colleagues."

David Blumenthal et al., Participation of Life

Science Faculty in Research Relationships with Industry, 335 NEW ENG. J. MED. 1734,

1 734 (1996).
190. See Ralph T. King, Jr., Bitter Pill: How a Drug Finn Paid For University Study,
Then Undermined It, WALL ST. J., Apr. 25, 1996, at A l . There is anecdotal evidence that
industry is tampering with scientific integrity. The "Synthroid affair" exemplifies the danger
of industry-financed research.

A manufacturer paid $250,000 to finance research to

establish that cheaper drugs were not as effective as its product. When the researcher
attempted to publish findings of bioequivalency between the drug and other, much cheaper
drugs, the manufacturer worked aggressively to discredit the research.

See id.

('The

Synthroid affair illustrates what some leading scientists decry as increasingly frequent
corporate attacks on open scientific debate, at a time when industry-supported research is
crucial because of a shrinking government role in medical research.").

Similarly, "[i]n a

recent article in the New England Journal of Medicine, Steven A. Rosenberg, chief surgeon
of National Cancer Institute, cited what he said were four instances of promising research
being squelched or slowed by corporate sponsors' demands for secrecy to preserve possible
competitive advantage." Id.

1 9 1 . See David Blumenthal et al., Relationships Between Academic Institutions and
Industry in the Life Sciences-An Industry Survey, 334 NEW ENG. J. MED. 368, 368 ( 1 996)
("Ninety percent of companies conducting life-science research in the United States had
relationships involving the life sciences with an academic institution in 1 994.
·

Fifty-nine

percent supported research in such institutions, providing an estimated $ 1 .5 billion, or
approximately 1 1 .7 percent of all research-and-development funding received that year.");
see also Steven A. Rosenberg, Secrecy in Medical Research, 334 NEW ENG. J. MED. 392,

392-93 (l 996) (
The conduct of medical research is in increasing jeopardy. . . . Secrecy
about methods and results has become a common and accepted practice. . . .

·
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the influence of the biotechnology industry over public health policy
must be checked, not augmented by a carte blanche federal regulatory
approach.

C.

Drawing Conclusions
The

present

regulatory

scheme

for

commercialization

of

predictive genetic testing services consists essentially of reliance on
market forces, legal liability, and the judgment of primary care
physicians. Through access to patient samples and the opportunity to
capture the costs of research, this approach is financing and advancing
biotechnology research. Innovative therapeutics and gene therapies for
life-threatening and widespread diseases such as breast cancer are
becoming vivid possibilities.
Nevertheless, the research-stage nature of predictive genetic tests,
such as

the

uncertainties

existing tests

for

make these tests

commercialization.192

B RCA mutations, and resulting
currently unacceptable

for broad

Legal liability places the burden of quality

assurance on health care consumers who are the people that need to be
protected, 193 and the transaction costs of shaping public health policy
through

litigation

can

be

immense.

Indeed,

several

cancer

organizations and Jewish community groups have drafted position
statements opposed to the commercialization of predictive breast
cancer testing given the lack of safeguards to ensure oversight and

The increasing involvement of for-profit biotechnology companies in
medical research has provided new sources of funding, but with this invol vement
has come an emphasis on the ethical and operational rules

of business rather than

on those of science.
)

.

1 92.

See Mark et al. , supra note 1 3 3 , at 405 ("Predictive testing should be considered

investigational, and testing for purposes other than health care should be discouraged.").
Despite the truth o f the statement, it has become almost cliche in circles of genetic experts to
say that we should have learned from the sickle cell experience in the early 1 970s in which a
screening program caused widespread anxiety and many breaches of confidentiality.

Brom, supra note 27, at 1 29; supra note 1 26.
193.

See

Law should be used to prevent predictable problems and minimize the harm.

See Annas, supra note 14, at 22 (rejecting laissez-faire strategy to let the market detennine
which genetic tests are done on the grounds that law should be used to prevent problems and
"lawsuits for breaches of privacy have not often been pursued (because the private
information is usually made known to even more people in the process)"). As observed by
Professor Paul Starr, "[t]he very circumstances of sickness promote acceptance of
[physicians' ] judgment."
MEDICINE 5 (1 982).

PAUL STARR, TI-IE SOCIAL TRANSFORMATION OF AMERICAN

accuracy,
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informed

and

consent,

confidentiality. 194

Regulatory

safeguards are needed to ensure that predictive genetic technology,
which offers much promise, does not detract from public health
because it is

applied

in

irresponsible

a shortsighted,

fashion.

Regardless of the failures and shortcomings of FDA regulation of
traditional diagnostics, medical and public health officials must
directly address the issue of quality assurance for predictive genetic
testing services.

They must

introduce and enforce

consumer

safeguards tailored to this innovative technology.

V.

PROPOSALS FOR CHANGE
Public health education developed with consumer input must be

included in any strategy to regulate the commercialization of genetic
testing services. 195 Nevertheless, a broader strategy is needed. Before
sorting through the numerous options, 1 96 medical and public health
officials

must

determine

which

approaches is likely to prove most effective.

combination

or

approach

of

A fundamental point of

differentiation is between protecting consumers

( 1) through

added

market review and approval restraints that more carefully monitor
market access to health care consumers or

(2) through the

health care

profession as a matter of good-medicine standards. In other words, the
two fundamental

regulatory

conjunctively) are

(1) to

approaches

(which

may

be

used

introduce restraints to keep health care

194. See, e.g., AMERICAN CANCER SOCIETY, MASSACHUSETTS DIVISION, GENETIC
PATIENT PRIVACY AND DISCRIMINATION CONSIDERATIONS ( 1 995); DRAFT
'fEsnNG:
STATEMENT, THE JEWISH WOMEN'S COALITION ON BREAST CANCER (1 996) ("The recent
identification of a genetic variation that may predict breast cancer is provoking immense
anxiety and obscuring vital information."); DRAFT STATEMENT, HADASSAH, BRCAl GENE,
GENETIC TEsTING AND INSURANCE DISCRIMINATION ( 1996) ("Hadassah is . . . concerned that
this new genetic information or individual's requests for genetic counseling services may
result in higher health insurance premiums, changes in terms or conditions, or outright
denial or cancellation of coverage."); MASSACHUSETTS BREAST CANCER COALITION, WHAT

You NEED TO KNOW BEFORE CONSIDERING GENETIC TESTING FOR HERITABLE BREAST

CANCER 1-2 (1996) (identifying the following considerations: (1) the potential advantage of
the test to an individual is limited, (2) there is no known effective prevention for breast
cancer, (3) a positive test result does not mean that you will get breast cancer, (4) a negative
test result does not mean that you will not get breast cancer, and (5) getting tested may carry
psychological, social, financial, and legal ramifications).

195. See generally BLATT, supra note 2 1 .
196. The mechanism for regulation recognized b y the

ELSI

Task Force includes:

(1) adoption of industry-wide codes or policy statements; (2) recommendations from
professional societies; (3) extension of existing state or federal regulations to cover unique
areas of genetic testing; and (4) new legislation.

TEsTING, supra note 1 , at 37.

See

ELSI

TASK FORCE ON GENETIC
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products that unduly endanger consumers off of the market or

(2) a

"good medicine" regulatory approach that uses professional self
regulation (peer review and norms) and legal liability. The principles
and recommendations proposed by the National Task Force combine
these approaches, with an emphasis on the good medicine approach:
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TABLE I

HlGlillGIITS: PROPOSED RECOMMENDATIONS OF TIIB TASK FORCE ON
GENETIC TEsTINd 97
KEY PRINCIPLES

VAllDTIY AND

I

As a prerequisite for acceptance in clinical practice,

UTIUIY OF GENETIC

data sufficient to demonstrate clinical benefits and

TESTS

risks from both positive and negative results must be
collected.

An IRB must approve the protocols used for genetic
tests.

198

CLIA certification requirement imposed

LABORATORY

Despite the

QUAlllYAND

on most clinical laboratories, "current regulations do

CEIUIFICATION

not

adequately
1)
19

ensure

the

quality

of

genetic

testing."
PROFESSIONAL

"Health care professionals involved in the provision of

COMPETENCE IN

genetic tests should be well-informed about their
200
implications, benefits and risks."

GENETICS

"[N]ot all providers in practice today may have
adequate competence to offer and interpret genetic
201
tests. "
RARE GENETIC
DISEASES

"At a time when genetic tests for common complex
disorders are increasing, tests for rare disorders may
202

be developed at a slower rate than in the past."
INFORMED CONSENT

"Informed consent for a validation study must be

AND

obtained whenever the specimen can be linked to the
203
subject from whom it came."

CONFIDENTIAllI'Y

'The responsibility for providing information to the

£

individual lies with the referring rovider, not with the
2
laboratory performing the test."

1 97. This summary is based upon Proposed Recommendations of the Task Force on
Genetic Testing, Meeting Notice, 62 Fed. Reg. 4539, 453 9-47 (1 997).

1 98.
1 99.
200.
201 .
202.
203.
204.

See id. at 4540.
Id.
Id.
Id.
Id.
Id.
Id.
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"Respect for personal autonomy is paramount. People
being offered testing must understand that testing is
5
voluntary."20
"Results should be released only to those individuals
to

whom the test recipient has
.
. .
,, 6
subsequent1y requested m wntmg. 20

consented

or

"Health care providers have an obligation to the
person being tested not to inform other

family

members without the permission of the person tested
.
.
,, 7
except m extreme crrcumstances. 20
RECOMMENDATIONS
A GENEFICS

I

The Secretary of HHS should create a federally

ADVISORY

chartered

COMMfITEE

Public

Advisory

Policy

Committee

("Advisory

members should
2 8
testing. 0

include

on

Genetics

Committee")

stakeholders

m

and

whose
genetic

The Secretary also should utilize an interagency group
to

assist

the

Advisory

Corrunittee

and

develop
2 9
coordinated and consistent genetic testing policies. 0

NEED FOR INTERIM

The Secretary of HHS should "use existing agencies

ACTION

and policies to ensure that the public

will have

adequate protection from predictive genetic tests that
have not been adequately validated and whose clinical
1
utility has not been established."2 0
To accomplish this, the Secretary may either
its authority under the MDA or

(2) reimburse

( 1 ) use
under

Medicaid and Medicare only when genetic tests are
performed in laboratories that can establish that the
test has been clinically validated and that they are
211

qualified to perform them.

205.
206.
207.
208.
209.
2 1 0.
21 1 .

Id.
Id. at 4541 .
Id.
See id.
See id.
Id.
See id.
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ASSURING THE

A National Genetics Board (NGB) should be created

VAIJDllY AND

"to assure the protection of human subjects in the

UTTUIYOFNEW

development of genetic tests with the potential to
. future d"isease. .. 2 1 2
predict

GENETIC TESTS

"NGB would develop a checklist that would enable
local IRBs to identify protocols that meet criteria for
stringent scrutiny.

"213

The FDA should establish a Genetics Advisory Panel
under the MDA that requires new genetic tests to meet
214
criteria for stringent scrutiny.
CDC, in cooperation with NCHGR, should expand
monitoring of genetic disorders to provide data on the
validity of tests

and

post-test interventions

and

establish procedures for tracking those who undergo
215
genetic testing.
The

FDA

should

grant

conditional

premarket

approval for genetic tests with the potential to make
significant public health contributions and place the
burden on developers to collect data and make it
216
available to the FDA.
NGB should serve as a clearinghouse for technology
assessments and make recommendations on appro
217

priate use of genetic tests.

ASSURING
LABORATORY
QUAllTY

A national accreditation program of quality assurance
and proficiency testing for genetic tests equivalent to
or more stringent than those of New York State and
the

College

of

American

Pathologists/American

College of Medical Genetics (CAP/ACMG), should

be established under CLIA.
program

should

include

The accreditation

proficiency

testing

and
218

inspection of laboratories that perform genetic tests.

2 1 2.
2 1 3.
2 14.
2 1 5.
2 1 6.
2 1 7.
2 1 8.

Id. at 4544.

Id.
See id. at 4544-45.
See id. at 4545.
See id.
See id.
See id.
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Until a national accreditation program i s established
under CLIA, the CAP/ACMG Molecular Pathology
program, expanded to encompass all genetic testing
methods currently in use, should be implemented as a
.
219
national program .
A Genetic Advisory Committee to CLIA should be
established to help address the deficiencies of CUA.
The work of this committee should be coordinated
with other HCFA programs and the work of FDA,
CDC,

and

other

federal

agencies involved
220
establishing policies for genetic testing.

m

CAP/ACMG should seek input from consumer groups
such as the Alliance of Genetic Support Groups and
National

Society of Genetic Counselors (NSGC)
22 1

when setting standards.

CAP/ACMG should periodically publish and make
public a list of laboratories perfonning §enetic tests in
2 2

compliance with its voluntary program.

"Managed care organizations and other third-party
payers should limit reimbursement for genetic tests to
223
the laboratories on the published list . . . . "
"[E]fforts should be made to harmonize international
laboratory standards to assure the highest possible
224
laboratory quality for genetic tests. "
PROVIDER

'The Task Force endorses the recent establishment of

COMPETENCE

a

National

Coalition

for

Health

Professional

Education in Genetics by the American Medical
Association, the American Nurses Association, and
2 5
the NCHGR." 2
A core curriculum in genetics should be developed.

219. See id.
220. See id.
22 1 . See id. at 4545-46.
222. See id. at 4546.
223. Id.
224. Id.
225. Id.
226. See id.

226
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Certification and

other credentialing mechanisms
227
should be used to promote competency.
"Predictive genetic tests requiring stringent scrutiny,
as previously described, should be among those for
.
"228
wh1ch spec1"al ered ent1"al s are needed .
Primary

care

providers

and

other

nongeneticist

specialists should be involved in genetic testin g but
only
after
gaining
229
knowledge.

sufficient

training

and

Credentialing bodies such as the Joint Commission on
Accreditation of Healthcare Organizations (JCAHO)
and the National Committee for Quality Assurance
230
(NCQA) should be utilized.
"Except when time is of the essence, such as with
certain prenatal genetic tests, obtaining informed
consent and actually performing the test should be
delayed several days after the test is offered and
231
information given to the patient. "

RARE GENETIC
DISEASES

''The quality of laboratories providing tests for rare
diseases must be assured, and a comprehensive system
to

collect

established. "

data
232

on

rare

diseases

must

be

''The Task Force recommends that NIH give [the NIH
Office of Rare Diseases (ORD)] a mandate

to

coordinate . . . public and private efforts to improve
233
awareness of rare genetic diseases. "
"ORD should identify laboratories world-wide that
perform

tests

for

rare

genetic

diseases,

the

methodology employed, and whether the tests they
provide are in the investigational stage, or are being
234

used for clinical diagnosis and decision making. "

227.
228.
229.
230.
23 1 .
232.
233.
234.

See id.
Id.
See id.
See id.
ld. at 4546-47.
Id. at 4547.
Id.
Id.
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"ORD should also be responsible for assuring that
tests for rare

genetic diseases, which have been

demonstrated to be safe and effective, continue to be
available

. . . : ms

"[A]ny laboratory performing any genetic test on
which

clinical

decisions are
236
CLIA."

diagnostic
made

and/or

should

be

management

certified

under

"Directories of laboratories providing tests for rare
diseases should indicate whether or not the laboratory
is CLIA-certified and whether it has satisfied other
quality

assessments,

program. ,,237

such

as

the

CAP/ACMG

In an era of deregulation, and in light of the deficiencies of CLIA

and a general failure to enforce CLIA regulations with any consistency,
the good-medicine approach to protecting consumers should be given
careful consideration.238 This provider-centered approach could prove
highly effective for physicians to control consumer access to predictive
genetic testing services . Their involvement is absolute, meaning that
consumers cannot have predictive genetic tests run on their samples
without a primary care physician "middleman" making the procedure
available. Lack of physician knowledge about the predictive services
they are discussing with and making available to their patients, and the
resulting lack of appreciation for the limitations of the technology and
its impact on patients' lives, is simply inexcusable.
Under no
circumstances should physicians be making health care technology
available unless they fully understand that technology. Patients, too,
must be given information regarding the nature of investigative testing.
Appropriate pretest counseling must be mandated.
The willingness of physicians to stray from such basic
responsibilities may reflect the fact that many consumers are paying
for investigational genetic testing services out of their pockets (due to
both the refusal of insurers to cover experimental services and
235.
236.
237.
238.
view that

Id.
Id.
Id.
See Meeting Minutes, supra note 1 , at 7 (stating that one member "expressed the
CLIA is ill-equipped for overseeing PT for genetics labs, and suggested that in this

era of de-regulation, professional genetics organizations may be better suited to the task");

see also Proposed Recommendations of the Task Force on Genetic Testing,
62 Fed. Reg. 4539, 4545 (1997) (discussing the insufficiencies ofCLIA).

Meeting Notice,
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Under this payment

consumer fears of genetic discrimination).

arrangement, physicians do not have to account to insurers and
managed-care administrators for the costs of genetic testing services.
Although consumer demand for access to predictive genetic testing
services may become (or already may be) significant, medical and
public health officials cannot accept consumer demand as an excuse
for the practice of substandard medicine.2 39 Acceptance of such an
excuse would carry tremendous ramifications,240 especially in an age
of managed care when physician compensation is tied to the number
of patients a physician maintains. Other potential conflicts of interest
are equally troubl i ng. 241 Similarly, the physician-patient relationship
does not allow the benefits from advancements in research, regardless
of how profound they may be, to serve as an acceptable rationale for
4
the practice of irresponsible medicine. 2 2
hnplementation

of

the

l aboratory

assurance

quality

recommendations of the ELSI Task Force (meaning a CLIA laboratory
accreditation program modeled after the CAP/ACMG Molecular

239.

Consumers cannot be entirely relied upon to assess their health care needs and

the quality of the care they receive. See generally Jason Ross Penzer, Note, Grading the

Report Card: Le.ssons from Cognitive Psychology, Marketing, and the Law of Information
Disclosure for Quality Assessment in Health Care Reform,

1 2 YALE J. ON

REG.

207 ( 1 995)

(discussing the limitati ons of consumer-directed infonnation disclosure proposals as a
quality assurance system). See, e.g. , David L. Kasennan, Reimbursement Rates and Quality

Care in the Dialysis Industry: A Policy Discussion,

8

ISSUES LAW & MED.

8 1 , 82 ( 1 992)

(noting that consumers tend to be more satisfied with shorter dialysis running times, even
though reducing running times correlates with increased incidents of hospitalization and
mortality).

240.

See generally Malinowski, supra note

physician's relationship

the patient in

with

1 25
that

(noting that managed care affects the
a large amount of discretion

in

decisionmaking belongs to the health care provider).

24 1.

See ELSI TASK FORCE ON GENETIC TESTING, supra note I , at 34 (Principle

III- 1 7

states i n p art that
Any actual or potential conflict of interest should be disclosed to persons being
offered genetic testing. . . .

One situation arises when the referring health care

provider, or a provider/investigator who has developed a test, has a financial stake
in a clinical laboratory.

Another situation arises when those counseling people

about testing are remunerated from funds generated by performance of the test
itself and not entirely from their counseling activities.

).
242.

See generally David Orentlicher, Health Care Reform and the Patient-Physician

Relationship,

5

HEALTH MATRIX

141 (1995)

(discussing concerns that health care reform

would impinge on patient-physician relationship). The paradox between advancing medical
science to benefit all children at the sacrifice of individual children who are the subjects of
research is addressed in Mclean, supra note

1 9,

at

1 14

('The paradox then may be that in

order to protect some children, we need to use other children as subjects of research to gain
the knowledge necessary for prevention and therapy.").
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Program)

to ensure

[Vol.

sequencing proficiency

71 : 1 2 1 1
must be

accompanied by comprehensive genetic medicine measures. Medical
and public health officials must introduce and enforce good medicine
guidelines that are carefully tailored to directly address predictive
genetic testing services.243

For example, federal regulators should

consider imposing a mandatory minimum PPV standard for genetic
testing services performed outside of major academic research centers
when results are made available to those who undergo the testing.
Moreover, written proof of compliance-a written showing of PPV
should be a prerequisite for charging to recover costs.

Similarly,

providers should be required to establish competence in genetics

as

a

prerequisite for reimbursement for the genetic testing services they
provide.244
243. The need to have regulations tailored specifically to genetics has been
recognized by many, including Dr. Holtzman, Chair of the ELSI Task Force:
"Genetic tests have many distinct, unique problems that cry out for a
separate regulatory category," noted Holtzman. For example, tests used for
predictive purposes are not used primarily in sick people, as are most other
diagnostic tests, but rather to predict future disease. Moreover, physicians often
have little in the way of clear-cut i nterventions to offer when a test reveals that a
patient is predisposed to develop a gene-related disorder. Predictive genetic tests
also may involve issues of prenatal testing and termination of pregnancy, and they
have implications not only for the individual being tested but for family members
as well.
Stephenson, supra note 1 5, at 1662. In the area of FDA reform, industry is requesting this
same level of detail. See Fox, supra note 82, at 698; see also Translating Advances in
Human Genetics into Public Health Action (undated) (background document prepared for a
meeting to discuss genetics in public health at the Center for Disease Control and Prevention
on January 27-28, 1 997) (on file with authors). An Ad hoc Task Force on Genetics in
Disease Prevention was appointed by the CDC Director in September of 1996 to (I) develop
a strategic plan for CDC-wide genetics programs; (2) coordinate and support program efforts
involving multiple centers, institutes, and offices at the CDC; and (3) convene constituents
and consultants to obtain input on strategic planning and priorities for CDC activities related
to genetics in public health. The stated mission is to "integrate knowledge of human
genetics into effective and ethical public health actions that promote health and prevent
disease and disability. CDC, in collaboration with its partners, will accomplish this mission
by assessing the public health impact of human genetic variation and its interaction with
modifiable risk factors; developing a sound framework of public health policies,
recommendations, and guidelines for the use of genetic tests and services; developing and
evaluating population-based prevention programs that include genetic tests and services in
the prevention of disease and disability; and disseminating genetics information and
providing public education and professional training." Id.
244. This proposal has received support from members of the ELSI Task Force. See
ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 , at 25. Because the field is evolving
and advancing so rapidly, even after making such a showing, physicians should be subjected
to continuing education requirements in genetic medicine. See id. at 23-24 ("Principle III-2:
Some documentation of continuing education in the area of human and medical genetics
should be required for physicians offerin g genetic tests, including primary care providers.");
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Such standards must be introduced nationally to avoid an
industry "race to the bottom" at the state level. Specifically, a failure
to introduce national standards is likely to instill the wrong public
health incentives

by rewarding states that adopt a

laissezjaire

approach to attract industry. Standards also must be explicit enough to
be enforceable. One of the advantages of express quality standards or
codes of practice is that they will remove the- amorphous standard of
care ("the rest of the profession is doing it") defense to liability.245
With more specific standards in place, physicians will be liable for not
adhering to these standards, regardless of what the rest of the
profession is doing.
There is ample support within the medical profession for such

standards, most notably from Francis Collins, head of the HGP.246
Ironically, many medical professionals vocally oppose making BRCA

see also Proposed Recommendations of the Task Force on Genetic Testing, Meeting Notice,

62 Fed. Reg. 4539, 4546 ( 1 997) (proposing the development of a satisfactory curricula and
examination and recertification programs).
245. The United States is like the United Kingdom in that, absent specific codes of
practice, the test for liability remains effectively a professional one:
The test . . . effectively states that a doctor will not be negligent if she acts
in accordance with a practice held to be reasonable by a responsible body of
medical opinion. Therefore, it could be said, although somewhat simplistically,
that as Jong as some doctors are behaving i n a certain way, then no liability will
attach. . . .
This makes it likely that a responsible body of medical opinion will be
found to endorse whatever the individual doctor has or has not done, thereby
virtually ensuring that legal liability will not be attributed. However, it should be
said that there is an increasing trend in contemporary medicine to develop codes
of practice that might be thought of as codes of best practice. If such codes are
developed in relation to genetic screening, i t will become harder to argue in favor
of the doctor who deviates from that code . . . .
Mclean, supra note 1 9, at 1 26-27.
246. See ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 , at 1 5 ("Professional
societies, such as the American College of Medical Genetics, the American Society of
Human Genetics, and the Council of Regional Networks for genetic Services have published
statements regarding appropriate and inappropriate use of specific tests."); Collins, supra
note 2, at 188 ("[I]t i s critical that we create safeguards to ensure that the benefits of testing
exceed the risks ."); see also Saltus, supra note 1 34 ("Dr. Francis Collins, the head of the
National Center for Human Genome Research, wrote in a medical journal last January that
he was concerned about commercial motives spreading the test outside research programs.
Last week he said he still believes testing should be under a research umbrella 'until such
time as we have better answers' about its usefulness."); Weiss, supra note 2 ("[S]everal
prestigious scientific organizations-including the American Society for Human Genetics,
the National Advisory Council for Human Genome Research and the National Action Plan
on Breast Cancer, which is coordinated by the U.S. Public Health Service-have come out
against commercialization of the BRCAl test, the first crude predictor of cancer risk to come
on the market.").
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testing available to consumers outside the major research centers, even
though the medical profession shares responsibility for this occurrence
by failing to effectively self-regulate.247 Moreover, generating tailored
standards at a national level with professional and consumer input has
been made more possible through recent advances in communication.
In fact, in an age of global communication, it also is possible to
review, and perhaps adopt, modified versions of health care quality
standards from abroad for innovative technologies that have been
proven effective in practice.248 One possibility is the U.K. ' s standards
(and underlying research) regarding genetic diagnosis for late-onset
disorders in children .249
Still, thoughtful standards alone may not be enough to counter
the pressures on providers from consumers, behind-the-scene managed
care administrators who want to keep consumers enrolled while
minimizing costs, and industry.

Therefore, to make the genetic-test

quality standards imposed on practicing physicians enforceable, the
introduction of codified professional standards must be accompanied

by regulatory restrictions on predictive genetic testing.250
247.

In light of

See Saltus, supra note 1 34, at 25; Weiss, supra note 2, at A l .

248.

See Malinowski, supra note 29, at 1 22.

249.

Professor George Annas is attempting to organize a Global Physicians and

Lawyers for Human Rights Network to introduce enforceable international standards for
medical technology such as genetic testing.
Genomics Rules,

See Vicki Brower, lawyers, Physicians Seek

1 5 NATURE BIOTECHNOLOGY

I O ( 1 997).

The

International

Bar

Association, the world's largest legal organization for lawyers, supports a treaty proposed to
set minimum standards for the use of genetic information. See id. This treaty was released
November 1 996 i n Berlin, Germany. See id. ; see also Mindy H. Chapman, Comment, RX:
Just What the Doctor Ordered: International Standards for Medical Devices, 1 4 Nw. 1.
INT'LL. & Bus. 566 ( 1 994).
250.
At

See Weiss, supra note 2, at A l (
the

[ELSI

Task

Force]

meeting

last

month,

representatives

of

the

biotechnology industry said it is the doctor's job to make sure that patients
understand the risks and benefits of being tested.

Doctors said they were still

getting up to speed in genetics and would be unable to stem the tide of patient

demand if testing were not subject to regul atory restrictions.

And insurers said

they would go out of business if they were restricted from having access to genetic
information.
); FDA Needs to Regulate, supra note 63, at 1 627 (
The US Food and Drug Administration (FDA, Rockville, MD) needs to muster
the political will to take up the regulation of genetic testing, not just of di agnostics
manufactured as kits, but also of the in-house protocols ("home brews") that
constitute most susceptibility tests.
Although the US Health-Care Financing Administration does have some
oversight (under the Clinical Laboratory Improvement Amendment of 1 988), as
do institutional review boards at various institutions, the oversight provided varies
widely and does not inspire confidence i n the end results.
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the public and political pressures on the FDA, such regulation might
best be introduced through the
example, modifying

CDC, FfC, HCFA, or HHS by, for

CLIA. To minimize duplication of regulatory

efforts, there must be horizontal regulatory coordination at the federal
level and vertical coordination between federal and state efforts. This
coordination cannot be accomplished without the establishment of a
federal body with the sole responsibility of achieving this objective
and the political independence and authority to do so.
One logical option is to introduce complementary criteria on
research laboratories (meaning any laboratory perfonning predictive
genetic testing) regardless of whether the testing they perform is
offered

as

research, investigational, or off-label.

Like physicians,

research . laboratories control access to predictive genetic testing
services, in that their involvement also is absolute.

Accordingly,

careful consideration should also be given to the laboratory-quality
principles developed by the
part

as

ELSI Task Force, which are attached in

Appendix II, and the more recent Proposed Recommendations

summarized in Table

I.

Another option is to introduce unifonn

proficiency testing (PT).251

As suggested by the

ELSI Task Force,

such a requirement could be enforced by making it a precondition for
reimbursement

for

testing

services.252

In

its

more

recent

recommendations, the Task Force has proposed introducing a registry
of laboratories in compliance with national standards, coupled with
limiting reimbursement by third-party payers to tests performed by

).
25 1 . See ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 , at 7 ('There was a
general consensus among Task Force members that, be i t mandatory or voluntary, a uniform
national genetics PT program would be preferable to the assortment of approaches used
today."). Some members of the ELSI Task Force have suggested that:
[W]hile CLIA does not require PT [proficiency testing] for genetic testing, genetic
labs would be subject to CLIA's quality assurance (QA) requirements. Under QA
inspection, laboratory surveyors could ask for evidence of quality testing, and may
obtain the results of voluntary PT by the lab.

(Labs cannot conceal poor PT

results from surveyors.) If the voluntary PT results showed the lab was deficient,
HCFA could take appropriate measures under CUA to make sure the l ab
improves. Such measures could include a plan of correction, on-site monitoring,
"cease and desist" orders , or perhaps even court action. Lebovic emphasized that
mandatory PT under CLIA is intended as more of an educational tool than a
punitive device.

Still, revising CLIA to require that genetics labs undertake PT

would help insure the quality of their testing.
Meeting Minutes, supra note 1 , at 6-7.

252. See Meeting Minutes, supra note 1 , at 7 .
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laboratories on the list.
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Regardless of what medical-science, quality

assurance safeguards are introduced on the federal level, there must be
recognition of the fact that genetic science is constantly and rapidly
254
evolving. Accordingly, all review must be ongoing.
Federal standards also must be introduced to ensure that the IRB
255
mechanism carries legitimacy.
At the very least, the CLIA
provisions calling for the use of IRBs and giving them authority must
be expanded to address their composition and to establish standards
for approval of any human research , federally funded or not. In light
of the authority IRBs carry and because they are

the primary

mechanism assuming the sufficiency of the scientific process and
protecting the rights of participatin g subjects, there must be prescribed
elements for structuring IR.Bs that promote impartiality and the
enforcement of good-medicine standards.

The discretion allowed
256
Strict
institutions when constructing IRB s must be curtailed.
253.

See Proposed Recommendations of the Task Force Genetic Testing, Meeting

Notice, 62 Fed. Reg. 4539, 4546 (Nat ' l Insts. Health 1 997).

254.

See ELSI TASK FORC E ON GENETIC TESTING, supra note l , at 36 (

Principle IV- l : All elements of the genetic testing process need ongoing review
and oversight. Ongoing review o f the genetic testing process is needed to ensure

the integrity of testing programs and to avoid potential abuses. . . . An expanded

role of institutional review boards, the recognition of genetics as a di screte entity
by CLIA administrators and FDA, and the creation of a special national body with
authority to review genetic testing are some options, which are not mutually
exclusive, currently under consideration.

).
What patients should be told about a test and its results may change considerably due to the
research nature of the testing and ongoing data collection and compilation. This is the cost
of making service available before thorough clinical study and under tight restrictions.

255.

The i ncredible lack of such standards is summarized in Palca, supra note 70, at 4

Since federal agencies clearly aren 't prepared to oversee research themselves, they
usually turn to IRBs to do the job. . . .

I n some cases, the board's workload is

such that it spends only one or two minutes on each study under review, and for
most IRBs that workload will increase. . . .
. . . Collegial ties among IRB members and researchers whose work they
were being asked to review could hamper an IRB member's ability to critically
evaluate protocols.

). See also Proposed Recommendations of the Task Force on Genetic Testing, Meeting
Notice, 62 Fed. Reg. at 4544 ('The Task Force is concerned that the high workload of IRBs,
their variability in community representation, in evaluating protocols, and in expertise
gennane to the review of genetic tests, as well as the conflicts of interest that can arise in
local review, impairs current review of genetic tests that warrant stringent scruti ny.").

256.

As recognized by some members of the ELSI Task Force, entities constructing

IRBs have significant discretion:
[T]he subject of IRBs is rife with questions.
should sit on IRBs?

Who should sponsor IRBs? Who

Are all IRBs equipped to oversee investigational use of
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conflict-of-interest and disclosure requirements are needed, including
requirements that any compensation for participation in IRBs be
reported and. disclosed publicly. Also, the composition of IRBs should
be regulated to the extent necessary to ensure rigorous, intellectually
honest, and scientifically valid review.

The importance of such

regulation is made especially acute by the proposed disbanding of the
Recombinant DNA Advisory Committee (RAC), "a venerable panel
of scientists, ethicists and other experts at the National Institutes of
Health that for two decades has shined the spotlight of public
accountability on the genetics revolution."257 The peer review nature
of IRBs suggests that the traditional research/clinical division in
medicine should be bridged for IRB standards by collaboration
between professional organizations that focus on both research and

genetic tests? Should more than one IRB be used? Are there conflict-of-interest
problems with IRBs established by entities with a financial stake in the products
being reviewed?
. . . Dr. Murphy of OncorMed explained that her company has created an
IRB group, and has no interaction with the IRB other than for review of
OncorMed's protocols. . . .

The IRB qualifies under both Health & Human

Services and FDA IRB regulations, and its members include two pathologists, a
bioethicist, a nurse, a consumer and a lawyer plus a variety of ad hoc experts who
rotate for different protocols.
Meeting Minutes, supra note 1, at 4-5. See generally ABRAHAM, supra note 71 (reporting a
lack of impartiality between science community representatives on IRBs and researchers
responsible for the science at issue, as there is a revolving door and often professional and
financial entanglements between those two groups).

257. Rick Weiss, It May be Overfor Biotech Oversight Panel, WASH. POST, May 29,
1996, at Al7 ("The Recombinant DNA Advi sory Committee [RAC) . . . is poised to get its
plug pulled.").

Despite its .accomplishments, which include ( 1 ) the first guidelines for

scientists wishing to create genetically engineered microbes; (2) the first formal review
system for proposals to insert new genes into people; and (3) the first approval of a human
gene therapy experiment, RAC faces a proposal in the federal register by NIH Director
Harold Varmus to disband it. See id. The rationale underlying this proposal is that "most
proposals today are straightforward enough that they can be reviewed directly by the Food
and Drug Administration." Id. One intended outcome is more reliance on IRBs (rather than
RAC), though reliance on IRBs has been the source of both concern and public criticism:
Abbey S. Meyers, Pres. of the National Organization for Rare Disorders,
rejected Varmus's contention that institutional review boards at the universities
where gene therapy experiments are conducted can be counted on to weed out
unworthy studies.

Those boards have neither the expertise nor the incentive to

critically assess gene therapy experiments . . . .

They are being reviewed by

people who don't know anything about it but are desperate for their institution to
become a gene therapy center. . . .

We have seen informed consent forms

approved by IRBs that are unbelievable . . . .

Id.

It is important to note, however, that RAC will continue one of its major missions

maintenance of a registry of all gene therapy experiments underway in the country. See id.
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aspects

of medicine,

such

as

the

American

Medical

Association and the National Hospital Association.
Even if enacted, reforms that conclusively control the quality of
predictive genetic testing services at the national

level through

restrictions on their delivery-though a considerable improvement
still would

not be

adequate.

The burgeoning

nature

of the

biotechnology industry and the field of biomedical science mandates
that there be no assumption of compliance with and enforcement of
such regulations.

Instead, public health officials must assume that

consumers will have access to genetic testing and that genetic
information will be generated in an increasing fashion. Accordingly,
reforms such

as

those proposed above must be accompanied by the

introduction of a regulatory infrastructure to protect consumers from
abusive uses of genetic information. Without such reform, "[a]nswers
to the next series of clinical questions may be jeopardized by the
injudicious use of genetic testing by physicians and continued concern
about the possibility of discrimin ation on the basis of the results."258
National legislation governing the use of genetic information by
insurers also is needed to overcome both regulatory disparities
between the states and the preemptive effect of the Employee
Retirement Income Security Act of 1 974 (ERISA).259

Otherwise,

those who choose to undergo genetic testing while a resident of a state
limiting the use of genetic information may find themselves unable to
obtain insurance coverage when they move to another state.260 Such
regulation

has

been

introduced

to

prevent

employers

from

discriminating on the basis of genetic information.261 Also, legislation
258. Olopade, supra note 177, at 1 455.
259. 29 U.S.C. §§ 1 001- 1461 ( 1 994). "Health care insurance may be declared an
employee benefit when employers self-insure, thereby subjecting the insurance provided to
regulation under ERISA." Malinowski, supra note 1 25, at 35 1 n . 1 43 ; see also Roberta
Casper Watson, Fiduciary Issues in the Administration of Health Plans, in ALl-ABA
COURSE OF STUDY MATERIALS: FIDUCIARY RESPONSIBILITY ISSUES UNDER ERISA 1996
June 6, 1996, at 1 007. Though recent federal cases have held that ERIS A preemption is not
an absolute defense to claims of medical malpractice, the statute generally has been
interpreted to preempt state laws and regulations. See Malinowski, supra note 1 25, at 351
n.143.
260. See NBC Nightly News (NBC television broadcast, July 20, 1 996), available in
1996 WL 1 03025 1 1 ("Although Ruth wants a genetic test, she says she doesn't dare,
because each state has different rules when it comes to privacy. RUTH: I f I' ve, while in
New Jersey, gone ahead and done this-the genetic testing, and then at a later point we
move, I've exposed myself.").
261 . In M arch 1995, the EEOC issued a new compliance manual, in which it
included people who experience discrimination due to their genetic profiles for protection
under the Americans with Disabilities Act (ADA), 42 U.S.C. §§ 1 2 1 0 1 - 1 22 1 3 ( 1 994). See
-

,
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has been proposed to place similar restrictions on insurers.

This

legislation includes the nondiscrimination provision in the health
insurance reform bills that address genetic information and that were
2
passed by the House and Senate during the last Congress. 26 In August
Clinton signed a version of these bills into law as the
Health Insurance Portability and Accountability Act.263

1996, President

Nevertheless, absent comprehensive consumer protection from
genetic discrimination at the federal level, the protection of citizens
and regulation of the insurance industry rests well within the purview
of the states' public health responsibilities. Moreover, while Congress
has been contemplating protective measures, states have been enacting
them.264

Some states, including Massachusetts, are contemplating

innovative measures.265

State public health officials should promote

EEOC COMPLIANCE MANUAL, supra note 1 27, § 902.8(a); see also Annas, supra note 14, at
1 9-22 (discussing genetic testing and potential privacy concerns); Lord, supra note 22, at
86; Richard Saltus, US Ruling Bars Discrimination Based on Genes; Prohibits Employer

from Denying Job Because of Predisposition to Illness, BOSTON GLOBE, Apr. 1 1 , 1 99 5 , at 4
("Now, a federal conunission has ruled that employers cannot deny a job or fire someone
because of his genes. The ruling covers only employment, not health or life insurance, but
consumers and researchers say it's an important precedent.").

Genetic alterations are

deemed "disabilities" in that those who have them are perceived as having a p hysical or
mental impairment that substantially limits one or more of a person's major life activities.

See Lord, supra note 22, at 86. An employer may, however, be able to exclude a category of
employees from certain exposure based upon his or her genotype, and "sectio n 50 l (c) of the
ADA permits employers to observe the terms of a bona fide health insurance plan based on
underwriting risks and classifications, provided there is no 'subterfuge ' to evade the
purposes of the act." Id.
262.

See supra note 82 (addressing Kassebaum-Kennedy sponsored bill).

But see

Piercey, supra note 1 27 , at 1 (reporting that, based upon alleged "internal documents" from
the Health Insurance Association of America (HJAA), "Kennedy claims that, while genetic
information and other health factors could not be used to deny coverage, they might be used
to 'design' coverage").
263.
the Act).

Pub. L. No. I 04- 1 9 1 , I 10 Stat. 1936 ( 1 996); see also supra note 1 27 (discussing

264.

As of July 1 996, notable state efforts included:

I.

laws barring both employers and insurance companies from discriminating

against individuals based upon the results of genetic testing enacted in New
Hampshire, New York, Oregon, and Wisconsin;
2.

laws prohibiting employers from using genetic information to discriminate

against employees or job applicants enacted in Iowa and Rhode Island; and
3.
pending bills in California, Massachusetts, Michigan, New Jersey, and
Pennsylvania.

See New York Bill Prohibiting Genetic Discrimination Signed Into Law, WEST'S LEGAL
NEWS , July 3 1 , I 996, at 7845, available in I 996 WL 423290; see also Genetic Testing
by Employers, Labor Organizations, and Licensing Agencies, 1996 N.Y. Laws Ch. 204,

§ I.
265.

See supra note 1 88. Massachusetts i s contemplating ( l ) delegation o f ongoing

quality assessment and implementation of effective informed consent standards to the
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legislation to protect consumers in the absence of federal legislation
and supplement any federal protections that are eventually enacted.
State responsiveness and ingenuity is especially needed to address
infonned consent for genetic testing and the broader issue of genetic
266
The best state solutions to these challenges ultimately
counseling.
could become national ones.
When proceeding to implement reforms such

as

those identified

above, legislators and medical and public health officials must
anticipate the reaction of the biotechnology industry and proceed with
267
market sensitivity.
At both the state and federal levels, the
biotechnology industry is recognized

as

an important sector in the

Department of Public Health, (2) consumer control over genetic information, such as the
option to have this information separated from medical records, and (3) a five-year
moratorium on the use of genetic information by insurers coupled with a provision that
would place the burden on insurers to have actuarial data in hand to establish the validity
and predictability of genetic tests before they may use the resulting information in any way.
See Observation by Michael Malinowski, Member of the Massachusetts Legislature's
Special Committee on Genetic Information Policy; see also Richard Saltus, Genetic Privacy
Bill in Works, BOSTON GWBE, Feb. 2, 1 997, at B2.
266. The Draft Interim Principles identified by the ELSI Task Force include the
following:
Principle III-5: Informed consent for a validation study must be obtained
whenever the specimen can be linked to the subject from whom it came.
Under FDA regulations informed consent is needed in the investigational
stage of device development, except when wai ved by an IRB.
Principle III-7: Health care providers must describe the features of the
genetic test, including potential consequences, to potential test recipients prior to
the initiation of predictive testing in clinical practice.
The informed consent process contributes importantly to the education of
people who are offering testing.
The responsibility for providing information to the individual lies with the
referring provider, not with the laboratory performing the test.
ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 , at 27-28. For a discussion of patient
autonomy in the context of genetic counseling, see Robert Wachbroit & David Wasserman,
Patient Autonomy and Value-Neutrality in Nondirective Genetic Counseling, 6 STAN. L. &
PoL'Y REv. 1 03 ( 1 995).
267. See M eeting Minutes, supra note 1, at 2 (
Dr. Holtzman commented on the importance of resolving regulatory and
other uncertainties, because genetic tests may not reach the marketplace unless
venture capitalists have the confidence to invest sufficient funds in their
development. For small firms which lack the financial resources and regulatory
expertise required to bring a test to market, a joint venture with a large
pharmaceutical firm may be the only practical solution.
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United States's economic future,268 and many of the products being
developed by that sector could greatly improve public health.
However, the diverse nature of the biotechnology industry and its
multitude of products should enable reforms necessary to ensure the
responsible application of predictive genetic testing services to be
enacted, assuming a market-sensitive approach is followed.
Initiatives to enact such reforms actually may benefit from
industry insight or prompt industry to introduce self-reforms that are
equally effective.

Although the guiding incentive of the industry

ultimately is profit, that incentive may be used to bring about the
consumer-protection regulation that is needed. For example (albeit to
preserve and increase consumer demand) biotechnology companies
have joined patient-advocacy groups i n lobbying policy makers to
reform the

FDA review process269 and prohibit insurance companies

from using genetic information.270 Similarly, OncorMed developed its
elaborate, thoughtful genetic testing protocols at great expense to
"Coase around"

FDA regulations that impede access to consumers

and, at times, unduly impede the advancement of life science.
Whichever

proposals

ultimately

are

adopted

to

regulate

the

commercialization of predictive genetic testing services, public health
officials should make heavy reference to supportive provisions from
responsible protocols developed by the biotechnology industry and its
academic allies both to win industry support and to quell opposition.
VI.

CONCLUSION

In

Oedipus Rex, the character Tiresias has the ability to see into

the future as if it were yesterday.

Tiresias's divine gift of vision,

however, gives him no ability to change what he sees. In his words to
King Oedipus, "Wisdom is a curse when wisdom does nothing for the
man that has it."271

Without established PPV, predictive genetic tests

offer much less certainty than Tiresias's vision. Although biomedical

268. See generally Malinowski & O'Rourke, supra note 20 (noting that technology is
becoming commercially viable, and companies are investing more resources to enforce their
patents).
269. See M IC HAEL J. MALINOWSKI, INTERNATIONAL GUIDE TO THE LAW, BUSINESS AND
REGULATION OF BIOTECHNOLOGY (forthcoming 1 997).
270. See Piercey, supra note 127, at I ("Biotechnology companies and patient
advocacy groups lobbied lawmakers to include language barring genetic discrimination
because many see it as a necessary precondition for the widespread use of genetic testing.").
27 1 . SOPHOCLES, OEDIPUS THE KING 37 (Stephen Berg & Diskin Clay trans., Oxford
Univ. Press ed. 1978).
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science carries the promise of therapeutics and gene therapies, in their
absence, the present inability to change the future remains.
This Article has analyzed the commercialization of predictive
genetic testin g for BRCA alterations linked to breast and ovarian
cancer. Beyond addressing this contemporary and pressing problem,
the objective has been to illustrate the public health implications of the
premature commercialization of this technology, to identify regulatory
shortcomings, and to introduce proposals for change.

As has been

emphasized throughout this Article, BRCA testing simply marks the
beginning of widespread predictive genetic testing.
Predictive genetic tests without established PPV are unacceptable
for broad commercialization.

Such tests are highly subject to

misinterpretation by those who undergo them and by the health care
providers who make them available.
biological tarot cards.

They are the equivalent of
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Public health officials must directly address the issue of quality
assurance for predictive genetic testing services. They must introduce
consumer safeguards tailored to this innovative technology and, more
importantly, they must enforce them.

This Article has proposed

numerous regulatory reforms to control access to and the quality of
predictive genetic tests. Many of these proposals center on remaining
faithful to the practice of good medicine.
Advances in biomedical research offer many patients hope, not
harm. The threat that accompanies this medical technology comes
from the temptation to use it prematurely and irresponsibly.

Just as

physicians should not sell a drug or diagnostic to their patients that
they do not understand (and, therefore, cannot measure the benefits
of), physicians should not be making research-stage predictive genetic
tests available without the precautions necessary to avoid doing hann.
Predictive genetic testing simply i s at the vanguard of an era of
unprecedented progress in medicine attributable to genetic science.
For centuries, the adage "First, do no harm" has guided the medical
profession.

The profession and the adage have endured jolting

advances in medical technology-from anesthesia, to antibiotics, to
vaccinations. Similarly, if contemporary public health officials look to
this adage, they will find guidance.

Promoting and enfarcing the

practice of responsible medicine continues to be the answer.
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APPENDIX I
Excerpt from Letter Summary of the OncorMed ProtocoI272
Patients who are eligible for testing under this protocol are:
persons with breast and/or ovarian cancer who have two or
I.
more first- or second-degree* blood relatives (related
through a single lineage) with either breast or ovarian
cancer,
person s with breast and/or ovarian cancer which developed
2.
at an early age (<45 years),
persons with breast and/or ovarian cancer with multiple
3.
primary cancers or bilateral disease,
males who develop breast cancer at any age,
4.
relatives of persons with documented mutations m the
5.
BRCA1 or BRCA2 gene.
*

first-degree relative:

parent, siblings, offspring; second-degree relative: aunt, uncle, grandparent,

grandchild, niece, nephew, half-sibling

Patients who may not be tested are:
1.
a person under the age of 18 years,
2.
a cognitively impaired person or one who is unable to
provi de informed consent,
3.
someone who has a psychological condition precluding
testing.
To test a patient under this protocol, the physician would agree to:
0 Call in or fax the family history to OncorMed before testing .
Pathological verification of the history should be obtained
whenever possible.
0 Identify a genetic counselor to evaluate the family history,
explain inheritance, discuss the benefits, risks, limitations,
and psychosocial impact of testing; a medical and surgical
oncologist to discuss management options; and a mental
health specialist to help in the decision to test, to provide
support during the testing process, or to help adjust to the
results. The patient should be offered these referrals both

272. This summary was taken from the Hereditary Breast Cancer Testing Packet
received from OncorMed in January 1997. OncorMed, Inc. may be contacted at 205 Perry
Parkway, Gaithersburg, Maryland 20877. The company may also be contacted by telephone
at 301 -208- 1 888 or facsimile at 301 -926-6329.
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before and after testing. OncorMed can help you locate a
genetic counselor in your area, if needed.
0 Ensure that informed consent is obtained and that the patient
receives pre- and post-test counseling by one or more
professionals knowledgeable about the genetics and
management of hereditary breast cancer syndromes.
0 Give the test results to the patient in person and develop a
management plan with the patient.
0 Refer the patient to the specialists you have identified as
needed, provide psychological support, and assist in
informing relatives if appropriate.
We have provided a number of items which may help you counsel and
test patients under this protocol.
0 A testing flow diagram which outlines the protocol and
which you can keep as part of your records to document
progress though the testing process.
0 A physician Q&A with information on BRCA 1 and BRCA2
and on testing patients.
0 A patient Q&A describing testing which can be given to
patients. Encourage the patient to take the Q&A and the
consent home to review prior to agreeing to be tested.
0 Counseling checklists which you can use to be sure all
relevant information is covered during the pre-and post-test
counseling sessions and which can be given to the patient as
a summary of the counseling.
0 A clinical history form and consent which should be signed
and returned with the blood sample if the patient agrees to
testing.
APPENDIX Il273

ELSI TASK FORCE DRAFf INTERIM PRINCIPLES FOR
LABORATORY QUALITY
The ELSI Task Force identified 4 categories for considerations related
to laboratory quality: ( 1 ) biologic materials and components, meaning
the reagents and equipment used by the laboratory; (2) laboratory start
up, meaning the introductions of new tests; (3) laboratory practice,
273. ELSI TASK FORCE ON GENETIC TESTING, supra note 1 , at 16-22.
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meaning the actual performance of tests, personnel, internal quality
control,

and

quality

assurance

mechanisms;

and

(4) laboratory

oversight, meaning proficiency testing, accreditation, and inspection.
The Task Force issued the following principles:

A.

Components and Biologic Materials
Principle 11- 1 : A genetic test must be analytically validated for

each

analyte

it

is

intended

to

measure.

It is

ultimately the

responsibility of each laboratory director to ensure analytic validity.
. . . [T]here is minimal external oversight of the components used
in genetic testing, except for those in FDA-approved kits or other
devices.

Although the Task Force is considering policies to change

this picture, for the moment the laboratory supervisor must be
responsible

for assuring the

performance characteristics

components used in the laboratory's testing repertoire.

of the

Under the

authority of CLIA (or of states that are at least as rigorous as CLIA),
government surveyors are supposed to determine whether laboratories
have developed new tests and, if so, to then review their data for
analytic validation . . . .
Principle II-2: Appropriate specimens from patients, carriers, and
controls should be available through a centralized system in order to
facilitate their availability to aid in analytical validation, improving
quality, or other needs.

B.

Start- Up
Principle 11-3 : Laboratories can offer new genetic tests only after

their analytical and clinical validity have been established by that
laboratory or elsewhere.
Principle 11-4:

Before routinely offering genetic tests that have

been clinically validated, a laboratory must conduct a pilot phase in
which it verifies the performance characteristics of its test.
Principle II-5:

Prior to beginning routine patient testing, the

laboratory must review and evaluate the data collected in the pilot
phase.
Principle 11-6: Research laboratories that provide physicians with
results of genetic tests, which may be used for clinical decision
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making, must validate their tests and be subj ect to . the same internal
and external review

C.

as

other clinical laboratories.

Practices
. . . The potential for errors in referral, the choice of an

appropriate test, the probabilistic, predictive, and conditional n ature of
test results place a greater burden o n communication between the
laboratory and the provider ordering and/or receiving results than is the
case for many other types oftests . . . .
Principle
interpretation,

II-7:

Because of the complexities in assessment and

requisitions for genetic tests require more intake

infonnation than those for most other clinical laboratory tests.

. . . If information that is critical to the performance or the
interpretation of the test cannot be obtained, the specimen should be
rejected. . . .
Principle Il-8:

Genetic test results must be written by the

laboratory in a form that is understandable to the nongeneticist health
care provider.
. . . Laboratory reports must include sufficient information in
order for the referring provider to interpret the results appropriately to
the person tested or, in the case of minors, to their parents. . . .

Il-9:

Principle

Personnel serving as directors or technical

supervisors of genetic testing laboratories must have formal training in
human and medical genetics.

II- 1 0:

Principle

Training

programs

for

laboratory

technicians/technologists should include more human and medical
genetics content than is currently available .
. . . Several fonnal training programs for cytogenetics technical
staff are available, but there are only one or two certificate-or
diploma-track

genetics

training

programs

for

technicians

or

technologists in the U.S . . . .

D.

External Review
Principle

II- 1 1 : A national accreditation program for laboratories

performing genetic

tests, which

includes on-site inspection and

proficiency testing, i s needed to promote standardization.
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Genetic testing laboratories must participate in

proficiency testing (PT) programs for each of its tests, if available.
When no relevant proficiency testing programs exist, laboratories
must, whenever possible, participate in inter-laboratory comparison
programs and help develop them if none exist in their particular area of
testing.

Proficiency testing programs should be broadly based since

the number of genetic disorders i s very large and the analytical
approaches to testing are numerous.

Laboratories and inspectors

should use PT results to help a l aboratory improve its quality.

In mandatory PT programs, some punitive action is taken if
laboratories

that

_subsequent rounds.

"fail"

do

not

improve

their

performance

on

